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Mycotoxins are toxic compounds mainly produced by fungi of the genera Aspergillus, Penicillium and 
Fusarium. They are present, often as mixtures, in many feed and food commodities including cereals, 
fruits and vegetables. Their ubiquitous presence represents a major challenge to the health and well 
being of humans and animals. Hundreds of compounds are listed as possible mycotoxins occurring in 
raw and processed materials destined for human food and animal feed. In this study, mycotoxins of 
major toxicological relevance to humans and target animal species were investigated in a range of crops 
of interest (and their derived products). Extensive Literature Searches (ELSs) were undertaken for data 
collection on: (i) ecology and interaction with host plants of mycotoxin producing fungi, mycotoxin 
production, recent developments in mitigation actions of mycotoxins in crop chains (maize, small grains, 
rice, sorghum, grapes, spices and nuts), (ii) analytical methods for native, modified and co-occurring 
mycotoxins (iii)  toxicity, toxicokinetics, toxicodynamics and biomarkers relevant to humans and animals 
(poultry, suidae (pig, wild boar), bovidae (sheep, goat, cow, buffalo), rodents (rats, mice) and others 
(horses, dogs), (iv) modelling approaches and key reference values for exposure, hazard and risk 
modelling. Comprehensive databases were created using EFSA templates and were stored in the 
MYCHIF platform. A range of approaches were implemented to explore the modelling of external and 
internal exposure as well as dose-response of mycotoxins in chicken and pigs. In vitro toxicokinetic and 
in vivo toxicity databases were exploited, both for single compounds and mixtures. However, large data 
gaps were identified particularly with regards to absence of common statistical and study designs within 
the literature and constitute an obstacle for the harmonisation of internal exposure and dose-response 
modelling. Finally, risk characterisation was also performed for humans as well as for two animal species 
(i.e. pigs and chicken) using available tools for the modelling of internal dose and a component-based 
approach for selected mycotoxins mixtures. 
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Summary 
Mycotoxins are toxic secondary metabolites produced by fungi. They are present, often as mixtures, in many 
feed and food commodities including cereals, fruits and vegetables. The most relevant mycotoxins worldwide 
reported are synthesized by fungal species belonging to three genera: Aspergillus spp., Fusarium spp. and 
Penicillium spp., and to a minor extent by Alternaria spp. and Claviceps spp. Mycotoxigenic fungi are commonly 
not host specific, but their occurrence is mainly associated with a specific crop depending on its growing area 
and the meteorological conditions. A fungus can produce different mycotoxins thus, there can be   concurrent 
contamination of food and feedstuff with multiple mycotoxins. Additionally and adding to the complexity, 
several fungi can, in quick succession, contaminate food and feed commodities. The native forms of 
mycotoxins can undergo modifications, as a result of fungi-host plant interaction or during raw product 
processing; therefore, modified mycotoxins can also occur in addition to the native varieties. Consequently, 
humans and animals are frequently exposed to more than one mycotoxin simultaneously. 
Extensive Literature Searches (ELS) have been performed giving an insight on the currently available data 
relevant for (i) ecology and interaction with host plants of mycotoxin producing fungi, mycotoxin production, 
recent developments in mitigation actions of mycotoxins in crop chains (maize, small grains, rice, sorghum, 
grapes, spices and nuts), (ii) analytical methods for native, modified and co-occurring mycotoxins (iii) toxicity, 
toxicokinetic, toxicodynamic and biomarkers (BM) for humans and animals (poultry, suidae (pig, wild boar), 
bovidae (sheep, goat, cow, buffalo), rodents (rat, mice) and others (horses, dogs)), (iv) modelling approaches 
and key reference values/statements to develop risk modelling. All selected papers contributed to the 
preparation of this report. Due to the large amount of data collected, a summary of this information has been 
included in the report while detailed information has been organised in different annexes and scientific 
publications.  
Chapter 2 presents the applied methodology, including review questions and eligibility criteria for study 
selection (Section 2.1), ELS strategy (Section 2.2) and study selection process (Section 2.3). Section 2.4 
described the data extraction process on occurrence and co-occurrence, toxicity and toxicokinetic as well as 
biomarkers. Section 2.5 presents the development of a structured database across the topics faced in this 
study. All data extracted for mycotoxin occurrence/co-occurrence, toxicity, toxicokinetics in vitro, toxicokinetic 
in vivo and biomarkers have been stored in the MYCHIF platform and EFSA knowledge junction 
(10.5281/zenodo.3615174). 
 
Temperature (T), relative humidity (RH), rainfall (R) and, above all, water activity (aw) are the most important 
ecological factors influencing fungal colonisation of the substrate, and every species has its peculiar ecological 
needs. Annex A provides a detailed description of the infection cycle and the ecological conditions that 
influence fungal activity. Fungal infection and subsequent production of mycotoxins begins in the field during 
plant growth and may continue through harvesting, storage, and processing if ecological conditions stay 
suitable for fungal activity. Mycotoxins are very stable compounds and accumulate over time, both during crop 
growth and post-harvest. Therefore, managing mycotoxin contamination requires a comprehensive strategy 
that includes the correct pre-harvest management and good harvest and post-harvest strategies. Processing 
will contribute to a reduction in the final mycotoxin content, but the relative reduction is very dependent on 
the type and sanitary conditions of the raw material, as well as on the technology and operating conditions 
employed whilst processing is undertaken. Dedicated annexes are presented on the infection cycle, ecology, 
plant-pathogen interaction of relevant fungi species in the specific host-plant and the state of the art regarding 
the crop chain management to mitigate the occurrence of mycotoxins in small grains, sorghum, nuts and 
spices (Annex B – E). In addition, three review papers, respectively on maize (Palumbo et al., 2020b), rice 
(Gonçalves et al., 2019) and grapes (Gonçalves et al., 2020) were prepared in the remit of MYCHIF project. 
 
The methods of analysis for the determination of mycotoxins are discussed in section 3.3. The list starts with 
relatively inexpensive rapid screening tools, for both lab and field-based testing, and includes the state of the 
art of laboratory based screening and confirmatory analytical instruments. Each method has a range of 
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when considering methodologies relative to their place of use, there is no one method superior across all 
envisaged sites of analysis. Combining approaches for field and laboratory-based settings remains an effective 
monitoring approach in immunological screening and physio-chemical analytical confirmation, though 
monitoring at the screening level can be limited to a single contaminant. Increasingly with the awareness of 
multiple mycotoxin contamination, enhanced screening tools are still required for field-based testing for the 
detection of more than one mycotoxin or mycotoxin families to ensure regulatory compliance. Quite a number 
of high or ultra-performance chromatography systems coupled to mass spectrometry have now been reported 
for their use in the determination of the co-occurrence of multiple mycotoxins in different feed and food 
commodities. However, the challenge still arises to the meaningful interpretation of toxin mixture data to their 
effects to human and animal health.  
Toxicity, toxicokinetics, and toxicodynamic parameters for humans and animals have been collected from 
papers obtained from ELS, and curated to build three databases: data of toxicokinetic in vitro, data of 
toxicokinetic in vivo, and in vivo toxicity data. A limited availability of scientific papers on mixtures in 
comparison with the single compounds was described. Mycotoxins dosage, exposure pathway, interspecies 
and intraspecies differences were identified among the most important parameters that may influence the 
toxicokinetics of mixtures. One review paper on toxicokinetic data in vivo for different animal species (Gkrillas 
et al., submitted), was prepared as part  of the MYCHIF project. In addition, one original paper was submitted 
and accepted for publication, on the design of a computational-based driven structure-based toxicodynamic 
study, comparing the estrogenicity of ZEN, its metabolites and the emerging mycotoxin alternariol (AOH) in 
human and trout (Dellafiora et al., 2020). 
Biomarkers, as a measure of the extent of the exposure to a toxic substance assessed and quantified in body 
fluids, as a parent molecule or as a metabolite, are examined either in animals (section 3.6.1 and 3.6.2) and 
in humans (section 3.6.2). For animal species, the review aimed to collect all BM studies assessing markers of 
exposure in animal species including carryover and residues as well as markers of effects reflecting 
toxicokinetics and toxicodynamics of mycotoxins (inclusion criteria). Five groups of animal species were 
categorised and clustered (poultry, bovidae, suidae, rat, mice, and other species). In a similar manner, the 
relevant literature on human was also reviewed for BM of exposure and effects with a particular interest on 
available correlations between mycotoxin exposure and health effects. Inclusion criteria selected BM studies 
for parent mycotoxins or their metabolites, particularly for relevant measurements on multiple mycotoxins. For 
BM studies, summary tables report measured BM, analytical methods, sampling strategies and summary 
statistics, including correlation with food intake or exposure assessment.  
Two animal case studies were selected and discussed, focussing on pigs and chicken, supported by a 
reasonable amount of information. For both species, dose-response modelling was performed for mycotoxin 
mixtures using a component-based approach (CBA) as well as a benchmark modelling approach, as described 
in section 3.8.1. However, toxicological data concerning mycotoxin mixtures in pigs and chicken were still 
unsuitable for modelling in terms of toxicokinetic and toxicodynamic parameters, mainly due to poor 
experimental design.  
The human case study (HCS) has been discussed in section 3.8.2. Two different approaches were investigated 
in the HCS, namely (i) the CBA and (ii) the provisional daily intake (PDI) for two selected mixtures of 
mycotoxins, which can occur and co-occur in cereal based food products.  The description of RA scenarios in 
hierarchy maps was possible for the HCS, considering the exposure to a defined mixture (i.e., Mixture-2, 
T2/HT2, DON and NIV) for adults, medium Lower Bound (MB) contamination and mean consumption values. 
The maps were defined for each mycotoxin of the mixture. These maps represent a useful picture in which it 
is immediately noticed where the highest ranks in the visual hierarchy are placed. 
Specific data gaps, common weaknesses in experimental design and future needs were highlighted. In the 
context of (co-) occurrence of mycotoxins, there is still limited knowledge on the presence and co-occurrence 
of multiple mycotoxins, both for native mycotoxins and their modified forms, in food and feed. Available 
analytical methods are, in general, satisfactory for the evaluation of the occurrence of mycotoxin mixtures, 
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factor for a routinary monitoring of modified mycotoxins in food and feed, both for the cost and the lack of 
suitable protocols. In the context of toxicity, it has been highlighted the lack of studies dealing with combined 
toxicity of multiple mycotoxins; further, the harmonisation of methodologies and consensus guidelines for 
generating in vitro and in vivo TK and is strongly suggested to provide consistent data for modelling of 
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1.1. Background and Terms of Reference as provided by the requestor 
This contract/grant was awarded by EFSA to: 
Contractor/Beneficiary: Università Cattolica del Sacro Cuore  
Contract/Grant title: Integrated methodologies for the risk assessment of mycotoxin mixtures in food and feed 
Contract/Grant number: GP/EFSA/AFSCO/2016/01 
Mycotoxins as mixtures are produced mainly by fungi of the genera Aspergillus, Penicillium and Fusarium co-
occurring in host crops. They include many food commodities based on cereals, fruits and vegetables. The 
ubiquitous presence of fungi and mycotoxins represents a challenge for human and animal health, and the 
environment. Over the last decade, EFSA has been very active in the area of risk assessment of mycotoxins in 
food and feed. Just to mention the main activities, aimed to 1) summarise existing knowledge and define 
scientific opinions; 2) use existing knowledge to predict future scenarios; 3) disseminate existing knowledge:  
 
1. Scientific opinions dealing with risk assessment of mycotoxins in food and feed. These have included 
well characterised mycotoxins (e.g. aflatoxins, T-2 and HT-2 toxins, zearalenone, etc.) and emerging 
mycotoxins (e.g. alternaria toxins, beauvericin, enniatins, etc.) (EFSA, 2007, 2011a, b, c, 2014b, 
2015b; Mo et al., 2015; EFSA, 2017c, b, a, 2018b); 
2. A grant investigating “modelling, predicting and mapping the emergence of aflatoxins in cereals in the 
EU due to climate change” (Battilani et al., 2012);  
3. 2 videos prepared in collaboration with FAO and Università Cattolica del Sacro Cuore. 
 
In addition, EFSA has initiated a series of projects dealing with the risk assessment of chemical mixtures in 
food and feed: review of the frameworks available for the human risk assessment of chemical mixtures, review 
of modern methods, including toxicokinetics (TK), OMICs and in silico tools, data collection activities, and an 
EFSA colloquium on the harmonisation of methods for human and ecological risk assessment of mixtures 
(EFSA, 2013a, 2014a, 2015a). 
 
From these activities and from the consultation with EFSA Panels and staff dealing with chemical risk 
assessment and with other experts from international bodies (ECHA, OECD, WHO, etc.), EFSA has formulated 
several recommendations to further develop methods for the risk assessment for mixtures. These include the 
refinement of:  
 
1. The detection and reporting of realistic mixtures in food and feed samples for exposure assessment, and  
2. The scientific basis to set cumulative assessment groups/assessment groups for chemicals based on their 
elimination patterns in a number of organisms (TK) and their combined toxicity profiles (dose addition, 
response addition) or interaction (i.e. synergistic effects/ antagonism) for further refinement of hazard 
characterization).  
3. Combining the refinements of 1 and 2 for risk characterisation and uncertainty analysis based on realistic 
mixtures in food and feed  
 
These recommendations are directly applicable to the refinement of methodologies for risk assessment of 
mycotoxin mixtures. In practice, mycotoxin data for specific realistic co-occurrence of free and 
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are then further combined with TK/toxicity profiles for risk characterization (De Mattsson, 2007; Steinmetz et 
al., 2009; Vettorazzi et al., 2013; Zhang et al., 2014; De Boevre et al., 2015).  
A major challenge is the understanding of the actual production of mycotoxin mixtures and consequently their 
realistic occurrence in plants and fruit (Streit et al., 2012). In order to address this challenge, the investigation 
of complex taxonomic, biochemical, genetic and environmental variables and conditions that would influence 
the biosynthesis and occurrence of mycotoxin mixtures in plants is needed. These variables include 
biosynthetic pathways, species/strain specificity on host species, climate change, temperature, resistance of 
the individual strains to fungicides and associated mechanisms, availability of nutrients and mycotoxin 
precursors etc., to name but a few (Abou et al., 2013; Blandino et al., 2015; Kabak and Dobson, 2015). 
1.2. Interpretation of the Terms of Reference 
The purpose of the contract is to develop an integrated innovative method, supported by modelling, for the 
risk assessment of mycotoxin mixtures in food and feed, promoting complex system understanding and 
knowledge gaps identification. Mycotoxins will be used as a model, for the development of a holistic approach, 
from accumulation during primary production to effects on human and animal health. MYCHIF (Mycotoxin 
mixtures in food and feed: holistic, innovative, flexible risk assessment modelling approach) method will be 
applied in case studies, defined in the project and in the future, it will be utilised by risk assessors dealing with 
mycotoxin mixtures for the food and feed area. The MYCHIF methods/tools development and validation will 
be described in detail to simplify any enlargement of their use to other contaminants or any integration with 
new data, if and when requested. The approach will focus on making the best use of the available scientific 
data, both for risk assessment and mitigation suggestions, and will underline the lack of knowledge as a driver 
to generate new data, all in a context of sustainability.  
 
The specific objectives are the following:  
 
Objective 1: Review knowledge available on relevant mycotoxin producing fungi in the main crops, 
accounting for fungi, host crops, environment and their interaction along the crop production chain; 
 
Objective 2: Generate a comprehensive database on occurrence/co-occurrence of mycotoxins in the 
considered crops; 
 
Objective 3: Review all toxicity data for single and co-occurring mycotoxins;  
 
Objective 4: Generate a comprehensive database on toxicokinetic, toxicodynamic, biomarkers and toxicity 
data; 
 
Objective 5: Develop a flexible and open access risk assessment model; 
 
Objective 6: Apply the risk assessment model to 5 case studies focused on the maize value chain (cropping 
system, food and feed, animal products, non-compliance, and future scenarios).  
 
2. Data and Methodologies 
Objectives 1-4 (Section 1.2) were addressed through Extensive Literature Searches (ELS). The protocol for 
the ELSs is described in the respective sections of the report including review questions (Section 2.1), 
eligibility criteria (Section 2.2) as well as the screening process (Section 2.3). 
2.1. Review questions and eligibility criteria for study selection 
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 Question WP1: fungi and mycotoxin production in the whole crop production chain, including 
modelling, fungal growth and toxin production. All relevant articles regarding fungi, host crops, 
mechanism of plant-pathogen interaction, cropping systems and the role of climate change on the 
biosynthesis of selected mycotoxins has been considered. 
 
 Question WP2: hazard identification and characterisation of mycotoxin mixtures (toxicity data)  
The following literature databases were searched to address WP1 and WP2: 
 
 MEDLINE® 
 CABI: CAB Abstracts® 
 FSTA® - Food Science Technology Abstracts 
 CAS - Chemical Abstracts Service 
 Biological Abstracts 
 ExcerptaMedica 
 SCI - Science Citation Index  
 
A pilot search was performed in order to check the consistency on the eligibility criteria. After the refinement 
of such criteria, ELSs were performed for WP1 and WP2. 
Due to the high number of publications retrieved from the databases, the searches were limited to papers 
published between 2010 and2017. Original articles published in languages such as Chinese, Japanese, Russian, 
or Arabic were excluded. Patents, editorials and letters were excluded from the searches.  
Table 1: Eligibility criteria for WP1 
STUDY QUESTION WP 1 Fungi and mycotoxin production in the whole crop production 
chain, including modelling fungal growth and toxin production. 
All relevant articles regarding fungi, host crops, mechanism of 
plant-pathogen interaction, cropping systems and the role of 
climate change in biosynthesis of selected mycotoxins has to be 
considered 
Study design  In In vitro/in vivo studies 
Out  
Language of the full text In Full-text document in English 
Out Chinese, Japanese, Russian, or Arabic 
Time In 2010-2017(a) 
Publication type In Report is primary research (i.e. studies generating new data) 
or data collection or systematic reviews 
Out Patents, editorials and letters 




Table 2: Eligibility criteria for WP2 
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Study design In Invitro/in vivo studies 
Out  
Language of the full text In  Full-text document in English 
Out Chinese, Japanese, Russian, or Arabic 
  
Time In  2010-2017(a) 
Publication type In  Report is primary research (i.e. studies generating new data) 
or data collection or systematic reviews 
Out  
(a) Additional records preceding 2010 were retrieved from the list of available references 
 
2.2. Extensive Literature Search (ELS) 
The strategy for the extensive literature searches was designed according to EFSA  guidance document on systematic review 
(EFSA, 2010a). Here, a strategy between Recall (retrieving as many relevant citations as possible) and Precision (eliminating 
as much noise as possible) was applied.  
All partners of the consortium were involved in the definition of: i) review questions, ii) search strategy and 
iii) identification of relevant key words. 
2.2.1. WP1: Fungi and mycotoxin production 
The search strategy was performed for seven (7) crops/crop groups, namely MAIZE, SMALL GRAINS, RICE, 
SORGHUM, NUTS, GRAPES and SPICES. 
The following crop-related terms were considered and searched within the title, the abstract or the keyword 
field: 
1. GRAPE#/TI,AB OR GRAPE#/BI 
2. MAIZE/TI,AB OR CORN/TI,AB OR ZEA MAYS/BI OR MAIZE/BI OR CORN/BI  
3. RICE/TI,AB OR RICE/BI OR ORYZA SATIVA/TI,AB OR ORYZA SATIVA/BI 
4. SORGHUM/TI,AB OR SORGHUM/BI 
5. SMALL GRAIN#/TI,AB 
BARLEY/TI,AB OR HORDEUM VULGARE/TI,AB 
WHEAT/TI,AB OR TRITICUM VULGARE/BI 
OAT/TI,AB OR AVENA SATIVA/TI,AB  
AVENA/BI 
RYE/TI,AB OR SECALE CEREALE/TI,AB OR SECALE/BI 
EINKORN/TI,AB OR TRITICUM MONOCOCCUM/TI,AB 
SPELT/TI,AB OR TRITICUM SPELTA/TI,AB 
TRITICALE/TI,AB OR TRITICALE/BI 
EMMER/TI,AB OR EMMER/BI 
6. SPICE#/TI,AB OR SPICES/BI 
7. PISTACHIO#/TI,AB OR PISTACHIO/BI OR PISTACIA VERA/TI,AB OR 
PEANUT#/TI,AB OR PEANUT/BI OR ARACHIS HYPOGAEA/TI,AB OR ALMOND#/TI,AB 
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HAZELNUT/BI OR OIL# SEED#/TI,AB OR NUT# TREE#/TI,AB OR TREE# 
NUT#/TI,AB 
Each group of crop-related terms was connected using the Boolean operator AND for the following sets of 
keywords: 
(FUNG##/TI,AB OR FUSARIUM/TI,AB OR ASPERGILLUS/TI,AB OR 
PENICILLIUM/TI,AB OR CLAVICEPS/TI,AB OR ALTERNARIA/TI,AB OR AAL TB 
TOXIN/TI,AB OR ALTERNARIOL/TI,AB OR ALTERNARIOL/BI OR FUSARIUM/BI OR 
FUNGI/BI OR ASPERGILLUS+NT/CT OR PENICILLIUM/BI OR CLAVICEPS/BI OR 
ALTERNARIA/BI) 
Afterwards, these were connected using the AND Boolean operator to a set of terms including all mycotoxin-
related terms and synonyms (e.g.: Mycotoxin# OR Aflatoxin# OR Ochratoxin# OR Fuminosin# 
etc.). 
Each set were subsequently connected using the AND Boolean operator for each of the following search-
group, namely, cropping, biosynthesis, occurrence and modelling. An example of search strings applied to 
maize is illustrated in Table 3. 
Table 3: Search strings applied to the extensive literature searches on maize mycotoxins (for WP1) 
WP1.  SEARCH STRINGS IN MAIZE 
 
Cropping [(maize OR corn OR Zea mays) AND (fung* OR Fusarium OR Aspergillus 
OR Penicillium OR Claviceps OR Alternaria OR AAL TB toxin OR Alternariol) 
AND (Mycotoxin* OR toxin* OR Aflatoxin* OR AF* OR Fumonisin OR FB* 
OR Deoxynivalenol OR DON OR Ochratoxin OR OTA OR Zearalenone OR ZEN 
OR ZEA OR Patulin OR PAT OR T2 OR HT2 OR Trichothecene* OR ergot 
alkaloids OR Beauvericin OR BEA OR Enniatin* OR ENN OR moniliformina 
OR MON) OR mycotoxin*(near)occur ORmycotoxin (near)Cooccur*OR 
mycotoxin (near)Co-occur* OR mycotoxin (near)Modified OR mycotoxin 
(near)Masked OR mycotoxin (near)Combined OR mycotoxin (near)Mixture 
OR mycotoxin (near)Conjugated)]AND[ (Cropping system OR Harvest OR 
Pre-harvest OR Irrigation OR Pest control OR Disease control OR Occurrence 
OR co-occur* OR growth OR sporulation OR ecolog* OR water activity OR 
Climat* change* OR meteorological(s)change* OR global warming OR 
weather conditions OR tropical* OR temperature OR climat* variation* OR 
metereological* variation*) AND (Post-harvest OR processing OR products 
OR storageORDerived products OR Processed products OR Final products) ] 
 
Biosynthesis [(maize OR corn OR zea mays) AND (fung* OR Fusarium OR Aspergillus OR 
Penicillium OR Claviceps OR Alternaria OR AAL TB toxin OR Alternariol) AND 
(Mycotoxin* OR toxin* OR Aflatoxin* OR AF* OR Fumonisin OR FB* OR 
Deoxynivalenol OR DON OR Ochratoxin OR OTA OR Zearalenone OR ZEN 
OR ZEA OR Patulin OR PAT OR T2 OR HT2 OR Trichothecene* OR ergot 
alkaloids OR Beauvericin OR BEA OR Enniatin* OR ENN OR moniliformina 
OR MON) OR mycotoxin*(near)occur ORmycotoxin (near)Cooccur*OR 
mycotoxin (near)Co-occur* OR mycotoxin (near)Modified OR mycotoxin 
(near)Masked OR mycotoxin (near)Combined OR mycotoxin (near)Mixture 
OR mycotoxin (near)Conjugated)]AND[Biosynthesis] 
Occurrence  [(maize OR corn OR zea mays) AND (fung* OR Fusarium OR Aspergillus OR 
Penicillium OR Claviceps OR Alternaria OR AAL TB toxin OR Alternariol) AND 





www.efsa.europa.eu/publications 14 EFSA Supporting publication 2020:EN-1757 
The present document has been produced and adopted by the bodies identified above as authors. This task has been carried out exclusively by the authors in the 
context of a contract between the European Food Safety Authority and the authors, awarded following a tender procedure. The present document is published 
complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food 
Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the 
rights of the authors. 
 
Deoxynivalenol OR DON OR Ochratoxin OR OTA OR Zearalenone OR ZEN 
OR ZEA OR Patulin OR PAT OR T2 OR HT2 OR Trichothecene* OR ergot 
alkaloids OR Beauvericin OR BEA OR Enniatin* OR ENN OR moniliformina 
OR MON) OR mycotoxin*(near)occur ORmycotoxin (near)Cooccur*OR 
mycotoxin (near)Co-occur* OR mycotoxin (near)Modified OR mycotoxin 
(near)Masked OR mycotoxin (near)Combined OR mycotoxin (near)Mixture 
OR mycotoxin (near)Conjugated)]AND[ (food OR dairy products OR milk 
OR yogurt OR  yoghurt OR cheese OR breakfast cereal* OR gluten free 
product* OR bread OR pasta OR wine OR raisin OR current OR juice OR 
beer OR malt OR feed OR silage OR forage OR fodder OR hay OR 
concentrate OR snaplage OR earlage OR By-Products OR Co-Products OR 
meal OR grain OR whole grains OR compliant OR legislation)] 
Modelling [(maize OR corn OR zea mays) AND (fung* OR Fusarium OR Aspergillus OR 
Penicillium OR Claviceps OR Alternaria OR AAL TB toxin OR Alternariol) AND 
(Mycotoxin* OR toxin* OR Aflatoxin* OR AF* OR Fumonisin OR FB* OR 
Deoxynivalenol OR DON OR Ochratoxin OR OTA OR Zearalenone OR ZEN 
OR ZEA OR Patulin OR PAT OR T2 OR HT2 OR Trichothecene* OR ergot 
alkaloids OR Beauvericin OR BEA OR Enniatin* OR ENN OR moniliformina 
OR MON) OR mycotoxin*(near)occur ORmycotoxin (near)Cooccur*OR 
mycotoxin (near)Co-occur* OR mycotoxin (near)Modified OR mycotoxin 
(near)Masked OR mycotoxin (near)Combined OR mycotoxin (near)Mixture 
OR mycotoxin (near)Conjugated)]AND[Modelling] 
 
For each group of crops, four (4) extensive literature searches were performed, for a total of 24 searches. 
From the total number of records, duplicate records from different database were removed. The number of 
selected records was 18774, as summarized in Table 4. 
Ad-hoc searches were made for specific topics leading up to 2000 when available information was insufficient. 
Table 4: Summary data regarding ELS for WP1 
EFSA SYSTEMATIC REVIEW  Extensive literaturesearch as preparatory work 
for: 
Fungi and mycotoxin production 
STUDY QUESTION  Fungi and mycotoxin production in the whole crop 
production chain, including modelling fungal growth and 
toxin production. All relevant articles regarding fungi, 
host crops, mechanism of plant-pathogen interaction, 
cropping systems and the role of climate change in 
biosynthesis of selected mycotoxins has to be 
considered 
Date access  April 2017 
Total N° of records retrieved 18774 
 
The references downloaded from literature databases, including all indexed fields per hit (e.g. title, authors, 
abstract, etc.), were managed - stored and classified - into separate Endnote TM 8 files, allowing a count of the 
individual hits per search and duplicate record removal.  
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For WP2, the ELS provided a basis for toxicity data collection for single and co-occurring mycotoxins.  
Due to the high number of documents present in the databases, the search was initially limited to papers 
published within the time span 2010-2017, as also agreed for WP1. Nonetheless, the paucity of relevant data 
for toxicity in vivo made searching the scientific literature published before 2010 necessary to reach a suitable 
data set for modelling (see sections below). This additional expert literature search found papers spanning 
from 1976. Also in this search, original articles published in languages such as Chinese, Japanese, Russian, or 
Arabic, as well as patents, editorials and letters were excluded from the search. 
The core of the ELS for WP2 is represented by the set containing all mycotoxin-related terms, in the title, the 
abstract or the controlled terms field of the record: 
 
MYCOTOXIN#/TI,AB  OR AFLATOXIN#/TI,AB OR FUMONISIN#/TI,AB OR 
DEOXYNIVALENOL/TI,AB OR OCHRATOXIN#/TI,AB OR ZEARALENONE/TI,AB OR 
PATULIN/TI,AB OR TRICHOTHECENE#/TI,AB OR ERGOT ALKALOID#/TI,AB OR T2 
TOXIN#/TI,AB OR HT2 TOXIN#/TI,AB OR T2 OR TRIOL/TI,AB OR BEAUVERICIN/TI,AB 
OR ENNIATIN#/TI,AB OR MONILIFORMIN/TI,AB OR MYCOTOXINS+NT/CT OR 
AFLATOXINS+NT/CT OR FUMONISINS/BI OR DEOXYNIVALENOL/BI OR 
OCHRATOXINS/BI OR ZEARALENONE/BI OR PATULIN/BI OR TRICHOTHECENES+NT/CT 
OR ERGOT ALKALOIDS+NT/CT OR BEAUVERICIN/BI OR ENNIATINS/BI OR 
MONILIFORMIN/BI OR FUMONISIN/BI OR OCHRATOXIN/BI ORTRICHOTHECENE/BI OR 
BEAUVERICINS/BI OR ENNIATIN/BI 
 




 ANALYTICAL METHODS 
 TOXICOKYNETICS 
 MODELLING 
Five (5) literature searches were performed, one for each aspect. Each search was later limited to the 
following species:  
 (HUMANS/BI OR CHILD/BI OR INFANT/BI) OR (MAN OR MEN OR WOMAN OR WOMEN) 
OR (CHILD OR CHILDREN) OR (FOETUS OR FETUS OR TODDLER#) OR  (INFANT# OR 
INFANCY OR ADOLESCENT#) OR (ADOLESCENCE OR ADULT#) OR ADOLESCENTS/BI OR 
(RAT OR RATS OR MOUSE OR MICE) OR  (PIG# OR SWINE OR COW# OR CATTLE OR 
CHICKEN) OR (POULTRY OR TURKEY OR DUCK OR FISH##) OR  (CAT OR CATS OR DOG 
OR DOGS) OR (RABBIT OR RABBITS) OR (RATS/BI OR DOGS/BI) OR  (CHICKENS/BI OR 
CATTLE/BI) OR (POULTRY/BI OR TURKEY/BI) OR (DUCKS/BI OR FISHES/BI)  
From the total number of records for each of the five subtopics, from different database were removed; the 
gran-total of selected records was 20440. 
 
Table 5: Summary data regarding ELS for WP2 
EFSA SYSTEMATIC REVIEW  EXTENSIVE LITERATURESEARCH AS PREPARATORY 
WORK FOR: 
Toxicity data for mycotoxins and hazard identification 
STUDY QUESTION  Toxicity data for mycotoxins and hazard identification 
Date accessed  May 2017 
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The research strategy and the terminology for the search were agreed upon and adopted in advance by the 
relevant partners responsible for managing WP2. The keywords used were related to mycotoxins, their toxicity 
(single and mixture) in human health, livestock and companion animals.   
The output of the search was organised in an Endnote TM 8 file where the total number of papers was counted 
and duplicates were removed.   
2.3. Study selection process 
2.3.1. WP1 
The resulting records underwent a two-step selection procedure after duplicate removal: 
1) Screening of title and abstract to identify potentially relevant studies that will be included for full-
text screening, applying the eligibility criteria described in section 2.1. If the information contained in 
the title or abstract was not relevant to the research objectives, the article was not selected for full-
text assessment. 
 
2) Full-text screening. Subsequent screening for studies passing the first step was based on the full-
text article to assess if the article was relevant to the research objectives. Regarding occurrence, the 
presence of quantitative data was considered as inclusion criteria. 
Articles that were excluded during screening were stored in Endnote TM 8. The outcomes of the screening 
process are reported in Table 6. Furthermore, the results of the different phases of the study selection process 
are duly reported in flowcharts by each crop search (Figure 1, Figure 2, Figure 3, Figure 4, Figure 5, Figure 6 
and Figure 7). 
The screening process followed the same approach for all considered crops. During the screening process, 
studies were categorised in different groups corresponding to the WP1 tasks. All selected papers contributed 
to the preparation of individual reports and review articles.  
 
Table 6: Number of records in each step of the selection flow by each crop search-groups 





















Maize      
Cropping 1611 154 942 515 452 
Modelling 82 1 58 23 17 
Occurrence 5016 97 4555 364 222 
Small grains      
Cropping 1311 29 979 303 241 
Modelling 83 1 50 32 25 
Occurrence 4449 0 3914 535 266 
Rice      
Cropping 990 18 850 122 107 
Modelling 38 2 32 4 3 
Occurrence 2968 49 2743 176 63 
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Cropping 161 3 135 23 23 
Modelling 6 1 5 0 0 
Occurrence 593 13 537 43 21 
Nuts      
Cropping 459 21 235 203 39 
Modelling 13 0 8 5 3 
Occurrence 1088 20 968 100 13 
Grapes      
Cropping 502 10 356 136 106 
Modelling 18 0 14 4 4 
Occurrence 1453 32 1322 99 33 
Spices      
Cropping 168 6 136 26 20 
Modelling 2 0 1 1 1 
Occurrence 383 14 297 72 39 
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Figure 2: Flow diagram of the study selection in small grains 
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Figure 4: Flow diagram of the study selection in sorghum 
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Figure 6: Flow diagram of the study selection in grapes 
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The ELS library for maize included 6709 records, organized as indicated in Table 6. The screening process 
selected 452 records accounting for fungi, host crops, environment and their interaction along the crop 
production chain and 17 regarding modelling. Regarding occurrence, the presence of quantitative data was 
considered as inclusion criteria. In maize, papers passing the full text screening were 222 (40 with occurrence 
data from EU countries and 182 with occurrence data from non EU countries). Only the papers with occurrence 
data from EU countries were extracted (Figure 1). Due to the limited number of papers retrieved on co-
occurrence in maize, an additional literature search was performed. The literature search was extended to the 
timeframe from 2000 to 2009 and 2017-2018 (June). In total an additional number of 12 papers were 
considered for the extraction of mycotoxin occurrence in maize. More details on the integrating ELS for maize 
are reported below. The following databases were used:  
• MEDLINE®  
• CABI: CAB Abstracts® 
• PubMed® 
 
The following terms were considered from the title and/or the abstract: 
((maize or corn or zea mays) and (fung* or Fusarium or Aspergillus or Penicillium or Claviceps or Alternaria or 
AAL TB toxin or Alternariol) and (Mycotoxin* or toxin* or Aflatoxin* or AF* or Fumonisin or FB* or 
Deoxynivalenol or DON or Ochratoxin or OTA or Zearalenone or ZEN or ZEA or Patulin or PAT or T2 or HT2 or 
Trichothecene* or ergot alkaloids or Beauvericin or BEA or Enniatin* or ENN or moniliformina or MON) and 
((occur* or co-occur* or cooccur*)) 
For small grains, records were initially screened for their relevance to WP1, considering the different species 
included (barley, oat, wheat and other grains). Within the set of data from the small grains library, 285 
publications reported the occurrence of mycotoxins in different food commodities and were included. Of these, 
151 were from non-EU countries, remaining 149 in which occurrence and co-occurrence data were present 
(Figure 2). Fifteen additional papers were included from 2000 to 2009. 
The ELS library for rice included 3996 records, organized as indicated in Table 6. After duplicate removal and 
first screening, 126 records were selected from cropping and modelling search-groups. The full text of most 
of these records was retrieved for the report preparation, but, at this stage, some records were excluded (16 
records) for different reasons: 
 
 a full text was not available (e.g., abstract published in conference proceeding books); 
 not possible to retrieve the full text (e.g., error in doi); or 
 other 
Based on the information retrieved so far, it is possible to state that most of the information relates to the 
occurrence of mycotoxins, mainly from fermented rice products, where citrinin is the main occurring mycotoxin. 
Although 63 records were selected, only 4 were used to extract data on occurrence in EU countries (Figure 3). 
Four additional papers were included from 2000 to 2009. 
The ELS library for sorghum included initially 760 records, organized as indicated in Table 6. The screening 
process selected 23 records accounting for fungi, host crops, environment and their interaction along the crop 
production chain. Regarding co- and occurrence in sorghum, 21 records passed the screening process, but 
only one has data from EU countries, while the remaining 20 have data from non EU countries. Due to the 
limited number of papers retrieved on co- and occurrence in sorghum in Europe, an additional literature search 
was performed. The literature search was extended to the timeframe from 2000 to 2009 and 2017-2018. Ten 
out of the nineteen additional records retrieved were selected after screening. However, of these ten only one 
record reported data from Europe. Thus, data on occurrence in sorghum were extracted from only 2 papers 
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More details on the integrating ELS for sorghum are reported below. The following databases were used:  
• MEDLINE®  
• CABI: CAB Abstracts® 
• PubMed® 
 
The following terms were considered, to be present either in the title and abstract: 
(((sorghum) AND (fung* OR fusarium OR aspergillus OR penicillium OR claviceps OR alternaria OR aaltb toxin 
OR alternariol)) AND (Mycotoxin* OR toxin* OR Aflatoxin* OR AF OR fumonisin OR FB OR deoxynivalenol OR 
DON OR ochratoxin OR OTA OR zearalenone OR ZEN OR ZEA OR patulin OR PAT OR T2 OR HT2 OR 
Trichothecene* OR ergot alkaloids OR beauvericin OR BEA OR Enniatin* OR ENN OR moniliformin OR MON)) 
AND (occur* OR co-occur* OR cooccur*) 
The ELS library for nuts included 1560 records. The screening process selected 39 records accounting for 
fungi, host crops, environment and their interaction along the crop production chain and 3 regarding modelling. 
Regarding occurrence in nuts, papers passing the full text screening were 13 (5 with occurrence data from EU 
countries and 8 with occurrence data from non EU countries). Only the available papers with occurrence data 
from EU countries were extracted (Figure 5).  
The ELS library for grapes included initially 1973 records, organized as indicated in Table 6. Following the 
same selection process, the number of selected records (after full-text retrieval and screening for occurrence 
data) was reduced to 239. Based on the information retrieved so far, it is possible to observe that most of the 
published works relates with the occurrence and the ecology of Aspergillus species (predominantly black 
Aspergilli species), the occurrence of ochratoxin A (OTA) in wines, and the inhibition of OTA production. 
Regarding mycotoxin occurrence, 33 records were retrieved, being 14 from countries outside the EU and the 
remaining 19 included in database (Figure 4). 
In ELS library for spices, 553 records were initially present. The screening flow led to 20 records retrieved 
from the cropping search-group and only 1 related to modelling. Of the final 39 records with occurrence data, 
30 were from countries outside the EU, remaining 9 to be included in database. Of these, studies included a 
wide range of spices, with different varieties of pepper being the most usually analyzed.  
Records on biosynthesis were initially divided by crop. In order to have them by mycotoxin, they were 
merged in one Endnote TM 8 library. The final number of records after duplicates removal and screening (title 
and abstract) was 306. However, most of the papers deal with the biosyntehsis of single compounds. 
Therefore, the authors integrated the ELS according to their expertise, and focus on the formation of modified 
mycotoxins in plants. The authors also noticed that the factors regulating the interaction between fungi and 
the subsequent accumulation of multiple mycotoxins are still unknown so far. 
 
Regarding modelling, 242 records were retrieved among the seven considered crop groups and, 53(21%) 
records passed the selection screening (full-text retrieval). 42 (80%) of the included records, concern maize 
and small grains, and 11 records (20%) regard the remaining crops (grapes (4), nuts (3), rice (3) and spices 
(1)). Among the small grain group, wheat is the predominant cereal crop with 18 records out of 25 (72%); 2 
papers were found on oat. No record has been found in sorghum. The majority of retrieved records regard 
modelling fungi growth and mycotoxin production under in vitro condition, whereas our interest refers to 
modelling mycotoxin contamination in crops under field condition. Based on the information retrieved, it is 
possible to notice that no major improvement have been achieved on this topic since the last review by 
(Battilani et al., 2016). We confirm the focus in modelling mycotoxin in few crops, including maize and other 
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2.3.2. WP2 
This section presents the inclusion/exclusion criteria and the outcome of the ELS for the toxicokinetics, toxicity 
and biomarker studies. 
Papers pertaining to WP2 were initially screened starting from toxicokinetics (TK), to set up common 
inclusion/exclusion criteria to be used for further refinement of the ELSs.  
2.3.2.1. Toxicokinetic data 
The screening of the papers providing toxicokinetic studies was based on the relevance of the papers with 
regards to absorption, distribution, metabolism, excretion, bioavailability and carry-over of selected mycotoxins 
in target species (as specified in the Section 2.2.2). The process consisted of two steps: 
1. Screening of the titles and abstracts of all publications. Publications included at this stage, were 
analysed in the second step; 
2. Screening of the full text of the publications included. Publications considered relevant, were examined 
for inclusion within the report. 
In order to perform the screening in a harmonised way appropriated inclusion and exclusion criteria were 
adopted, as reported below  
Inclusion criteria: 
 
 The paper addressing toxicokinetic data for single and/or co-occurring mycotoxins 
 Study design: 
-in vivo experimental laboratory studies 
-in vivo field/semi-field studies  
-in vitro model-based studies 
 Outcome of interest: 
Data and information relating to the toxicokinetic effects of single or mixtures of mycotoxins (ADME, 
bioavailability, carry over) 
Exclusion criteria 
 Duplicated studies: the most recent one was usually carried to data extraction 
 Studies reporting data on mixtures having a potential antagonistic interaction effect on toxicity (i.e. 
mycotoxin + quercetin). The outcome of the ELS for both in vitro and in vivo toxicokinetics is shown 
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Figure 8: Flow diagram on the study selection for toxicokinetics (in vivo and in vitro) 
As complementary activity, UNIPR set up a template for data collection, to be used for literature meta-analysis 
and modelling. A spreadsheet format has been agreed for practical reasons (i.e. wider distributability and 
usability among the WP operators than other options). The template to collect toxicokinetic data in vitro and 
in vivo (Appendix B.5 and B.6) attached to this report is based on modifying the toxicokinetic OECD template 
to facilitate data mining and data extraction for modelling. It is highly detailed and allows for the collection of 
a large number of parameters.  
In the final filtering, which covered also the full text of articles, the following strategy was applied: 
Mixture data 
 Collection of data from papers mentioning co-occurrence/co-exposure of mycotoxins  
 Separation of papers by experimental animal species 
 Identifying the papers with dose response data  
Single compound data 
 Division of papers by mycotoxin  
 Separation of papers by experimental animal species 
 Identification of papers with dose response data  
 
2.3.2.2. Toxicity data  
Concerning the filtering process for toxicity data, 7599 papers were identified in the ELS and were filtered on 
the basis of the most common occurring mycotoxins (deoxynivalenol, aflatoxins, fumonisins, zearalenone) as 
single compounds and their possible co-occurrence. Target species included the most relevant farm animal 
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The inclusion criteria for the data extraction and to design the template for the data collection were defined 
as:  
- in field, semi-field or laboratory in vivo study 
- relevant endpoints for risk assessment  
- toxicity assessed for single compound AND mixture 
- multiple doses for a possible dose response (BMDL) assessment 
Exclusion criteria were the same used for TK (i.e., duplicated studies and studies reporting mixtures with 
compounds having potential protective effects were not considered for the data extraction). In addition, in 
vitro experiments and studies addressing individual toxins assessment or mixtures assessment lacking the 
assessment of single compound effects were excluded too. The outcome of the papers screening regarding 
toxicity is shown in Figure 9 below. 
 
Figure 9: Flow diagram on the study selection for in vivo toxicity 
From the total number of papers only 53 papers matched the above-mentioned inclusion criteria although the 
papers identified included only single mycotoxin exposure. Therefore, an additional literature search before 
2011 was done resulting in an additional set of relevant papers (n=65), including both single and mixture 
treatments and published between 1976 and 2010, which were not included in the ELS output. This selection 
of papers was used for the data extraction. As done for TK analysis, a template for data collection and 
modelling has been provided as a framework method tool. The templates developed to collect data are 
reported in (Appendix B.1).  
 
2.3.2.3. Biomarkers of exposure and effects 
In this research, the extensive literature search retrieved a total of 5753 records that were submitted to the 
inclusion/exclusion criteria step. Figure 10 shows the outcome of the papers screening regarding biomarkers. 
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• All studies on food analysis (ex. occurrence); 
• All studies on toxicology (without biomarker info); 
• All studies on biomarker of effect where the effects affected cell mechanisms or cellular metabolites 
or changes in protein pathway or DNA repair pathway and genetic expression; 
• All studies on parameter associated to mycotoxins but not H/A exposure specific (fungal activity, 
plant activity); 
• All studies on analytical methods not intended for biomarkers 
 
Figure 10: Flow diagram on the study selection for biomarkers 
 
The 86% (n=4943 over 5753) of the records were excluded as not inherent with the specific biomarker 
topic; while the rest of the records (n=810) where categorized as follows: 
 Records reporting biomarkers of exposure information (human and animal) (70%) 
 Records focused on studies about biomarkers of effect (41%) 
 Records focused on toxicological study but containing biomarkers information (18%) 
 Records focused on toxicokinetic study but containing biomarkers information (6%) 
 Validation of the analytical method for biomarker analysis (5%). 
Table 7: Percentages of papers found for each screening category divided for human and animal species 
(screening not completed) 
Screening category Human Mice Broilers Pig Dog Cow beef 
Biomarkers of exposure  58% 0 1% 45% 5% 2% 
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Toxicological studies with data 
on biomarkers  
10% 0 0 3% 4% 0 
Toxicokinetic study with data 
on biomarkers  
1% 2% 3% 0 0 0 
Validation of the analytical 
method for biomarker analysis  
4% 0 0 0 0 1% 
 
Thus, all the included records were scrutinized to derive the list of indicators and parameters to be used. The 
list was shared with partners for further discussion and a final definitive list was established. 
For the prioritisation of the biomarkers paper scrutiny, the following strategy was performed for both mixture 
and single biomarker data. 
 Collection of data from papers mentioning biomarker measurements;  
 Collection of all critical information from the paper; 
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2.3.2.4. Analytical methods 
A total of 12057 records retrieved from the literature were submitted to the inclusion/exclusion criteria step. 
The 55% (n= 6714) of the records were excluded as not inherent with the specific topic; while the included 
records (n=5343) where grouped in 11 categories, as shown in Figure 11. 
 
 
Figure 11: Flow diagram of the study selection process for methods of analysis 
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2.4. Data extraction 
2.4.1. Data extraction on occurrence and co-occurrence 
Data on occurrence and co-occurrence of mycotoxins in maize, small grains, rice, sorghum, nuts, grapes and 
spices were extracted from the included papers. Data extraction was performed partially manually or by using 
the tool called Tabula 1.1.1. A data model for data collection on mycotoxins occurrence/co-occurrence at 
aggregated level was developed according to EFSA requirements (Appendix A.1). The aim of this collection 
was to review available information on occurrence/co-occurrence to be used for further analysis. Moreover, 
UCSC prepared a second excel table for data collection at sample level according to the SSD2 standards, to 
be performed at a later stage and submitted to EFSA for validation. However, the restricted number of studies 
retrieved on occurrence data at sample level, did not allow any further analysis. 
2.4.2. Data extraction on toxicity and toxicokinetics 
For the prioritisation of the toxicity and toxicokinetic studies the following strategy was performed. 
 Mixture data 
- Collection of data from papers mentioning co-occurrence/co-exposure of mycotoxins  
- Separation of papers by experimental animal species 
- Identifying the papers with dose response data  
 
 Single compound data 
- Division of papers by mycotoxin  
- Separation of papers by experimental animal species 
- Identification of papers with dose-response data  
To represent the type and amount of data available and in accordance with the aforementioned criteria, two 
tables were prepared (Appendix B.3 and B.4).   
Template forms for data extraction, structured according to the relevance of the data provided and based on 
the outcomes of interest were developed. The extraction grids were prepared separately for each literature 
search and for each relevant endpoint (toxicity, toxicokinetics in vitro and toxicokinetic in vivo).   
2.4.2.1. Toxicity  
After a preliminary screening of the selection of papers, the template was outlined taking into consideration 
the relevant toxicological endpoints accounted in the studies. The original design aimed to provide an overview 
of the studied endpoints, summarizing each study in a single row. A posterior version of the template allocated 
each dose group to an individual row for higher detail. In the final version of the template numerical values 
and unit of measurement were included in the design to facilitate data mining and modelling. As mentioned 
in section 2.3.2.2 an additional search was performed for single and mycotoxin mixture studies covering the 
years before 2010, both templates are presented below and examples can be found in the Appendix B.1 
and B.2. 
The template for the toxicity studies ranging between 1976 and 2010 included the following: 
 The first columns present the toxin being tested as well as the study in question: “Toxin”, “DOI” and 
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 The following columns give information on the species, exposure time and route of administration: 
“Production (Purity)”, “Origin”, “Species”, “Duration of exposure”, “Exposure” and “Route of 
administration”, “Dose”, “Replicates”, “Number of animals” and “Sex”; 
 The next columns reflect on toxicological endpoints such as “Weight”, “Microscopic findings”, 
“Macroscopic findings”, “Haematology”, “Biochemistry”, “Cancer incidence” and “Mortality rate”. 
Parameters typically included in toxicity which will be detailed in the next criteria. 
An example of the template columns including information extracted from the literature can be found in the 
Appendix B.1. 
The template for toxicity studies ranging between 2010 and 2017 included the following: 
 The first columns include details on the study (“Author”, “Year”, “Title”)  
 Columns covering species information (“Species”, “Strain”, “Sex”, “Initial age”, “Initial body weight”, 
“Sample size”)  
 Mycotoxin information including dose and exposure (“Mycotoxin”, Time of exposure”, “Dose in the 
feed”, “Dose”, “Exposure feed/gavage”) 
Toxicological endpoints including the observed effect values (“Effect”, “NOAEL”, “LOAEL”, “Mean observed 
value”, “Statistical descriptor”. 
2.4.2.2. Toxicokinetics 
The purpose of the template for toxicokinetics in vivo was the collection of all the relevant quantitative and 
qualitative TK parameters in order to feed the predictive models. 
 The first columns present the reference, the experimental animal with its “sample size”, the 
“administrated dose” (in harmonised units), the “toxin source” and its “route of administration”. 
 The following columns represent relevant TK parameters relevant to absorption like the “per cent of 
the total absorption” and “bioavailability (%)”. 
 Additional grids are added for the metabolic and distribution criteria; “t1/2 el”: the time it takes for 
the concentration of the compound to decrease by 50%, “AUC”: area under the plasma (blood) level 
vs. time curve from zero up to a certain measured time point, “Cmax”: maximum (peak) concentration 
“Tmax”: time to reach peak or maximum concentration following administration, “Vmax”: maximum 
elimination capacity, “Km”: concentration at 50% of Vmax 
 The next columns address excretion parameters like; “excretion route”, “% of dose excreted”, 
“excretion time observed”. 
 Finally, the last grids of the template refer to “carry-over rate”, “target tissue” “toxin concentration” 
and the “analytes considered for evaluation". 
 
Analogously, the purpose of the template for toxicokinetics in vitro was the collection of relevant aspects of 
mycotoxins kinetics such as:  
 Cell/tissue type, or cell organells involved in the process 
 Types of transports, exposure time and excretion rate 
 Production of phase I and phase II metabolites, and respective transformation yield  
 Transforming enzymes (e.g. CYPs)  
 Kinetic parameters such as Ki, Km, permeability, intrinsic clearance (Clint), maximum bioavailability 
(fmax) and Vmax 
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After sharing and adjusting for the most appropriate format with the kind of indicators of interest, the following 
info/group of information were identified to be registered from each record to feed the dataset: 
 Reference   
 Information about the biomarker and the study (Type of study, Mycotoxin, Biomarker, Substrate, 
Country, SampleSize, SampleType, Age, SamplePeriod) 
 Information on the quantification and statistics of the biomarker (Mean, Median, GeometricMean, SD, 
Percentile, Percentile_ INFO, Unit, Min, Max, Creatinine/Albumine corrected, Biomarker 
Creatinine/Albumine, Biomarker creatinineUnit, Biomarker_INFO) 
 Information about the analytical methods (Analytical method, Method Validation, Method 
Validation_INFO, Method LOQ, Method LOD, LOQunit, LODunit, Other_parameter_ 
labeledstandards_INFO_NOTA  
 Type of sampling strategy used  
 Information about the correlation with food intake or exposure assessment calculations 
(Correlation_food, Any correlation with food intake, Exposure assessment, ExpAss_Value, Expass_Unit
 
 Information on biomarker validation process  
 Other notes 
The comprehensive indicator list is reported in (Appendix B.5). The list of recurrent indicators and 
explanation retrieved is reported in (Appendix B.6). 
The template characteristics were defined to record one line for each biomarker and to ensure: 
 an easy legible content with the best information  
 relevant information of the selected indicators  
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2.5. Database development 
2.5.1. Development of a structured database across the WP1-2 
All data extracted for mycotoxin occurrence/co-occurrence (Section 2.4) were stored in proper databases 
and interfaced to R environment for statistical computing and graphics. Appendix A.1 provide a 
comprehensive data elements description about the database as a whole for occurrence and co-occurrence of 
mycotoxins in maize, small grains, rice, sorghum, grapes, nuts and spices. 
This approach has been shared with all project partners and the following description is also common for the 
in-progress databases related to toxicity, toxicokinetics in vitro, toxicokinetic in vivo and biomarkers 
(Appendix B.1, B.2, B.3 and B.6). This common approach enables the data analysis through a set of R 
functions to be able to find, access and use data and it will facilitate modelling implementation (WP3). All the 
DB files and functions are currently available on the MYCHIF project repository and EFSA knowledge junction 
(10.5281/zenodo.3615174). 
Appendix C.1 and C.2 provide, respectively, the list of abbreviations and encoding keys.  
2.5.2. Data Analysis  
The following query keys were assigned to extract data and perform a qualitative and a first quantitative 
analysis assessment: 
each "PARAMTYPE" & each "sampMatbased" & each "sampMatType" 
where "PARAMTYPE" are all the toxins reported in (Appendix C.2). 
where "sampMatbased" are maize, rice, grapes, almond, barley, buckwheat, caraway, cereals, durum 
wheat, millet, oat, peanuts, rye, soft wheat, soy, spelt, triticale, walnuts, wheat, glutenfree 
where "sampMatType" are food, feed and raw materials 
For each data extraction a ECDF object and plot (empirical cumulative distribution function) has been created 
(Figure 12) for the "Concentration" value and if not available for the "meanTot" value. All the ECDFs plots are 
available on MYCHIF project repository and EFSA knowledge junction (10.5281/zenodo.3615174). Two kinds 
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Figure 12: fitting ECDF example for Maize+ZEN+Raw material, "meanTot" value 
 
Figure 13: simple ECDF example for Maize+ZEN+Raw material, "meanTot" value 
 
After the ECDF analytics, the first basic step in a Quantitative Risk Assessement (QRA) is to generate amplified 
data by using a Monte-Carlo simulation (R package mc2d) that considers the parameter (toxin) as a random 
variable having a predefined theoretical probability distribution. Considering that each parameter is both 
uncertain and variable, we have specified a bounded set of candidate parametric distribution (Poisson, 
lognormal, exponential etc.) and obtained distribution plot representing the potential variability of parameters 
investigated (Figure 14 and Figure 15). 
 
Figure 14: QQplotfor DON+RawMaterial+Maize, "concentration value", a graph of the cumulative empirical 
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Figure 15: QQplot for DON+RawMaterial+Maize, "concentration value", a) theoretical quantiles; b) Poisson 
parametric distribution 
Furthermore, for each data extraction a summary table has been exported with the following data (Table 8). 






















































































(a): Keys: the assigned keys for data extraction; Concentration_Mean: mean of total samples; TotresValUncertSD_Mean: mean of 
standard deviation of total samples; meanTot: mean of mean total samples; POSresValUncertSD: mean of standard deviation of 
positive samples; meanPos: mean of mean positive samples; min: minimum of minimum total samples; mas: maximum of 
maximum total samples; LOD: mean of total LOD samples (%); tot sample: number of total samples; Record: number of total 
records; Nsample_concentration: number of samples with concentration value; Nsample_meanTot: number of samples with 
meanTot value. 
Regarding co-occurrence analysis, a first attempt of analysis has been performed, data extraction rules are 
based on the following keys: 
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where "sampMatbased" and "sampMatType" are the same as defined above, "Co-occurrence=1" means only 
samples where co-occurrence has been reported, "Ref" and "SampSize" are the papers and the size of samples 
to group only the same samples data.  
All the tables are available on MYCHIF project repository and EFSA knowledge junction 
(10.5281/zenodo.3615174). 
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3.1. Mycotoxin producing fungi 
Worldwide, the most relevant and studied mycotoxins are synthesised by fungal species belonging to three 
genera: Aspergillus spp., Fusarium spp. and Penicillium spp., and on a minor extent by Alternaria spp. and 
Claviceps spp. Mycotoxigenic fungi are commonly not host specific, but their occurrence is mainly signalled in 
a specific crop depending on its growing area and meteorological conditions (Table 10).  
Table 10: Some fungal species of interest with corresponding mycotoxins and their primary crop hosts 
Fungi source Mycotoxins(a)(b) Crops of primary concern 
Aspergillus spp.   
A. carbonarius OTA grapes, pistachio nuts 
A. flavus AFB1, AFB2, STC maize, rice, grapes, sorghum, nuts (mainly peanuts, 
pistachio and almond nuts) 
A. niger OTA, FB2 grapes, sorghum, nuts (mainly peanuts, pistachio and 
almond nuts) 
A. ochraceus OTA rice, grapes, nuts 
A. parasiticus AFB1, AFB2, AFG1, AFG2, 
STC 
maize, nuts (mainly peanuts, pistachio and almond 
nuts) 
A. tubingensis OTA sorghum 
A. versicolor STC rice 
Fusarium spp.   
F. armeniacum T-2, HT-2 rice 
F. avenaceum ENNs, MON small grains (mainly wheat, barley, oat), grapes 
F. culmorum DON, AcDONs, NIV, ZEN maize, small grains (mainly wheat, barley, oat) 
F. equiseti   ZEN maize, small grains (mainly wheat, barley, oat) 
F. fujikuroi FB1, MON, GA rice 
F. graminearum DON, AcDONs, NIV, ZEN maize, small grains (mainly wheat, barley, oat), rice 
F. incarnatum ZEN sorghum 
F. langhsethiae T-2, HT-2 maize, small grains (mainly wheat, barley, oat) 
F. nivale NIV small grains (mainly wheat, barley, oat) 
F. oxysporum  ENNs, MON, BEA grapes 
F. poae NIV, T2- HT2, DON, AcDONs, 
DAS, ENNs 
small grains (mainly wheat, barley, oat) 
F. proliferatum 
FBs, BEA, FUS, MON 




DON small grains (mainly wheat, barley, oat) 
F. pseudonygamai FBs sorghum 
F. sporotrichioides T-2, HT-2 maize, small grains (mainly wheat, barley, oat), grapes 
F. subglutinans BEA, FUS, MON maize, rice 
F. temperatum FBs, BEA, FUS, MON, ENNs maize 
F. thapsinum ZEN sorghum 
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Penicillium spp.   
P. aurantiogriseum PAC  rice 
P. citreonigrum CTN rice 
P. citrinum CIT rice 
P. commune CPA rice 
P. expansum  PAT, CIT grapes 
P. islandicum CC, uteoskyrin rice 
P. rugulosum Rugulosin rice 
P. verrucosum CIT, OTA wheat, rice, grapes 
Alternaria spp.   
A. alternata ATs  grapes 
A. infectoria ATs rice 
A. tenuissima ATs rice 
Claviceps spp.   
C. africana EAs sorghum 
C. purpurea EAs small grains (mainly wheat, barley, oat) 
C. sorghi EAs sorghum 
C. sorghicola EAs sorghum 
(a) AFs: aflatoxins; AFB1: aflatoxin B1; AFB2: aflatoxin B2; AFG1: aflatoxin G1; AFG2: aflatoxin G2; ATs: Alternaria toxins; 
BEA: beauvericin; CC: cyclochlorotin; CIT: Citrinin; CPA: cyclopiazonic acid; CTN: citreoviridin; DON: deoxynivalenol; AcDONs: 
acetyldeoxynivalenols; EAs: ergot alkaloids; ENNs: enniatins; FBs: fumonisins; FB1: fumonisin B1; FB2: fumonisin B2; FUS: 
fusaproliferin; DAS: diacetoxyscirpenol; GA: gibberellic acid; HT-2: HT-2 toxin; MON: moniliformin; NIV: nivalenol; OTA: 
ochratoxin A; PAC: penicillic acid; PAT: patulin; STC: sterigmatocystin; T-2: T-2 toxin; ZEN: zearalenone 
(b) the complete list of mycotoxin abbreviations is provided in Appendix C.2  
 
Temperature (T), relative humidity (RH), rainfall (R) and, above all, water activity (aw) are the most important 
ecological factors influencing fungal colonisation of the substrate, and every species has its peculiar ecological 
needs. Fungal growth can occur in a wide range of aw and T and, optimal conditions for fungal growth do not 
always correspond to those appropriate for mycotoxin biosynthesis. Furthermore, host crop-fungi interaction 
impacts on the ecophysiology of fungi; therefore, it is difficult to withdraw summary information. For a general 
overview, main findings regarding T and aw range for fungal growth and mycotoxin production in the most 
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Table 11: Temperatures (°C) needed for the fungal growth and mycotoxin production for same of the most 
relevant species isolated in different crops  
 
 
Data on ecological needs are available for several Aspergilli, A. flavus, A. carbonarius, A. ochraceus and A. 
versicolor. A. versicolor is reported as the most flexible in term of T requirements, being able to grow from 5 
to 40 °C; A. carbonarius has the narrower useful T range, from 15 to 40°C. Regarding toxin production, the 
suitable range of T is always much more limiting compared to growth and they all produce toxins optimally 
between 25 and 30°C. Fusarium graminearum and F. verticillioides are the most important species among 
Fusaria. F. verticillioides is known to be more thermophilic compared to F. graminearum, but they have 
comparable suitable T ranges for growth. Optimum for FBs production is switched towards lower temperature 
respect to fungal growth. Interesting for F. graminearum is the difference between optimal conditions for DON 
and ZEN production, the former close to 30°C the latter below 25°C. Penicillia are less thermophilic compared 
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Table 12: Values of the water activity (aw) needed for the fungal growth and mycotoxin production for 
same of the most relevant species isolated in different crops 
 
3.1.1. Good agricultural and management practices  
Managing mycotoxin contamination requires a comprehensive strategy that includes a correct pre-harvest 
management and good harvest and post-harvest procedures. Figure 16 summarizes the effect of the main 
growing, handling and processing steps in the occurrence and  fate of mycotoxins for the main crops 
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 Figure 16: Table reporting the effect of good agricultural and management practices pre- and post-harvest 
and their impact on the occurrence and fate of mycotoxins in the food and feed chain 
 
3.1.1.1. Pre-harvest management 
Several research efforts have defined good agricultural practices (GAPs) to apply during pre-harvest, including: 
(i) choice of variety/hybrid, (ii) soil management, (iii) burial of crop residues and crop rotation, (iv) control of 
plant stresses, (v) control of toxigenic fungi and (vi) restrain of pest insects (Battilani et al., 2012). 
Sowing time 
Fungi infection and mycotoxin contamination depend on the fungal inoculum, the co-occurrence of a 
susceptible plant growth stage, favourable environmental conditions, and vector activity. These factors are 
correlated with the sowing period, and therefore setting the right planting date can significantly influence the 
mycotoxin risk.  
In maize, an earlier sowing date generally results in a lower risk of FB and AF contamination across diverse 
locations (Blandino et al., 2009). It is recommended to plant when there are good agronomic and 
meteorological conditions (soil temperature at least 10 °C since few days and sow 5 cm in depth); they allow 
an optimal root development making the plant less susceptible to water stress. 
Plant density 
Planting density affect mycotoxin risk in two possible ways: i) high density (more than 20% compared to the 
reference density for the crop/hybrid) affect water consumption causing water stress in plants, increasing their 
susceptibility; and ii) create a favourable microclimate for fungi development. It is therefore recommended to 
avoid forcing plant density to prevent water stress, especially in soils with low fertility and poor water 
availability. 
Genotype (Variety – Hybrid) 
The first stage of plant active defence is the detection of invading microorganisms, which is operated by plant 
receptors located both in the cytoplasm and on the plasma membrane. It is generally considered that 
comprehensive knowledge of plant defence mechanisms may help to identify resistant mechanisms, and assist 
the development of targeted and innovative approaches for breeding crop resistance. Thus, plant breeding 
has been used during the past years as a tool to develop maize lines resistance to abiotic and biotic stresses. 
However, no hybrids were found to be completely resistant to either fungi infection and/or mycotoxin 
Nuts















Legend effect on mycotoxin content 1- only for Red Yeast Rice
intermediate effect on mycotoxin content 2- removal of the mycotoxin in fermented products
no effect on mycotoxin content 
no studies/not (yet) applicable 
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contamination because of the need to select for multiple traits and associated genes that contribute collectively 
to plant resistance. 
In maize, consistent efforts were devoted and several research outputs are available regarding plant-pathogen 
interaction and host resistance; these are very promising starting points for future developments, but clear 
suggestions regarding hybrid selection, considered the best prevention tool, is not actually feasible. 
More successful stories can be told regarding wheat, where resistant, or at least moderately resistant cultivars 
are available. 
Soil management 
Soil conditions influence plant root development. Crops with a poorly developed root system are more 
susceptible to stress, especially in sandy soils. Therefore, it is suggested to take care of soil drainage, especially 
in clay soils. It is also suggested to adapt tillage strategies to soil conditions to avoid drought stress. Tilled 
fields tend to dry more quickly and, under some circumstances, this drying can increase drought stress. Under 
other conditions, tillage may instead improve water availability to the plants by disrupting the compacted 
layers in the soil profile. Furthermore, cold soils can slow crop development. The resulting delay of flowering 
promotes the development of Fusarium verticillioides (FBs), while delayed ripening favouring Fusarium 
graminearum (ZEN and DON). 
Mycotoxin producing fungi survive in soil or in crop residue on soil. Crop residue is the most important source 
of inoculum for A. flavus and several Fusarium spp.  Crop rotation and tillage are good agricultural practices, 
recommended to reduce the inoculum of fungi overwintering in crop residues. In general, the efficacy of crop 
residue management varies by pathogen, by location and by the combination with other strategies. In small 
cereals, soil tillage and crop rotation managements are considered to be of major importance on mycotoxins 
control because of the splash borne dispersal of F. graminearum. On the contrary, A. flavus spores are air-
dispersed, which means a long-distance distribution, and F. verticillioides is both air and splash dispersed. In 
this case, crop residue and soil management have almost no impact on fungal inoculum because it can arrive 
from neighbour fields. 
Aspergillus carbonarius mainly survive in soil, with a minor contribute of grape crop residue and it is air 
dispersed. Therefore, similarly to other cited fungi, it is not significantly influenced by tillage in case other 
vineyards are around as possible inoculum source. 
Irrigation 
Even when irrigation as a mean of avoiding drought and consequent yield losses is required, its impact on 
Aspergillus and Fusarium development needs to be taken into account, as irrigation leads to an increased 
moisture, that can favour fungal growth, but it is well documented that limited water availability predisposes 
plants to AF contamination (especially relevant in maize). 
In maize, with regards to A. flavus infection, water stress is particularly critical during silk emergence and 
kernels ripening. For FBs there is not such a clear evidence. 
In wheat, irrigation should be minimized specially during anthesis, which is the most susceptible phase for 
Fusarium head blight (FHB) fungal infection. This was confirmed in wheat experiments with less FHB 
development observed when less irrigation was applied; however, late-season irrigation may reduce toxins 
possible due to leaching of these substances (Annex B; (Gautam and Dill-Macky, 2012)). 
Weeds control 
Weeds compete with the crop for water and nutrients, increasing the probability and magnitude of stresses. 
Therefore, it is suggested to apply accurate and timely weed control in pre or post-emergence, preferably 
integrated with the mechanical control on the row. Weeds may also act as a vector for cross contamination 
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Insect damages are well known to cause significant losses in yields and to be conducive of toxigenic A. section 
Flavi and Fusarium infection. Insects in the Order Lepidoptera typically have the biggest impact on mycotoxin-
producing fungi. In particular, there are strong evidences of the big role played by the European corn borer 
(ECB), Ostrinia nubilalis, in Fusarium verticillioides infection. In small grains this action is mainly due to aphids 
and, particularly in wheat, F. graminearum spread can be double when plants host these insects. 
In grapes, Lobesia botrana was shown to increase consistently OTA contamination; therefore, pest control is 
a very effective preventive action. 
Fungal control (chemical) 
Reported results are not conclusive regarding the use of fungicides to mitigate mycotoxin contamination in 
cereals. Several positive data have been published on the in vitro effect of fungicides on several pairs fungi-
crop, but these results were not always supported by field trials. 
In fact, the use of fungicides was ineffective in controlling A. flavus infection of maize at it showed a very 
limited effect against F. verticillioides. An important consideration, when deciding to use fungicides, is the 
possible effect on fungal population. Since the use of fungicides can promote the reduction of antagonistic 
fungi and contribute to more conductive conditions for pathogenic strains.  
The most successful experience regards triazole fungicide treatments to lower DON contamination in wheat at 
the desirable level; however, in susceptible cultivars most fungicides fail to reduce mycotoxins levels to a 
desirable value. 
The application of natural compounds is achieving increasing recognition as a potentially eco-friendly 
alternative to the use of synthetic chemical pesticides instead.  
Fungal control (biocontrol) 
The optimization of agricultural management practices to reduce the effects of drought and heat stress can 
reduce the gravity of aflatoxin contamination in maize, but these techniques are commonly insufficient. During 
the last decade, the biological control of pathogenic Aspergillus flavus has rapidly garnered the scientist’s 
attention becoming the only recognised effective method for aflatoxin mitigation in some areas of the USA, 
Africa and Italy. This technique is based on the use of nontoxigenic isolates of A. flavus which act through 
competitive exclusion of aflatoxin producers in the environment and during crop tissue infection. It is applied 
for prevention of AF in maize, peanuts and pistachio nuts. 
Far less information is available for the control of Fusarium spp., and for other crops, but promising results 
were produced regarding the prevention of Fusaria infection through the distribution of biological control 
agents on crop debris in small grains. 
 
3.1.1.2. Harvest management and in-farm initial handling of crops 
 
Fungal infection and subsequent production of mycotoxins begins in the field during plant growth and may 
continue through harvesting, storage, and processing if ecological conditions stay suitable for fungal activity. 
Mycotoxins, as stated before, are very stable compound and cumulate in time, both during crop growth and 
post-harvest. Therefore, the adopted procedures must always have this concept in mind. Factors as harvest 
time, sanitation conditions of the crop, and harvest techniques play an important role in the fate of the crop 
throughout its life time. 
In cereals, grain moisture, or aw, is crucial for fungal activity and it is directly influenced by harvest timing. 
Thus, it is good practice to harvest at moisture levels low enough to prevent post-harvest production of 
mycotoxins. This is commonly applied for wheat and small grain, with Fusaria as mycotoxin producing fungi 
of interest, because their activity is stopped by aw decrease. In maize, A. flavus is of crucial interest and its 
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Therefore, it is suggested to balance between the risk of strong increase in contamination and harvest with 
suitable humidity for storage in defining harvest time and promptly artificially dry.  
It is also important to test the field, or better predict with modelling approaches, for fungi contamination 
before harvesting, thus field with high risk of mycotoxin contamination should be harvested sooner, although 
with aw higher than that suitable for storage, and dried immediately. Techniques applied from cutting during 
harvest may cause increased levels of fungal contents, with all the undesirable consequences. An effective 
crop management should allow harvesting at the right moment to assure the intended grain development and 
the reduction of contamination risks. Since a later harvest period is associated to a higher pathogenically 
fungal load, recorded for barley (Chen et al., 2016), and should be avoided. 
Regarding fresh fruits, like grapes, harvest time is based on criteria related to the crop production quality, 
more than on mycotoxin contamination risk, but the stability and additive accumulation of these toxic 
compounds cannot be forgotten. This is of particular relevance for dried vine fruits (Gonçalves et al., 2020), 
and may be also considered for similar products (e.g., dried figs). 
Both for dry and fresh product, harvest should be managed avoiding as much as possible, damages to 
products, grain or fruit. In fact, mycotoxin producing fungi are commonly weak parasites and they take 
advantage of openings to easily enter and rapidly activate their metabolism. 
A further point which should not be overlooked is the beneficial impact of operating a properly sanitation of 
load compartment used for the transport of harvested crop. In fact, dirty trucks with residue of contaminated 
crop may also be the source of risk contamination of the new load. 
Depending on the crop and on-site facilities, initial handling of crops may include a few processing steps (as 
drying or sorting), before storage and commercialization. 
Drying 
Being moisture content an important factor for fungal development, drying represents an effective way of 
make cereals suitable for storage. The utilization of airflows has proven successful in avoiding OTA 
contamination by Penicillium verrucosum, and this may be extrapolated for different fungi (Annexes A and B; 
Palumbo et al. 2020b). 
As an example, the drying process is commonly applied to maize grain to guarantee a safe storage. If the 
moisture content of the maize at harvest is not low enough for safe storage, then it must be dried either 
naturally, with ambient air forced through the storage bin, or artificially in a heated air dryer. Many technologies 
as well as different temperature x time combinations can be applied for artificial drying. In general, dryers 
using heated air, with the possibility to change air temperature and flux speed according to the grain batch, 
are the most commonly used for drying maize in Europe. In general, the product should be dried to less than 
14% to be safely stored. Furthermore, a prompt reduction of grain humidity, in combination with lower 
moisture content (<13%), is suggested when A. flavus is present. 
Drying is also applied for some grape derived products, like currant, raisin or dessert wines. The drying period 
duration changes a lot in case of natural or artificial drying conditions, always shorter in the latter. Because A. 
carbonarius is the crucial fungus of interest, the drying period deserves risk of OTA increase, being the fungus 
more efficient in toxin production with aw compatible with the early drying period, till when aw is above 0.93. 
Even if artificial drying should be always suggested, some products are anyway naturally dried; attention to 
OTA risk should be paid in this case. 
Cleaning and sorting 
Susceptibility of the crop to fungal colonization is not only dependent on temperature and aw, but also on 
nutrient availability. Harvesting, transportation, drying, and handling of crops generate broken product, foreign 
material, weed seeds, and other fine materials such as dirt and debris which may act as potential source of 
mycotoxin contamination. For this reason, segregation of broken, damaged or infected grains, kernels, or lots 
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Cleaning and sorting intend to screen cereal grains and eliminate undesirable materials, both other than the 
cereal itself and damaged kernels or grains that do not met the required specifications. 
As examples, removing broken kernels and smaller parts from maize reduced DON and ZEN contamination by 
around 70–80%. For maize, it has been also demonstrated that intact kernels contained about 10 times less 
fumonisins than broken corn kernels or smaller parts. The effect of cleaning and sorting in wheat samples 
leads to lower levels of contamination, with greater impact being caused by mechanical gravity separation. 
Besides that, on oat experiments, the effect of cleaning step on reduction of T-2 and HT-2 was not significant. 
One effective way to reduce mycotoxins contaminations might be the inclusion of colour sorting in the cleaning 
step. In fact, this method was proven to be successful in reducing mycotoxins risks, since it provides an 
appropriate segregation of Fusarium species contaminated grains. 
Several physical processes are applied to feed commodities in order to mitigate targeted mycotoxins (e.g., 
sorting, sieving, flotation, density segregation, etc.). Sorting can be achieved by several automated removing 
systems. Originally, grain sorting machines were based on particle weight and size grains and sorting was 
obtained using centrifugation force and flotation in air flow. Contemporary grain sorters are mainly based on 
optical sensors. Grain sorting using UV light illumination for AF reduction is widely used.  
The efficacy of sorting is strongly related to target fungi and mycotoxin. It is commonly confirmed that kernels 
infected by F. graminearum show visible symptoms, like bleaching and shrivelled kernels. It is therefore logic 
that sorting based on optical sensors contributes significantly to DON reduction. On the other hand, in F. 
verticillioides natural infection relationship between visible symptoms and FUM contamination was never 





The essential parameters to control storage are temperature, aw, and time. Before any processing step, and 
depending on crops, storage of variable length, depending on the product and its destination, occurs. 
Products as cereals are stored for long periods, after the initial management steps. Grain aw, together with 
temperature and relative humidity conditions during storage, are the main driven forces for safe storage 
(Annexes B; Palumbo et al., 2020b). In these cases, drying, sorting, and storage are the critical steps, since 
later processing stages will commonly not mitigate the occurrence of mycotoxins. Other crop products may be 
included in this set of commodities, as dried vine fruits (Gonçalves et al., 2020) or spices (Annex E). 
Products with high aw, that may not be dried to safe conditions without changing their nature should be stored 
for shorter periods of time, having in mind that their natural aw content will favour fungal development. These 
products should be processed as soon as possible, or stored in modified conditions (e.g., refrigeration). 
Examples of this kind of products are fruits, and grapes for wine. 
Processing 
Food processing can interfere with the stability of mycotoxins present in a certain matrix. Parameters used 
during processing may reduce, or sporadically increase concentrations, by the different distribution of 
mycotoxins among the obtained fractions. Control of temperature, time and size of the samples is essential 
when studying the fate of mycotoxins under process conditions. Reduction of mycotoxin content during 
processing may be achieved due to physical, (bio) chemical or biological interactions. 
It has been clearly reported in the literature that food processing can reduce mycotoxin exposure by (i) 
destroying or eliminating mycotoxins, by (ii) transforming them into less toxic derivatives, by (iii) adsorbing 
mycotoxins to solid surfaces or by (iv) reducing their bioavailability due to chemical attachment to food matrix 
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cooking; baking; frying; roasting; flaking; alkaline cooking; nixtamalization; and extrusion. Most of the food 
processes have variable effects on mycotoxins, with those that utilize high temperatures having the greatest 
effects. In general, processes reduce mycotoxin concentrations significantly, but complete elimination cannot 
be achieved with processing commonly applied, therefore keeping products according to consumer 
expectation. 
Although generally processing will contribute to a reduction in the final mycotoxin content (Figure 16 and 
(Gonçalves et al., 2019; Gonçalves et al., 2020; Palumbo et al., 2020b); Annex A-D), the relative reduction 
in the content is very dependent on the type and sanitary conditions of the raw material, as well as on the 
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3.2. Biosynthesis of modified mycotoxins 
Mycotoxin mixtures may have different origins in the field. Different mycotoxins can actually be produced by 
the same fungi on the crop, or different fungi may infect the same crops in the field leading to the co-
occurrence of multiple parental mycotoxins. As previously described in this report (section 3.1), many 
environmental, ecological, and agronomic factors may affect the relative abundance of co-occurring 
mycotoxins in the contaminated crops, which may vary from year to year. 
However, the number and diversity of potentially co-occurring mycotoxins is even more increased by plant 
metabolism. Indeed, the contamination of food by mycotoxins is due to host–guest infectious processes, 
wherein mycotoxins may act as pathogenicity or virulence factors (Hof, 2008). Therefore, plants have 
developed effective detoxifying systems to counteract fungal infection. 
As for other xenobiotics, plants can alter the structures of mycotoxins through their defence mechanisms, via 
three main phases: chemical modification (phase I and II metabolism) and compartmentalization (phase III 
metabolism) (Berthiller et al., 2013).  
Overall, these reactions may reduce mycotoxin phycotoxicity, and facilitate their sequestration in the plant 
vacuole or apoplast. Modified forms may also be incorporated into cell wall components (Berthiller et al., 
2013). 
While hydrophilic xenobiotics already have reactive groups and, therefore, there is no need to undergo phase 
I metabolism, this mainly occur for introducing on the lipophilic backbone of the parent compound, a chemical 
moiety prone to conjugation. Typical phase I reactions involve hydrolysis, reduction or oxidation, and are 
catalyzed by esterases, amidases, P450 monooxygenases, and peroxidases. Typical phase I modifications of 
trichothecenes involve the hydrolysis of acetylated derivatives, e.g., the transformation of T2 into HT2 in plants 
(Nathanail et al., 2015). 
It must be noticed that phase I biotransformation not always reduces the toxicity of the parental compounds, 
and in some cases the toxicity may even be increased (Berthiller et al., 2013). This is the case, for instance, 
of α-ZEL formation from ZEN, being the former far more estrogenic than the latter (EFSA, 2016). 
Phase II metabolism is aimed at transforming the parent compound in a more polar – and therefore less toxic 
– metabolite through conjugation, being indeed a detoxification step itself. These reactions occur through the 
binding of hydrophilic biomolecules (i.e. glucose, glutathione, fatty acids) to the parent mycotoxin or to its 
phase I metabolite. The major pathways are glycosylation catalyzed by UDP-glycosyltransferases (UGTs) and 
glutathione conjugation catalyzed by glutathione-S-transferases. Among Fusarium modified mycotoxins, DON-
3-O-β-D-glucoside (DON-3-Glc) is so far the best documented phase II metabolite of DON, but sulfate-, 
glutathione-, and cysteine-conjugates were also reported.  
The higher polarity of the conjugate metabolite leads to an increase in solubility, and therefore facilitates its 
phase III elimination or storage (i.e. vacuole, apoplast or cell walls). The overall effect of this process is a 
reduction of the mycotoxin phytotoxicity (Berthiller et al., 2013). The β-glucosides of Fusarium mycotoxins, 
DON-3-Glc, HT2 toxin-3-Glc, and ZEN-14- Glc, are the most common compounds (EFSA, 2017c, b, a). 
It must be underlined that, while the lower toxicity of conjugated mycotoxins per se is demonstrated, these 
compounds can undergo cleavage in the gastrointestinal tract of animals, or along the food processing chain, 
thus releasing the parent mycotoxins (EFSA, 2017a, b, c, 2018b). Therefore, their formation and co-occurrence 
with parent compounds must be regarded as a relevant contribution to the overall toxic load. 
A number of studies have addressed the biosynthesis of modified mycotoxins, with a focus on the enzymes 
catalysing the process. The efficiency of the detoxification process of mycotoxins in plants depends indeed on 
the effectiveness of the enzyme produced by the plant in reaching and acting on the mycotoxin. 
In particular, the ability to convert DON to DON-3Glc has been proven to be associated with the plant resistance 
toward Fusarium Head Blight (FHB), a plant disease which causes severe yield losses in cereal crops (Cirlini et 
al., 2014; Amarasinghe et al., 2016; Nakagawa et al., 2017). Studies comparing the conversion abilities of 
DON to DON-3Glc in several wheat lines indicated that low glycosylation ability is related to high susceptibility 
toward fungal infection and toxin accumulation. Gene expression studies allowed to identify the most effective 
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mapped on chromosomes 3B (Fhb1, Qfhs.ndsu3BS) and 5A (Qfhs.ifa-5A) (Buerstmayr et al., 2002; Lemmens 
et al., 2005; Kluger et al., 2015). 
Conjugation of mycotoxins with glucose by UGTs in phase II metabolism is one of the primary plant 
detoxification mechanism for resisting mycotoxin accumulation (Broekaert et al., 2015a). 
The earliest study on the detoxification of DON in Arabidopsis thaliana, reported on the ability of UGT73C5 to 
encode for a UGT that catalyzes the transfer of a glucose moiety from UDP-glucose to the hydroxyl group at 
C-3 of DON. The authors demonstrated that constitutive overexpression of UGT73C5 in A. thaliana led to 
enhanced tolerance towards DON (Poppenberger et al., 2003). 
Moving from this first observation, several studies over years reported on different UGTs able to catalysed 
mycotoxin glycosylation in plants, as summarised in Table 13. In relation to trichothecene glycosylation, 
reported UGTs shared a regioselectivity towards C-3-OH position. 
More recently, some authors identified in wheat 179 UGT genes that could be responsible for the regulation 
of resistance mechanisms towards FHB infection and DON accumulation (He et al., 2018). 
 
 
Table 13: Genes encoding for UGTs reported in the literature for the formation of modified mycotoxins 
 
UGTs encoding genes Mycotoxin Glucosides Reference 
UGT73C5 (A. thaliana) DON DON-3-Glc (Poppenberger et al., 
2003) 
UGT73C6 (A. thaliana) ZEN ZEN-14-Glc (Poppenberger et al., 
2006) 






(Li et al., 2017; Michlmayr 
et al., 2018; Mandalà et 
al., 2019) 






(Michlmayr et al., 2015; 
Michlmayr et al., 2018) 




(Wetterhorn et al., 2017) 




(Schweiger et al., 2013; 
Pasquet et al., 2016; Gatti 
et al., 2018; Michlmayr et 
al., 2018) 






(Michlmayr et al., 2017) 
TaUGT-2B (Triticum aestivum) DON DON-3-Glc (Sharma et al., 2018) 
TaUGT-3B (Triticum aestivum) DON DON-3-Glc (Sharma et al., 2018) 
 
 
3.2.1. Fusarium modified mycotoxins: trichothecenes 
DON-3Glc is largely the most reported and described modified mycotoxin. It is formed in plants by conjugation 
of a glucose moiety to the C-3 hydroxy group of DON. Since the hydroxyl group in C-3 is responsible for the 
binding of DON to the ribosome binding pocket, thus inducing ribotoxicity, glycosylation induces a loss of 
toxicity. In addition, it alters the polarity of the molecule, favouring the exit of the cytosol, due to access to 
membrane-bound transporters. The conjugated mycotoxin is then stored in the plant vacuole or apoplast or 
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Among cereals, a higher DON-to-DON-3-Glc conversation rate was observed in spelt, followed by wheat and 
barley, and at lower extent in corn and rye. No conversion was observed in oats so far. The conversion seems 
to occur mainly at the germination stage, when glucose level is higher (Maul et al., 2012). In addition, DON-
3-Glc formation seems to be affected by the parent toxin level. Higher DON concentrations were reported to 
alter the efficiency of DON to D3G conversion, thus suggesting a limitation in the glycosylation capacity of the 
plant. In addition to glycosylation reaction through glycosyltransferases, also the glutathione pathway has 
been described for DON detoxification in plants, mainly mediated by glutathione-S-transferases. Sulphation 
has been reported as well, with the formation of DON-3-sulfate and DON-15-sulfate. 
Accordingly, besides DON-3-Glc, other modified forms of DON have been reported in cereals, mainly wheat, 
among them DON-hexitol, DON-S-cysteine, DON-S-cysteinyl-glycine, DON-glutathione, DON-di-hexoside, and 
DON-malonyl-glucoside. In addition, conjugation products of 15-acetyl-DON have been described as well, i.e. 
15-acetyl-DON-3-β-D-glucoside.  
The biotransformation occurring to other type B trichothecenes, has been understudied compared to DON. 
However, several authors reported the formation of FUS-X and NIV glucosyl-conjugates in wheat (Nakagawa 
et al., 2011; Nakagawa et al., 2013; Yoshinari et al., 2014). 
Concerning type A trichothecens, the biotransformation of T2 have been studied in barley and oats (Nathanail 
et al., 2015), leading to the annotation of a number of putative T2 and HT2 glycosyl- and/or malonyl- 
conjugates. Notably, the authors described the quick phase I conversion in plants of T2 into HT2 through 
deacetylation. Simultaneously, the HT2 formed was further metabolized through glycosylation to HT2-3Glc. 
 
3.2.2. Fusarium modified mycotoxins: zearalenone 
Biotransformation in plants has been described for the xenoestrogenic mycotoxin ZEN, as well. In particular, 
it undergoes both phase I and phase II metabolism in plants, with the formation of glucoside- and sulphate-
conjugates of ZEN and its phase I metabolites α- and β-ZEL. 
Glucosilation may occur at both OH group in the phenolic ring, although the formation of ZEN-16-Glc is 
sterically unflavoured compared to ZEN-14-Glc (Paris et al., 2014; Michlmayr et al., 2017). Unlikely DON, ZEN 
undergoes an extensive biotranformation in plants, leading to a plethora of different conjugates originated 
from the parent compounds and its phase I metabolties, as described by Berthiller et al. (2006) in A. thaliana 




3.2.3. Fusarium modified mycotoxins: fumonisins 
 
Several modified forms of fumonisins have been described so far (EFSA, 2018b, a), mainly due to the effect 
of processing along the food and feed production chain. However, the possible formation of fatty acid esters 
of FB1 (O-fatty acyl FB1) and other fumonisins with variation in fatty acid chain length and position of 
esterification (3-O-, 5-O- or 10-O-acyl-fumonisins), have been described in maize by Bartok et al (2010, 2013a, 
2013b) and Falavigna et al. (2013, 2016) (Bartok et al., 2010; Bartok et al., 2013a; Bartok et al., 2013b; 
Falavigna et al., 2013; Falavigna et al., 2016). 
Differently from what described for modified forms of trichothecenes and zearalenone, these conjugates are 
formed by the fungus when growing on a plant substrate and not by the plant itself.  Besides O-fatty 
acylfumonisins, the corresponding N-fatty acyl fumonisins were also detectable in low amounts in F. 
verticillioides cultures (Bartok et al., 2013b). These phase II metabolites have been found in maize at very low 
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3.2.4. Ochratoxin A modified forms 
Little is known so far about the possible biotransformation of OTA in plants. Preliminary studies were performed 
in plant-cell suspension cultures by Ruhland et al. (1996)(Ruhland et al., 1994). A very quick biotransformation 
was observed in carrots, tomatoes, and corn cell cultures, while longer time was required for degradation in 
wheat, barley and potatoes. Among metabolites, OT-α, 4S-OH-OTA, 4R-OH-OTA, OH-OTA-β-Glc, and OTA 
methyl ester, were described. 
A follow-up study was performed by Wang et al. (2014) in A. thaliana model system, showing that glutathione 
synthase, glutathione-S-transferase and glutathione peroxidase, significantly increased in tissues treated with 
OTA, thus suggesting the activation of a glutathione-based detoxification pathway. However, no further studies 
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3.3. Methods of analysis 
The methods of analysis can be divided into two broad categories. Those that are referred to as ‘screening 
tests’ which give a qualitative or semi-quantitative results.  They are generally based on antibody recognition 
methods such as ELISA and lateral flow. The former is usually laboratory based whilst the latter can be applied 
in the field. They are often specific to one mycotoxin such as AF, DON, FB etc and require relatively straight 
forward sample preparation, in some cases simple aqueous extractions can be performed. In more recent 
times some multiplex rapid screening test have entered the commercial markets allowing up to 5 or 6 
mycotoxins to be detect simultaneously. The most promising techniques in terms of multiplexing are based on 
biosensor platforms but as yet few have made their way to commercial products. This is in part due to the 
cost of the technology platforms themselves which can detract from the ‘low cost’ element needed for 
screening tests. However, there is a growing number of publications outlining that electrochemical biosensors 
may provide a low cost multiplex solution in the future. In virtually every case the mycotoxins covered by 
immunoassay based screening tests are for mycotoxins that are regulated. Thus clearly it can be seen that 
regulations drive testing.   
The second tier of testing is often referred to as ‘confirmatory analysis’. The methodologies are virtually all 
based on some form of physio-chemical platform. There are a small number of publications that outline the 
use of capillary electrophoresis but it is not a widely used technique either in the research or routine testing 
environments.  The most widely used method for a long time was High Performance Liquid Chromatography 
(HPLC). Quite a number of variations to this methodology in terms of sample preparation, mobile phases etc 
have been published.  HPLC was the method of choice for many to produce quantitative analysis for single or 
all regulated mycotoxins present in feed and food. In some cases, this is still the method of choice, particularly 
in the laboratories in Developing Countries where the lack of more sophisticated physio-chemical equipment 
limits choice. In contract, in the Developed World the most frequently used technology is liquid 
chromatography coupled to mass spectrometry (LC-MS). The liquid phase is used to separate the compounds 
of interest from interfering molecules while the mass spectrometry portion of the methodology is used to 
identify and quantify the mycotoxins themselves. There are many variations in terms of the types of sample 
preparation methods applied, the forms of liquid chromatography used and mass detectors employed. There 
is a large range of differences in method performance in terms of speed, sensitivity, specificity and robustness 
across these methods. There is also a large number of mycotoxins that can be detected and quantified on the 
LC-MS platforms. Some authors report over 400 compounds being measured simultaneously. Not only the 
regulated mycotoxins can be measured but many other hundreds of other known mycotoxins for which 
analytical standards are available. Where sample contain mixtures of mycotoxins (which is a considerable 
number) the application of such testing methods is vital to determine accurately the range and concentrations 
of mycotoxins present. These methods can be very expensive to perform, not only because of the cost of the 
equipment but also the costs associated with sample preparation, analytical standards and highly trained staff 
to conduct the analysis.  Yet in terms of fully understanding animal and human exposure to the board family 
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3.4. Occurrence and co-occurrence of mycotoxins in different crops 
The thorough analysis of (co-)occurrence data provided a literature and data-driven insight on the presence 
of mycotoxins in cereal-derived feed and food commodities in Europe, and their natural co-occurrence intended 
for publication in the scientific literature (Palumbo et al., 2020a). In brief, a total number of 8406 records and 
1,440,646 samples were collected. The vast majority of the studies reported data from more than one cereal, 
and the most studied crops were found to be respectively wheat (34 %), maize (28 %), barley (10 %), oat (9 
%) and rice (6 %). The database for the occurrence and co-occurrence data of mycotoxins in cereals includes 
12 crop aggregations: barley, buckwheat, cereals, maize, oat, rice, rye, sorghum, spelt, triticale, wheat and 
others (millet and soy). Mycotoxins were mainly reported in wheat and maize showing the highest 
concentrations of FBs, DON, AFs, and ZEN. The maximum concentrations of FB1+FB2 were reported in maize 
both in feed and food and were above legal maximum levels (MLs). Similar results were observed in DON-
food, whose max concentrations in wheat, barley, maize and oat exceeded the MLs. Co-occurrence was 
reported in 54.9 % of total records, meaning that they were co-contaminated with at least two mycotoxins. 
In the context of parental mycotoxins, co-occurrence of DON was frequently observed with FBs in maize and 
ZEN in wheat; DON+NIV and DON+T2/HT2 were frequently reported in barley and oat, respectively. Apart 
from the occurrence of ZEN and its phase I and phase II modified forms only a limited number of quantified 
data were available for other modified forms; i.e. mainly the acetyl derivatives of DON. 
All data, plots, fitting distribution parameters and R-code produced regarding mycotoxin occurrence/co-
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3.5. Toxicokinetic and Toxicity (toxicodynamic) 
3.5.1. Toxicokinetic and Toxicity and databases 
Toxicity and toxicodynamic data for selected mycotoxins (further information on the mycotoxins analysed in 
this work are detailed in Section 1) are reported in specific databases: toxicokinetic database (in vitro and in 
vivo), and in vivo toxicity database. 
The in vitro toxicokinetic database was built from 48 peer reviewed articles selected from the ELS wherein 
data on buffalo (1 paper), bovine (3 papers), carp (1 paper), chicken (3 papers), Chinese hamster (1 paper), 
dog (1 paper), duck (1 paper), goat (1 paper), human (22 papers), pig (5 papers), quail (1 paper), trout (2 
papers), rat (5 papers) and turkey (1 paper) were included. The inclusion criteria used to include papers are 
detailed in the Section 2.3.2.1.    
The in vivo toxicokinetic database was built from 109 peer reviewed articles including TK studies on chicken 
(18 papers), buffalo (3 papers), cow (10 papers), donkey (1 paper), duck (1 paper), sheep (3 papers), goat 
(2 papers), horse (1 paper), human (8 papers), fish (4 papers), mouse (8 papers), monkey (2 papers), pig 
(23 papers), rabbit (1 paper), rats (24 papers) and turkey (5 papers).  
Finally, in vivo toxicity database was built from an ELS covering the years 2010-2017 with a total of 53 papers 
were included in the database. The focus went on chickens (38 papers) and pigs (15). The mycotoxins 
addressed were DON (7), ZEN (8), FBs (5) and AFs (33) with dose response data. Moreover, an additional 
literature search for the period 1976-2010 before 2010 was performed because of the limited data available 
for the period 2010-2017 and a total of 62 papers including data on chicken (26 papers), mouse (5 papers), 
fish (2 papers), rat (5 papers), pig (13 papers), hamster (1 paper), quail (3 papers), turkey (5 papers), rabbit 
(1 paper) and lamb (1 paper) were collected. A review paper is in preparation with provisional title “Overview 
of the European Food Safety Authority guidelines on the adverse effects of mycotoxins and their derivatives 
forms on farm animals”.  
As supported by several reports, humans and animals are generally exposed to several co-occurring 
mycotoxins. The toxicity of combinations cannot be predicted based on the toxicity of individual mycotoxins, 
but only few studies analysed the combination of mycotoxins in vivo (Grenier and Oswald, 2011) and in vitro 
(Alassane-Kpembi et al., 2017). Therefore, the lack of studies dealing with combined toxicity of multiple 
mycotoxins suggested the need for a review providing a summary of the current knowledge, underling the 
weakness of some studies, and guidelines for a proper planning of future studies on toxicity of mycotoxin 
mixtures in vivo. In addition, this review should collect the toxicity values with the doses tested and the adverse 
effects observed by animal species.    
 
3.5.2. Toxicokinetic in vivo 
Data collection and subsequent analysis of in vivo toxicokinetic data provided the basis to for a review on the 
topic to be published in the scientific literature. Such a review covers the analysis and comparison of kinetic 
parameters for single and multiple mycotoxins in different animal species (Gkrillas et al., submitted). In brief, 
the review highlighted the complexity of studying the toxicokinetic of mycotoxin mixtures, which needs to be 
addressed in a case by case scenario. An extensive literature search was performed giving an insight on the 
currently available data (4057 papers screened) relevant to the hazard assessment of mycotoxins and 
mycotoxin mixtures by addressing their toxicokinetic parameters in different animal species. The richest 
datasets and most important from an agroeconomic point of view are pigs and chickens. Comparison on the 
sensitivity of chickens, pigs in respect to rats and calculation of uncertainty factors on interspecies toxicokinetic 
variability was performed. Additionally, the main challenges in the hazard assessment of multiple mycotoxins 
are reported and the toxicokinetic data needed to perform a more reliable hazard assessment of the co-
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Mycotoxins dosage, exposure pathway, interspecies and intraspecies differences were identified among the 
most important parameters that may influence the toxicokinetics of mixtures. As a general remark, a limited 
availability of scientific papers on mixtures in comparison with the single compounds was described. Since 
testing of all mycotoxin mixture combinations is unfeasible, focus should be on the prioritisation of mycotoxin 
mixtures, creation of harmonised methods for generating in vitro and if necessary in vivo TK data and finally 
making use of predictive kinetic modelling that include uncertainty and inter and intraspecies variability 
analysis. All the above will assist in reducing the overall uncertainty and the production of a more robust risk 
assessment of chemical mixtures for animals and humans. 
 
3.5.3. Toxicodynamic: an example of an in silico structural approach  
The thorough analysis of toxicity data allowed the design of a computational-driven structure-based 
toxicodynamic study, intended for the publication in a scientific journal, comparing the estrogenicity of ZEN, 
its metabolites and the emerging mycotoxin alternariol (AOH) in human and trout. Inter-species differences in 
their toxicokinetic and toxicodynamic may occur depending on evolution of taxa-specific traits. As a proof of 
principle, this manuscript investigates the comparative toxicodynamic of ZEN, its metabolites (alpha-zearalenol 
and beta-zearalenol), and alternariol (which is an emerging threat in fishing farming) with regards to 
estrogenicity in humans and rainbow trout. An in silico structural approach based on docking simulation, 
pharmacophore modelling and molecular dynamics was applied, and computational results were analyzed in 
comparison with available experimental data. The differences of estrogenicity among species of ZEN and its 
metabolites have been structurally explained. Also, the low estrogenicity of alternariol in trout has been 
characterized here for the first time (Dellafiora et al., 2020). 
Overall, the work described the usability of in silico modelling to better understand the toxicodynamics of 
mycotoxins focusing on the inter-species variability. Such approaches will provide a useful analysis to 
complement the characterization of inter-species mycotoxins toxicity by: i) understanding the structural basis 
of mycotoxins toxicity; ii) predicting the capacity to differentially trigger biological and toxicological stimuli; iii) 
driving future analysis through the evidence-based prioritization of compounds, endpoints and species of 
interest to risk assessment; iv) integrating toxicokinetic data for a more comprehensive understanding of 
mycotoxins toxicity; v) supporting biologically-based interpretation of toxicological data to improve 
extrapolation between species and the assessment of human relevance.  
3.5.4. Coarse-grained calculation of individual kinetic parameters for selected mycotoxins 
A list of selected mycotoxins underwent a coarse-grained and qualitative calculation of individual kinetic 
parameters using the SwissADME tool (Daina et al., 2017). In particular, passive human gastrointestinal (HGI) 
absorption, blood-brain barrier (BBB) permeation, glycoprotein (Pgp)-mediated permeability and possible 
inhibitory activity versus a number of cytochromes P450 (i.e. CYP1A2, CYP2C19, CYP2C9, CYP2D6 and 
CYP3A4) were calculated. The calculation of passive HGI absorption and Pgp-mediated permeability is based 
on the BOILED-Egg model (Daina and Zoete, 2016 ), which defines favourable and unfavourable zones in the 
hydrophobicity (expressed as logP o/w) versus polar surface area physicochemical space for passive diffusion 
through both physiological barriers. The calculation of Pgp-mediated permeability and possible inhibitory 
activity versus a cytochromes P450 relies on support vector machine (SVM) algorithm, properly feed with 
meticulously cleansed large data-sets of known substrates/non-substrates or inhibitors/non-inhibitors, as 
reported by Daina and co-workers (Daina et al., 2017). The results collected are summarized in Table 14.  
Table 14: Individual TK parameters for selected mycotoxins 
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AFB2 High Yes No No Yes No Yes Yes 
AFG1 High No No No Yes No No No 
AFG2 High No No No Yes No Yes No 
Alternaria 
toxins 
AOH High No No Yes No No Yes No 
AME High No No Yes No No No No 
TEA High No No No No No No No 
ATX-I High No Yes Yes No No No No 
ATX-II High No No Yes No No Yes No 
Enniatins 
ENNA Low No Yes No Yes No No No 
ENNA1 Low No Yes No Yes No No No 
ENNB High No Yes No No No No No 
ENNB1 Low No Yes No No No No No 
BEA Low No Yes No No No No No 
Fumonisins 
FB1 Low No No No No No No No 
FB2 Low No No No No No No No 
FB3 Low No No No No No No No 
FB4 Low No No No No No No No 
Trichothecene
s 
15-ADON High No Yes No No No No No 
3-ADON High No Yes No No No No No 
DON High No Yes No No No No No 
DAS High No No No No No No No 
NEO High No Yes No No No No No 
NIV Low No Yes No No No No No 
T2 High No No No No No No Yes 
HT2 High No No No No No No Yes 




ZEN High No No No No Yes No Yes 
alpha-ZEL High No No No No No No No 
beta-ZEL High No No No No No No No 
ZAN High No No No No No No Yes 
Other 
mycotoxins 
CIT High No No No No No No No 
CPA High Yes Yes Yes No No Yes No 
OTA High No No No No Yes No Yes 
PAT High No No No No No No No 
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The results collected highlighted the passive GI permeability of the all set of mycotoxins considered, while 
CPA, STM, AFB1 and AFB2 were also described able to cross BBB. In addition, ATX-I, ENNA, ENNA1, ENNB, 
ENNB1, BEA, 15-ADON, 3-ADON, DON, NEO, NIV, FUS-X, CPA were described as likely substrate of P-gp, 
which is a pivotal actor in xenobiotics disposition and distribution to organs (Couture et al., 2006). Many 
mycotoxins were also computed as possible CYPs inhibitor. Specifically, STM might inhibit all the isoforms 
considered in the analysis. Taking into account the possible multiple and simultaneous exposure to some of 
those mycotoxins (vide infra), the results presented here described the likely existence of a complex network 








www.efsa.europa.eu/publications 56 EFSA Supporting publication 2020:EN-1757 
The present document has been produced and adopted by the bodies identified above as authors. This task has been carried out exclusively by the authors in the 
context of a contract between the European Food Safety Authority and the authors, awarded following a tender procedure. The present document is published 
complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food 
Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the 
rights of the authors. 
 
3.6. Biomarkers 
Specific molecular markers, biomarkers (BM), may be used to measure the extent of the exposure to a toxic 
substance (Groopman et al., 1994). Biomarkers may be measured in body fluids or tissues as parent molecule 
or as a metabolite, anyhow, to be functional, a biomarker shall correlate with the dietary intake, be available 
with a suitable persistence, and be measurable in the specimen with suitable specificity and precision. 
Biotransformation pathway may differ depending on the contaminant so that the biomarker measured may be 
found in urine, blood, breast milk and, more rarely, in other fluids or tissues such as sputum and faeces or 
biopsies tissues of lung, liver and brain.  
Biomarkers have been divided in three categories: i) biomarkers of exposure, which indicate that the 
exposure to a particular contaminant has taken place in a certain extent; ii) biomarkers of effect, which are 
indicators of the biological response of the exposure; iii) biomarkers of susceptibility, which act as 
indicators of the intrinsic sensitivity of individuals to the toxic agent (Timbrell, 1988; Groopman et al., 1994).  
The measurement of biomarkers of exposure represent an exceptional method either to directly confirm an 
exposure event or to substantiate the relevance or applicability of results derived from probabilistic exposure 
studies (Kroes et al., 2002). However, biomarkers represent a measure of the overall exposure not 
discriminating between different sources (i.e. food or air) (Aitio and Kallio, 1999). This is not a limit for some 
chemical contaminants, such as mycotoxins, whose exposure is mainly due to food ingestion. Anyway, 
biomarkers represent a complementary method to the classic estimates of exposure based on food 
consumption and concentration levels, and they have indubitable advantages for measuring the exposure over 
time, for estimating the exposure directly (not relying on models and uncertainty assumptions) and for 
assessing individual estimates (especially for specific subpopulations e.g. vegetarians, celiac, etc). Moreover, 
biomarkers measurements is not subject to drawbacks for the heterogeneity of food contamination, nor to 
variability in food processing and cooking (Wild and Gong, 2010), both critical in the measurement of 
mycotoxins contamination in food. Certainly, to be reliable and to provide accurate estimate of exposure, 
biomarkers must be validated. The validation process is complex and implies a parallel experimental design to 
confirm the connection between the marker and the exposure (Groopman et al., 1994). 
3.6.1. Biomarkers of exposure and effects in animals 
Biomarker measurements are a useful tool to be used to complete the information about exposure, 
metabolism, toxicology and the carry-over rates of the different parent compounds or metabolites in the 
context of animal exposure to hazards. Specific studies, focused on the fate of the mycotoxin in different 
tissues and organs (e.g. cardiac muscle, kidney, liver) or biological fluids (blood, urine or milk), have been 
performed so far to put evidence on the big potential of the BM studies to depict exposure scenarios.  
The focus of the data review managed in this project was driven by the rationale to have included all the 
studies where BM were used for assessing animal exposure, for measuring the carryover and for driving 
knowledge for toxicological study and understanding the toxicodynamic. The selection criteria foresaw to 
include the kind of toxicological studies that were planned to study toxicokinetic (TK) or toxicodynamic (TD) 
parameters, in which the outputs from the BM perspective were considered as valuable information. 
Regardless of the study, a fundamental point highlighted was the availability of validated analytical methods 
able to produce sound and transferable data. On this purpose the gathered information provided a systematic 
review of the available data on BM measurement also giving evidence on the reliability of the methods, in 
terms of performance characteristics such as LODs and LOQs and validation. 
The final number of references about the animal studies after the selection criteria summed up 65 articles; 
those addressed to multi-biomarker measurements where the 40%, the remaining 60% focused on a single 
mycotoxin, most often the parent compound.  
Table 15 summarizes the number of records registered for each mycotoxin. The number of references and the 
type of study are also reported. As it is shown, the number of publications on aflatoxins is the majority followed 
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exposure and TK study with data on biomarkers) and the number of references that populated the animal 
dataset.  
Table 15: Summary of the mycotoxins, number of records, number of references and the type of study 
present in the dataset of animal studies on biomarkers 
Mycotoxin N# records N# of references Type of study 
AFs 243  22  13 BM of exposure 
9 Tox studies with data on BM 
OTA 87  11  9 BM of exposure 
2 Tox studies with data on BM 
DON 213 12  6 BM of exposure 
6 Tox studies with data on BM 
T2/HT2 6 1  Tox studies with data on BM 
NIV 32 1  Tox studies with data on BM 
FBs 108 3 1 BM of exposure 
2 Tox studies with data on BM 
ZEN 306 9  BM of exposure 
BEA 10 1 Tox studies with data on BM 
ENNs 22 4 Tox studies with data on BM 
STC 6 1 BM of exposure 
 1033 65 references in 
total 
39 studies BM of exposure 




Figure 17: Distribution of the type of studies (BM of exposure and Toxicokinetic study with data on 
biomarkers) and the number of references for single and multi-mycotoxin study 
Annex K reports supplementary material as tables (K1-K6) which summarise the single biomarker history for 
AFs (K1), OTA (K2), DON (K3), FBs (K4), ZEN (K5), NIV (K6), and ENNs, BEA and STC (K7). Supplementing 
tables list the substrate, the kind of study (either for exposure or a toxicological study), the animal (sample 
type), the analytical technique used and the range of levels found (including the LOQ or LOD value). Moreover, 
supplementing tables K8-K12 summarizes the information from the animal perspective: K8 for poultry, K9 for 
suidae, K10 for bovidae, K11 for rat and mice, and K12 for horse and dog. For each group of animals clustered, 
supplementing table lists the biomarker, the sample description, the substrate, the range of values, the 
analytical method and the conclusions. 
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3.6.1.1. Aflatoxins 
The largest number of publications (N=22) examines AFs. This is understandable due to the toxicological 
concern of AFB1 and for the issues that still remain unsolved about the definition of the excretion rate of all 
the different metabolites. The majority of the studies is about the BM measurement for exposure assessment. 
In fact, AFM1 in animal milk is the most represented biomarker (14 references). However, AFB1 in faeces, 
rumen fluid, milk, and plasma and AF-adducts (albumin, lysine or guanine) are also considered both in 
toxicological studies and in exposure assessment. Seven out of the reported publications dealing with a multi-
biomarker study where the assessment of AFB1 is in combination with one or more metabolites or with other 
mycotoxins (most often OTA).  
As regards the BM analytical technique, ELISA methods for AFM1 are used in the majority of publications, 
lamentably, often without indicating the LOD/LOQ of the method that represents a crucial information to 
assess the strength of the analytical results. HPLC-FLD and LC-MS/MS techniques are also reported almost in 
combination with purification step, which is necessary to reach a suitable sensitivity. 
Table K1 in annex K shows AFs and each AF BM reported in the different substrates of the associated animal. 
3.6.1.2. Ochratoxin A 
OTA is present in 11 publications of which 9 are about the BM presence in exposure studies whilst 2 are about 
toxicological studies. OTA has been studied in a wide range of substrates (see table K2). Either for its 
metabolism and distribution this toxin can be found in kidney, liver, bile, rumen fluid, faeces, plasma and urine. 
OTα, the hydrolysed form of OTA, is the only metabolite that is reported in the present dataset. OTA is present 
in a number of multi-biomarker publications especially in combination with AFs. The majority (82%) of the 
scrutinized references have been reported OTA in exposure assessment studies. OTA analyses are mainly 
carried out by HPLC-FLD or LC-MS/MS with good sensitivity and few are the authors who did not reported 
analytical LOD or LOQ. 
Table K2 in annex K shows the list of substrates and the range of levels found for OTA and OTα. 
3.6.1.3. Deoxynivalenol 
DON and its numerous metabolites are present in 12 publications, 6 about the biomarker presence in exposure 
studies and 6 in toxicological studies. Urine, serum and plasma are the most common substrates for the 
biomonitoring studies of DON, nevertheless there have been publications about the presence of DON and its 
metabolites in bile, eggs, excreta and faeces (see table K3). DON has a high number of metabolites, de-
epoxidised form (DOM1), gucuronidizated metabolites (3 and 15 DON glucuronide forms), and sulfonates 
forms that are measured in various substrates. Due to the complex metabolism, DON is often measured in 
combination with its metabolites, and also with other toxins, which with it may co-occur in the exposure.  
Table K3 shows the list of substrates and the range of levels found for DON and DON metabolites. 
3.6.1.4. Fumonisins 
Quite few publications were found in literature. Hydroxylated derivatives of FB1 (HFB1 and pHFB1 a/b) are 
the BM reported in animal studies for fumonisin B1 and summarized in table K4. FBs are known to have a 
rapid distribution and excretion rates; the BM were detected in faeces and urine. Between the BM of exposure, 
the ratio of Sa and So (Sa/So rates) is a well-known parameter used for FBs exposure and Masching (Masching 
et al., 2016) reports values of Sa, So and Sa/So rates (table K4).  
Due to the recurrent occurrence in maize, FBs are often studied in multi-biomarker studies, where the presence 
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3.6.1.5. Zearalenone 
ZEN is studied in combination with a high number of metabolites; it is present in 9 publications of which 7 
report the entire metabolites group. ZEN, ZAN, α- and β-ZEL, α- and β-ZAL unconjugated, glucuronide and 
sulphate forms have been quantified in different substrates, urine and faeces being the preferable excretion 
route (table L5). However, there have been publications about the presence of ZEN and its metabolites also 
in bile, cardiac muscle, kidney, liver, lung, muscle, ovary, spleen, uterus and plasma (Winkler et al., 2014; 
Gajęcka et al., 2016; Ueberschär et al., 2016). Due to the complex metabolism, ZEN is always measured in 
combination with its metabolites and in combination with other Fusarium toxins (Winkler et al., 2014) or other 
toxins (Gambacorta et al., 2016). 
Table K5 shows the list of substrates and the range of levels found for ZEN as biomarker. 
3.6.1.6. Nivalenol and T2 toxin 
Two references, one for NIV and one for T2, have been selected in this database (Sun et al., 2014; Kongkapan 
et al., 2016a). Both are toxicological studies carried out to study metabolic pathways of these molecules (see 
table K6).  
Of the possible metabolites of T2, HT2 and T2triol are those monitored in plasma and urine. The study has 
measured a positive value of the metabolites in urine, excepting for HT2. Sun (Sun et al., 2014) studied the 
fate of the toxin in different substrate. Colon, heart, kidney, liver, muscle and plasma reported a positive 
measurement of NIV, but no metabolites were reported. 
Table K6 shows the list of substrates and the range of levels found for NIV and T2 as BM. 
3.6.1.7. Enniatins, beauvericin, sterigmatocystin 
Six references, 4 for ENNs, 1 for BEA and one for STC, have been selected in this database (see table K7). All 
the references regard toxicological studies carried out to learn about metabolic pathways of these molecules.  
Only parent molecules have been measured for these 3 mycotoxins; in fact, no phase II metabolites have 
been reported for these molecules yet. Fushimi (Fushimi et al., 2014) investigated STC in urine only. ENNs 
and BEA were monitored in brain, cervical cancer tumor, colon, fat, kidney, faeces, liver, muscle, plasma, 
serum and urine (table K7). 
3.6.1.8. Multi-mycotoxin multi-biomarker 
The multi-mycotoxin studies collected comprised all kind of publications showing either study of a single 
mycotoxin and its metabolites or those studies where a group of 2 or more mycotoxins (with or without 
metabolites) were simultaneously monitored in different substrates. In the animal dataset the majority of the 
studies regarded the analysis of the parent toxin with its metabolites, while only 4 publications analysed a 
group of different mycotoxins.  
In Figure 17 the histograms representing the number of studies for each mycotoxin are showed. 
 
3.6.2.  Biomarkers of exposure in animal species 
Mycotoxins are natural contaminants ubiquitous in agricultural commodities. Cereal and cereal products for 
animal feeding are regulated with two legislative acts: the Directive EC/32/2002 (European Parliament, 2002), 
which sets maximum levels for AFB1 and in feed and feed products intended for farming animals, and the 
Recommendation EC/576/2006 (European Commission, 2006) which establishes guidance values to be applied 
to verify the acceptability of compound feed and cereal and cereal products for animal feeding. Occurrence 
data for all the mentioned mycotoxins in feed and feed products are available and data is produced through a 
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Five groups of animal species were categorised and clustered: 1) poultry (chicken, hens, and turkeys), 2) 
bovidae (cow, cattle, buffalo, sheep and goat); 3) suidaes (pigs and wild boars); 4) rat and mice; and 5) other 
animals (dog and horses).  
All the selected studies listed in the dataset were taken into consideration to gather information on the BM 
presence tracing the parent molecule and the metabolite into the different substrates.  
3.6.2.1. Poultry 
Chickens and turkeys have been clustered in this group. As it is shown in Figure 18, among all the publications, 
the most numerous deal with broilers, with DON as the most common mycotoxin studied, while excreta and 
liver are the most common analysed substrate.  
Table K8 sets out data about poultry listing the BM, sample and study description, substrate, range of values 
and analytical method in each of the reported reference. 
 
 
Figure 18: Distribution of biomonitoring and toxicokinetic studies in poultry reporting markers of exposure  
and the number of BM measurements for poultry species, organs and mycotoxin congeners 
 
Aflatoxin 
In poultry, AFB1 and AFM1 measurements in different substrates were used to investigate the effects of lactic 
acid bacteria on growth performance, and AFs metabolism (Liu et al., 2017) or to check the efficacy of grape 
seed proanthocyanidin extract (a power antioxidant) in the detoxification of AFB1 in broilers (Rajput et al., 
2017). Both the lactic acid bacteria and the supplementation of grape seed proanthocyanidin extract were 
shown to be effective in the detoxification of AFB1, reducing AFB1 residues. On the other hand, Yaser (2017) 
explored the efficacy of humic acid as an AFB1 binder in broiler chickens exposed to a AFs-contaminated feed. 
Humic acid showed protective effects against liver damage and some of the hematological and serum 
biochemical changes associated with aflatoxin toxicity (Yaser et al., 2017). 
Ochratoxin A 
Bile (Armorini et al., 2015), liver and kidney (Joo et al., 2013) have been reported as good substrates for the 
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experimental diet treatments where a good correlation between the ingested OTA and the findings confirmed 
that OTA in these substrates could be considered a good indicator and a suitable biomarker of exposure. 
Joo et al. (2013) and Qu et al. (2017) have verified that the use of mycotoxin deactivators or mixed adsorbent 
in OTA contaminated diets significantly decreased the OTA accumulation in organs and significantly increasing 
fecal excretion of OTA and its metabolite OTα (Joo et al., 2013) and reduce adverse effects of ochratoxicosis 
in broilers (Qu et al., 2017). The carryover in eggs was found to be below the limit of detection (Armorini et 
al., 2015). 
Deoxynivalenol and nivalenol 
DON and DON metabolites are the most investigated mycotoxins in poultry. From feeding trials with turkeys, 
chickens, pullets, and roosters Schwartz-Zimmermann (Schwartz-Zimmermann et al., 2015) found out that in 
excreta and chyme samples DON3sulfate resulted to be the major DON metabolite in all poultry species 
studied. Devreese (Devreese et al., 2012) set a model for testing the efficacy of DON detoxifying agents in 
plasma where concentrations of DON were significantly reduced by the detoxifying agents, without detecting 
the main metabolite, DOM1 (Devreese et al., 2012). DOM1 was not found in none of the plasma and bile 
samples tested in the feeding trial conducted by Ebrahem (Ebrahem et al., 2014) whose diet included DON 
contamination (0.4 and 9.9 mg DON/kg). As regards the carryover rates of DON levels transferred in egg yolk 
and albumen, Ebrahem found ranges from 0.0 to 0.000016, indicating that very low levels of DON are 
transferred into eggs so that their contribution to human exposure is considered from very low to insignificant 
(Ebrahem et al., 2014). 
NIV is poorly absorbed orally and it is rapidly eliminated via faeces. NIV was found to be able to penetrate 
into various tissues: small intestine, kidney, heart, liver and muscle (Kongkapan et al., 2016b). The largest 
quantity of NIV was found in the small intestine suggesting that NIV in broilers is absorbed from the 
gastrointestinal tract with low bioavailability and has the ability to diffuse into various tissues (Kongkapan et 
al., 2016b). 
Fumonisins 
All studies on FBs concern the testing of different agents for their detoxifying capacity. Commercial 
carboxylesterase or nosilicate clay platelets were supplied to the animals with FBs contaminated diets. A 
feeding trial was performed by Masching (Masching et al., 2016) to compare a control group with a group fed 
with a fumonisin contaminated diet. When the supplemented carboxylesterase (FUMzyme) was introduced in 
the diet, a significant decreased FB1 levels in excreta and a consequent significantly increase of HFB1 
concentrations were registered confirming that carboxylesterase is effective to detoxify FB1 in the digestive 
tract of turkeys (Masching et al., 2016). The same conclusions were obtained by Grenier et al. (2017) who, by 
the analysis of the sphingoid base, showed an increase of the Sa/So ratio in the serum and liver of broiler 
chickens fed with FB-contaminated diet as compared to ones fed with an uncontaminated diet (Grenier et al., 
2017). The addition of carboxylesterase (FUMzyme R) significantly reduced this specific increase of the Sa/So 
ratios in serum and liver and was able to hydrolyze FBs in the gastrointestinal tract of chickens. Likewise, Yuan 
et al. (2017) concluded that nanosilicate clay platelets are as a safe and effective agent for FB1 detoxification 
as effectively improved the growth performance and ameliorated FB1 toxicosis (Yuan et al., 2017).  
Enniatins 
ENNB1 and ENNB measurements were included in a toxicokinetic study by Fraeyman (Fraeyman et al., 2016). 
Both ENNs were found to be poorly absorbed after oral administration and readily distributed to the tissues. 
The mean total body clearance was rather high, namely, 6.63 and 7.10 L/h/kg for ENNB1 and B, respectively. 
The study also evidenced that oxygenation was the major phase I biotransformation pathway for both ENNB1 
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3.6.2.2. Suidae (pig and wild boar) 
Pig and wild boar were included in this group. As it is shown in Figure 19, among all the publications, ZEN is 
the most popular mycotoxin studied, while urine is the preferred most common analysed substrate. 
In Annex K supplementing table K9 reports the biomarker, the sample description, the substrate, the range of 
values, the analytical method and conclusions for suidae studies are listed. 
 
Figure 19: Distribution of biomonitoring and toxicokinetic studies in suidae (pig and wild boar) reporting 




The articles about AFs are from Di Gregorio (Di Gregorio et al., 2017a; Di Gregorio et al., 2017b) who for one 
hand set and optimized a method for the determination of AFB1-lys in serum and heparinized swine plasma. 
This study verified that the use of EDTA did not interfere in AFB1-lys standard detection, but they suggest that 
EDTA should be avoided during blood collection since it affects the pronase activity in AFB1–albumin adduct 
digestion and, consequently, causes a reduction in the AFB1-lys levels. Di Gregorio’s research also verified that 
AFB1-lysine is a good AFB1 biomarker for diagnostic purposes and for evaluating the efficacy of 
chemoprotective interventions of a hydrated sodium calcium aluminosilicate in pigs fed AFB1.  
Ochratoxin A 
All the publications about OTA in suidae are referred to bio-monitoring studies where the animal exposure was 
investigated in different countries. This strengthens the reliability to use direct OTA measurements in biofluids 
to measure OTA levels and possibly prevent the occurrence of ochratoxicosis in animal production, reduce 
economic losses, and minimize hazards to human health (Kruger et al., 2010). 
Pozzo (Pozzo et al., 2010) investigated the different exposure patterns in organic and conventional swine 
farms in Italy. Despite the fact that all the complementary and complete swine feedstuffs were under the EU 
recommended guidance values, the OTA contamination of organic feed and serum samples of swine organically 
fed was found to be significantly higher than that of conventional feed and serum samples (Pozzo et al., 2010).  
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Four major geographical regions of Brazil were monitored by Kruger (Kruger et al., 2010) with the aim to 
investigate OTA distribution. OTA distribution in foodstuffs was found to be very heterogeneous. The direct 
relationship found between the higher concentrations of OTA in serum and the highest concentrations of OTA 
in food intended for animal consumption strengthens the strategy of measuring the presence of OTA in swine 
serum samples as an alternative to the feedstuff analyses. Grajewski (Grajewski et al., 2012) compared the 
OTA presence in kidney of pigs and wild boars during 2006-2007 seasons. Higher level of OTA in the kidneys 
and serum of wild boars than the levels present in pigs were found in both years (Grajewski et al., 2012). 
Besides in a study where the impact of the farming system (organic, Label Rouge and conventional) was 
assessed, the levels of OTA were tested and the liver–muscle pairs of French pigs (muscle and liver) showed 
OTA liver concentration systematically higher (2.9×OTA) than the muscle (Hort et al., 2018). 
Deoxynivalenol, nivalenol and T2 toxin 
DON Contamination in grains is common worldwide and pigs are the most susceptible species to this 
mycotoxin. Deng (Deng et al., 2015) investigated the distribution of DON in plasma, bile and 27 tissues after 
i.v. administration (250 μg/kg bw and 750 μg/kg bw) and verified that concentrations of DON in tissues differ 
when pigs are exposed to various dosages and that DON causes lesions in many pig tissues (Deng et al., 
2015). The same conclusions were reached by Alizadeh (Alizadeh et al., 2015), who measured the effects of 
a short-term and comparable DON exposure (0.28 mg/kg bw) on various gut health parameters in pigs. They 
found out that the DON contaminated diet negatively affected weight gain and induced histomorphological 
alterations in the duodenum and jejunum. Even after level exposure to DON considered as acceptable in animal 
feeds, the clinically-relevant changes were measurable in markers of gut health and integrity. 
The oral bioavailability of DON3G and its metabolites was assessed by Nagl (Nagl et al., 2014) and seems to 
be reduced by a factor of up to 2 compared with DON. The authors carried out oral and intravenous application 
of DON and DON3G. The majority of orally administered DON3G was excreted in form of DON, 
DON15glucuronide, DOM1 and DON3glucuronide, while urinary DON3G accounted for only 2.6%. In faeces, 
just trace amounts of metabolites were found. When administered intravenously, DON3G was almost 
exclusively excreted in un-metabolized form via urine. Data indicate that DON3G is nearly completely 
hydrolyzed in the intestinal tract of pigs, while the toxin seems to be rather stable after systemic absorption 
(Nagl et al., 2014). 
In a DON-controlled feeding study on weanling piglets (Hopton et al., 2012), the DON ingestion was found to 
be associated with plasma glucose concentration.  
DON sulfonate is another one of the DON metabolites that are urinary excreted. It can be degraded back to 
DON under physiological conditions as it has been put in evidence in the urinary balance experiment carried 
out by Frobose (Frobose et al., 2017). The feeding trial set by Frobose and co-authors was performed to 
assess the effect of commercial products of adsorbent clays and the metabisulfite product. They found out 
that feeding diets contaminated with 4 mg/kg DON to nursery pigs reduced nursery pig growth, primarily via 
feed intake suppression. The addition of a commercial product of adsorbent clays (blended with preservatives) 
did not alleviate the DON-associated effects on pig growth nor did reduce DON absorption and urinary 
excretion compared to pigs fed DON-contaminated diets alone. However, treating DON-contaminated diets 
with 1.0% sodium metabisulfite product restored feed intake and improved feed efficiency markedly (Frobose 
et al., 2017). Gambacorta (Gambacorta et al., 2016) experimented the effect of four agricultural by-products 
to be used as alternatives to commercial binders to reduce the gastrointestinal absorption of a mixture of 
mycotoxins. Urinary mycotoxin BM were tested in piglets fed with bolus containing 769 μg of FB1, 275 μg of 
DON, 29 μg of ZEN, 6.5 μg of AFB1 and 6.6 μg of OTA (2.2, 0.8, 0.08, 0.02, and 0.02 μg/g in the daily diet, 
respectively). The reduction of mycotoxin absorption was up to 69% and 54% for agricultural by-products and 
commercial binders, respectively. White grape pomace of Malvasia was the most effective material as it 
reduced significantly urinary mycotoxin biomarker of AFB1 and ZEN, whereas statistically not significant 
reductions were observed for FB1, DON, and OTA.  
Sun and co-workers (Sun et al., 2014) developed a method for the analyses of T2 and HT2 that was 
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metabolites in pigs. Animals were administered with T2 intravenously and the results provided information for 
evaluating and controlling human exposure to residual T-2 toxin and its major metabolites. 
Zearalenone 
ZEN and its metabolite αZEL are nearly exclusively conjugated to glucuronic or sulfuric acid in bile and urine 
of pigs. Ueberschär (Ueberschär et al., 2016) fed a group of sows with ZEN contaminated diets and ZEN and 
αZEL concentrations were assessed in urine and bile. In bile samples, both mycotoxins increased significantly 
with the ZEN concentration of the feed. In urine, such a dependency was found only for αZEL. The percentage 
of the free ZEN and αZEL varied between 1 and 6 %. The proportion of glucuronidated conjugates of ZEN in 
bile and in urine of sows was >95 % and no sulfated conjugates were present. The relation of glucuronidated 
to sulfated conjugates of αZEL was 82 to 17 % in bile, whereas in urine the sulfated form of αZEL was 
predominant to the glucuronidated form (62 % and 33 %, respectively). 
All plant ZEN metabolites (ZEN14- and ZEN16- glucoside) and fungal ZEN metabolites (ZEN14S) can be present 
in feed, therefore, exposing animals to absorption, distribution, metabolism and excretion (ADME) (Binder et 
al., 2017). After oral administration of ZEN 10 g/kg bw, ZEN14Sulfate 12.5 g/kg bw, ZEN14G 12.5 g/kg bw, 
ZEN16G 12.5 g/kg bw, Binder measured the biological recovery of ZEN in urine (26% +/- 10%), and the total 
biological recovery in excreta. ZEN14sulfate, ZEN14ObGlucoside and ZEN16ObGlucoside were neither detected 
in urine nor in faeces. After ZEN14sulfate supplementation, 19% of the administered dose was recovered in 
urine. None of the ZEN metabolites were detected in faeces. The total biological recoveries of 
ZEN14Obglucoside and ZEN16Obglucoside in the form of their metabolites in urine were 19% and 13%, 
respectively (Binder et al., 2017). 
Multi-mycocotoxins 
There is only one study in the animal dataset reporting a multi-mycotoxin study for pigs. The efficacy of four 
agricultural byproducts and two commercial binders to reduce the gastro-intestinal absorption of a mixture of 
mycotoxins was tested in piglets using urinary mycotoxin BM as indicator of the absorbed mycotoxins. The 
study demonstrated that grape pomace reduces the gastrointestinal absorption of AFB1, DON, FB1, OTA and 
ZEN and it can be considered an alternative to commercial products (Gambacorta et al., 2016). 
3.6.2.3. Bovidae 
Cows, buffalos, goat and sheep were included in this group. As it is shown in Figure 20, among all the 
publications considered AFs, more specifically AFM1 in cow milk, are strongly represented.  
In Annex K supplementing table S10 lists the biomarker, the sample description, the substrate, range of values, 
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Figure 20: Distribution of biomonitoring and toxicokinetic studies in bovidae reporting markers of exposure 
and the number of BM measurements for bovidae species, organs and mycotoxin congeners. 
 
Aflatoxins (AFB1 and AFM1) 
Mycotoxins metabolites produced by phytopathogenic and spoilage fungi in animal feed as a result of poor 
storage, can originate in the field and are excreted in milk when dairy animals consume these contaminated 
feeds, posing a public health risk concern (Makau et al., 2016). AFM1 is the major metabolite of AFB1 in 
mammals; it is partially excreted into milk, and is a possible human carcinogen. Milk yield and the carry-over 
of AFB1 in the feed to AFM1 in the milk are highly correlated, so the definition of the AFM1 carry-over in dairy 
cows is considered of extreme importance.  
A population of Israeli-Holstein cows of high milk production (world record milk production) (Britzi et al., 2013) 
were used to determine AFM1 carry-over following daily oral administration of feed containing ~86 μg AFB1 
for 7 days. The carry-over appears to increase exponentially with milk yield and is described by the equation: 
carry-over% = 0.5154 e 0.0521 × milk yield, with r2 = 0.6224.  
The monitoring of AFM1 in animal milk is an official control activity performed by the Member States to verify 
that the provisions set by the EU food low legislation are enforced and complied. The AFM1 limit in cow milk 
set in EU is a legislative reference also for other countries. In India, Nile (Nile et al., 2015) monitored a total 
of 600 samples of milk from buffalo, cow, goat, and sheep from urban, semi-urban and rural areas for the 
content of AFM1 in milk. In this work, it is shown that AFM1 contamination was found in 36% of the samples 
of which 16% of buffalo, 44% of cow, 10% of goat, and 12% of sheep milk samples were above the maximum 
limit accepted by the EU. Both in the Nile et al. monitoring study and the in the Kenyan study (Makau et al., 
2016), the level of AFM1 concentration was found minimal in milk coming from rural areas. 
Oral supplementation of clay (at 0.5%, 1%, 2%) to dairy cattle has been reported to reduce toxicity of AFs in 
contaminated feed (100 μg of AFB1/kg of dietary dry matter intake) (Sulzberger et al., 2017). Concentrations 
of AFM1 in milk, AFB1 in faeces and AFB1 in rumen fluid were reduced in cows fed with clay compared with 
positive control with no clay. 
Multi-mycotoxins 
The consumption of feeds contaminated with mycotoxins (particularly AFs, OTA, and ZEN) by the animals 
causes various hepatic and renal disorders, severe immunodeficiency and reproductive disorders. The presence 
of these mycotoxins in different organs depends on the selective place of metabolisation of these mycotoxins 
(Simion et al., 2010). Various studies have determined the presence of AFM1 and of ZEN in milk, of AFB1 in 
the hepatic tissue and in the serum, of OTA in the liver, of ZEN in the bile. The presence of AFs (AFB1, AFB2 
and AFM1), OTA and ZEN, or their metabolites, was investigated in various bovidae fluids (milk, ruminal fluid, 
urine and bile) by Simion (Simion, 2010). The presence of mycotoxins resulted in all the analysed matrices: 
total AFs and OTA in the ruminal fluid, AFM1 in milk. In contrast AFB1, AFB2 and ZEN were absent in the 
samples of urine and bile. 
High-production dairy and beef farming systems require the supplementation of diets rich in starch. This 
practice may induce ruminal acidosis and also increase exposure to mycotoxins because starches in starch-
rich diets are the main vehicles of mycotoxin contamination (Pantaya et al., 2016). The effects of low ruminal 
pH on the bioavailability of 4 major mycotoxins AFB1, OTA, DON, FB1 was scrutinized by Pantaya (Pantaya et 
al., 2016) in a feeding trial of high and low starch diet with and without yeast supplementation contaminated 
by AFB1, OTA, DON, FB1. In conclusion, after fecal and urinary analyses it came out that the bioavailability of 
DON and FB1 remained unchanged; in contrast, high-starch diets increased the OTA and AFB1 bioavailability, 
most probably through the lowering effect on ruminal pH. Urinary excretion of OTA after mycotoxin 
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fecal excretion of AFB1 was accompanied by an increase in urinary excretion of its major metabolite, aflatoxin 
M1. 
In a study (Hashimoto et al., 2016) where cows were supplemented with OTA contaminated diet (5–100 
μg/kg), OTA appears not to be carried over into milk and tissues (such as liver, kidney, muscles, fat and 
jejunum ileum) of cows. In contrast, a small amount of OTA (0.1 μg/kg) was detected in the blood plasma 
concluding that the ingestion of diets containing up to 100 μg/kg of OTA over 28 days does not affect feed 
intake or milk production of cows and the dietary OTA is not carried over into milk and edible tissues such as 
liver, muscles and fat.  
The increased plasma concentrations of ZEN, DON and DOM1 may hint on toxin exposure through the diets. 
Urinary ZEN levels decreased when the rice straw feeding contaminated with ZEN was substituted with new 
rice straw with lower ZEN contamination (Hasunuma et al., 2012). A linear relationship between toxin intake 
and plasma levels was established by Winkler (Winkler, 2014). DON, DOM1 and ZEN levels were measured in 
plasma of dairy cows supplied with diets DON and ZEN contaminated close to the current guidance values and 
the authors (Winkler et al., 2014) established that DON, DOM1 and ZEN were detected simultaneously in all 
plasma samples but the average performance level (e.g. daily dry matter intake, energy balance and milk 
yield) was not affected by DON and ZEN levels in feed.  
3.6.2.4. Rats and mice 
Mice and rat were included in this group that presented only toxicokinetic study with data on BM. As it is 
shown in Figure 21, among all the publications considered DON is the higher mycotoxin represented while 
faeces and urine are the most common analysed substrates.  
 
Figure 21: Distribution of biomonitoring and toxicokinetic studies in rat and mice reporting markers of 
exposure  and the number of BM measurements for rat and mice species, organs and mycotoxin congeners 
 
Aflatoxins 
Huang (Huang et al., 2017) investigated the potential binding capacity of Lactobacillus plantarum isolated 
from Chinese traditional fermented foods to reduce the toxicity of AFB1 toxicity, and its subsequent 
detoxification mechanism. The L. plantarum strains were orally administered to mice with liver oxidative 
damage induced by AFB1. L. plantarum may alleviate AFB1 toxicity by increasing fecal AFB1 excretion, 
reversing deficits in antioxidant defense systems and regulating the metabolism of AFB1. 
Brain concentration of AFB1 was used to evaluate the modulation of AFB1 passage into the brain. Tras (Tras 
et al., 2017) conducted the first in vivo experimental study intended to verify if plasma and brain concentrations 
of AFB1 are affected by the modulation of trans-membrane proteins, namely the ATP-binding cassette 
transporter superfamily (e.g. P-glycoprotein and the breast cancer resistance protein), by using 2 drugs: 
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prazosin, an alpha-adrenergic blocking agent, and Zosuquidar, a compound of antineoplastic drug candidates. 
Both drugs significantly reduced the brain concentration of AFB1 but not the plasma concentration. They 
evidenced that AFB1 may be a substrate of both P-glycoprotein and the breast cancer resistance protein (P-
gp and BCRP).  
Rat blood and faeces were analysed to verify the efficacy of the oxidized tea polyphenols (OTP) to complex 
AFB1. Lu et al. (2017) demonstrated that AFB1 can be complexed and the absorption of the complexed-AFB1 
is inhibited in rats. In fact, AFB1 plus OTP group had significantly (P < 0.05) decreased AFB1-albumin 
compared to the AFB1 group at 4 h after ingestion significantly promoting (P < 0.01) the elimination of AFB1 
in faeces (Lu et al., 2017). 
Enniatins and beauvericin 
The Fusarium toxins ENNB and BEA have recently aroused interest as food contaminants but data about their 
toxic profile are limited. Short and long exposure were studied for these two Fusarium toxins. 
Both Fusarium toxins were investigated by Rodríguez-Carrasco (Rodriguez-Carrasco et al., 2016) in mice 
treated intraperitoneally. ENNs and BEA were found in all tissues and serum but not in urine. Moreover, they 
were measured in liver and fat demonstrating the molecules’ tendency to bioaccumulate in lipophilic tissues.  
While for BEA no metabolites could be detected, for ENNB phase I metabolites were found in liver and colon, 
namely deoxygenated-ENNB, mono- and di-demethylated-ENNB. As it is reported in table S11 the 
deoxygenated-ENNB gave the higher quantitation indicating that the contribution of hepatic and intestinal 
metabolism seems to be involved in the overall metabolism of ENNB. 
In a study performed by Juan (Juan et al., 2014), Wistar rats were dietary supplemented with ENNA during 
28 days of exposure time to determinate its levels in serum, urine and faeces and to evaluate the immunologic 
effect in peripheral blood lymphocytes (PBL). 
Ochratoxin A 
OTA and OTα in urine and faeces were measured in Fisher rats (Abbas et al., 2013), which were allocated 
with dietary treatments consisting of flavonoid-free balanced diet containing 10 mg OTA/kg and the same diet 
supplemented with 100 mg quercetin/kg. OTA was mainly excreted as OTα (93%), and only a small part (6–
7%) appeared in its original form. Similar as in urine, OTα and OTA accounted for 94% and 6%, respectively, 
in faeces. Quercetin supplementation had no effect (P > 0.05) on feed consumption, OTA-intake, water intake 
and body weight gain. Faecal and urinary excretion of OTA and OTα and concentrations of OTA in all tissues 
were not affected by quercetin supplementation concluding that the polyphenol quercetin has no impact on 
the toxicokinetics of OTA in vivo. 
Deoxynivalenol 
DON, DON3G and DON metabolites (deoxynivalenol-glucuronide and DOM1) were monitored in rats’ urine and 
faeces (Nagl, 2012) after administration of DON3G and DON contaminated diet. DON3G was recovered only 
for the 3.7±0.7% of the given dose in urine in the form of analysed analytes (14.9±5.0% after administration 
of DON, and only 0.3±0.1% were detected in the form of urinary DON3G). The majority of administered 
DON3G was recovered as DON and DOM1 in faeces. These results suggest that DON3G is little bioavailable, 
hydrolysed to DON during digestion, and partially converted to DOM1. 
3.6.2.5. Other animal species: horses and dogs  
Ochratoxin A and zearalenone 
OTA was determined in blood samples of healthy and affected by chronic kidney disease dogs (Meucci et al., 
2017). CKD group showed higher incidence of OTA than healthy dogs (96 vs. 56%) and a significantly higher 
median value of OTA plasma concentration (0.008 vs. 0.144 ng/ml). While plasma, urine and faeces were 
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al., 2013). The study concluded that the main conversion of ZEN was into βZEL in horses explaining this animal 
species is not susceptible to ZEN in comparison with swine. The βZEL levels found in plasma were detected at 
higher level on day 10 of the study. βZEL and αZEL were the major metabolites in urine and ZEN, βZEL and 
αZEL were predominantly found in faeces. The degree of glucuronidation was established in all sample types, 
approximately 100% in urine and plasma, whilst low glucuronidation was found in faeces samples.  
 
3.6.3. Biomarkers of exposure in humans 
The focus of the reviewed literature was addressed for selecting all studies where the biomarker was used for 
assessing human exposure and for driving knowledge of all the possible correlations between mycotoxin 
exposure rates of intake and health effects. The selection criteria followed included the kind of bio-monitoring 
studies that were planned to study either the parent molecule or its metabolites, especially in multi-toxin 
measurements. A number of studies that were published for the purpose of the method setting/validation, 
was also taken into consideration. This is considered a topic of crucial importance in the bio-monitoring field, 
in fact, whenever available, performances of the method (LODs and LOQs and validation performances) were 
also included to substantiate the reliability of the method. 
The final number of the references about the human studies after the selection criteria summed up 176 articles 
focused on biomarker studies of a single mycotoxin or of multi-mycotoxin. The 176 articles produced more 
than 2500 records. It was defined as a multi-biomarker study that one where the parent and one or more 
metabolite was analysed; thus, the number of multi-biomarker measurements accounted for 37.5%, the 
remaining 62.5% regarding publications that reported studies of a single mycotoxin.  
Table 16 summarizes the number of records registered for each mycotoxin, the number of references and the 
number of combinations where the toxin was studied in a single or multi analysis (either in combination with 
its metabolites only or with other mycotoxins). As it is shown the number of publications on aflatoxins are the 
majority followed by DON, OTA, FBs and ZEN. There are a number of other mycotoxins (i.e. ALT, TEA, FUSX, 
NEO, CIT, NIV, T2, DAS, ENNs) that have been scrutinized in quite a few publications. 
Figure 22 synthesizes the number of the total references that populates the human dataset indicating the 
distribution between the two groups of studies, i.e. single and multi BM study. The figure shows also the 
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Table 16: Summary of mycotoxins, number of records, number of references and the type of study 





N° of references with a 
single-BM 
N° of references with a 
multi-BM (b) 
AFs 453 102 74 12/16 
ALT 2 1 - -/1 
OTA 199 45 23 4/18 
DON 279 31 3 11/17 
FBs 100 22 5 3/14 
TEA 5 2 1 1/- 
FUSX 7 2 - -/2 
NEO 4 2 - -/2 
CIT 51 9 - 3/6 
NIV 10 4 - -/4 
T2 17 4 - -/4 
ZEN 142 19 - 5/13 
DAS 7 2 - -/2 
ENNs 4 1 - -/1 
Multi-BM 805 66   
Single-BM 454 110   
a) Number of references where the parent mycotoxin or a metabolite has been considered either in a single or multi-/BM study 
b) Parent plus its metabolites/multi-mycotoxin 
 
 
Figure 22: a) The number of the total references in the human dataset and the distribution between the 
single biomarker study and multi biomarker study (left) and the distribution of number of references for 
each mycotoxin reporting single biomarker data, multi biomarker data, i.e. parent + its metabolites, and 
multi-mycotoxin data (right). 
Supplementing tables (L1-L6) are reported. Supplementing tables summarize the single biomarker history for 
AFs (L1), OTA (L2), DON (L3), FBs (L4), ZEN (L5), CIT and TeA (L6). Supplementing tables report the 
substrate, the population group, the analytical method, the range of values, the information on the study, the 
association with the diet and the exposure values (when available) for each BM in the reference. Moreover, 
supplementing table L7 collates the same BM info extracted specifically from multi-biomarker studies. 
3.6.3.1. Aflatoxins 
In the dataset, the largest number of publications examines AFs. This is understandable due to the toxicological 
concern of AFB1. The aflatoxin alb adducts in serum (more specifically the aflatoxin-lysine adduct) and 
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aflatoxin B1-N7-guanine, aflatoxins-mercapturic acid and aflatoxin M1 in urine (Zhu et al., 1987; Gan et al., 
1988) represent the first BM of exposure that were validated and used for the mycotoxin risk assessment. The 
majority of the data in the dataset regards AFM1 analysed in urine (66%), in breast milk (28,5%) and in serum 
(5,5%). In fact, due to the long half-life of alb in humans, the measurement of aflatoxin alb adducts in blood 
and its derivatives is strongly preferred with respect to urine, and it indicates an exposure extent over a period 
of 1-2 months (Sabbioni et al., 1987; Leong et al., 2012). However, AFB1, AFB2, AFG1, AFG2, AFM2, AFalb, 
AFB1lysine, AFB1guanine and AFOH are also extensively considered. Figure 23 shows the number of 




Figure 23: Number of measurements of AFs metabolites and substrates analysed 
As regards the BM analytical technique, 41% of the works used ELISA methodology, 32% HPLC-FLD, 21% 
LC-MS or LC-MS/MS, and 6% used alternative techniques (RIA, TLC, AflaCheck test or VFM). In 28% of 
publications, lamentably, neither LOD nor LOQ of the method were reported.  
In Annex L, supplementing table L1 reports the substrate, the population group, the analytical method, range 
of values, the information on the study, the association with the diet and the exposure values (when available) 
for each single biomarker in the reference. 
3.6.3.2. Ochratoxin A 
Given the extensive occurrence of OTA, which is found in a wide range of foods (i.e. cereals, dried vine fruit, 
wine, coffee, and liquorice), molecular epidemiology studies are particularly important and helpful for 
biomonitoring the extent of the exposure. 
OTA is present in 45 publications of which 23 are about single mycotoxin exposure study, 4 are about OTA 
and metabolites and 18 are publications where OTA is analysed in a multi-mycotoxin study. As for AFs, OTA 
has been studied in a wide range of substrates (see Figure 24 and table L2 in ANNEX L). OTα, the hydrolysed 
form of OTA, is the unique metabolite that is reported in the dataset; however, OTαAglicone and 2R’OTA are 
also measured. In addition to urine and serum, OTA levels have been measured also in breast milk, especially 
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offspring. Up to now, the pattern of OTA distribution in milk is still unclear and few works attempted to 
correlate the dietary intake with OTA concentration in milk, nevertheless it is to highlight that, being the new-
borns exclusively breast fed during the first weeks, the biomonitoring of OTA in human milk is an assessment 
of the risk for infants (Valitutti et al., 2018). 
OTA analyses are mainly carried out by HPLC-FLD (61%). When multi mycotoxin are analysed, LC-MS/MS is 
the preferred analytical technique. However, still a number of ELISA methods are carried out (29%). In 9 of 
the publications there is a lack of information about LOD or LOQ. 
Table L2 shows the list of substrates and the range of levels found for OTA and OTA metabolites, table L7 
shows the synthesis of the papers where OTA was studied in a multi-mycotoxin work. 
The Klassen and Breitholtz equation (Gilbert et al., 2001; Scott, 2005) is currently used to obtain the estimate 
exposure values to OTA starting from plasma concentrations (ng/ml from serum analyses), plasma clearance 
(i.e. renal filtration rate) and OTA bioavailability (considered for most animals of 50%). It is noteworthy to 
mention that recent comparative studies failed in correlating blood levels and dietary intake (Duarte et al., 
2010) probably due to the lack of information on the toxicokinetic mechanisms and the fact that the long half-
life and continuous OTA exposure result in a steady state concentration (EFSA, 2006). Hence, the use of OTA 
in blood as validated biomarker is substituted by the measurement of urinary OTA whose content is lower but 
constitutes a promising alternative especially when further developments on the relationship between OTA 
intake and the urinary biomarker will be defined.  
 
Figure 24: Number of measurements of OTA and OTA metabolites and substrates analysed 
3.6.3.3. Deoxynivalenol 
DON is present in 31 publications of which 3 are single mycotoxin exposure study, 11 are about DON and 
metabolites and 17 are publications where DON is analysed in a multi-mycotoxin study. In the dataset 
considered, DON has been studied only in urine and in fact, it was estimated that 70% of the ingested DON 
is excreted to urine. DON is partially de-epoxidised into DOM1 metabolite and the main biotransformation of 
DON is conjugation with glucuronic acid leading to the presence of DON3glucur, DON15glucur and also 
DOM1glucuronides were analysed (Turner et al., 2010; Turner et al., 2011; Brera et al., 2015; Ali et al., 2016).  
Due to the difficulty to analytically distinguish the two glucuronide forms, often publications report methods 
which imply the use of a double extraction procedure with and without enzymatic treatment for de-
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glucuronization; this leads to obtain a total DON measurement from which by subtraction of the free DON 
contribution, the glucuronidized form contribution is obtained (Turner et al., 2011; Cunha and Fernandes, 
2012; Brera et al., 2015). 
Warth (Warth et al., 2016) reported for the first time a 3-sulfate form of DON in human urine; 70% of the 
urine samples of 40 individuals’ cohort study, resulted positive to DON3Sulfate while none of the samples was 
found positive to DON15S. The exposure to DON acetylated forms was also explored in human urinary 
samples: Rodriguez-Carrasco (Rodriguez-Carrasco et al., 2014) found any positivity while Duringer et al. 
(2016) found one positive sample to 3AcDON (Duringer et al., 2016).  
Excepting for 3 works (10%), which used GC chromatography coupled with spectrometric detection, DON and 
its metabolites are analysed by LC-MS/MS (90% of the publications) and all reported LOQ/LOD values. 
In ANNEX L, table L3 shows the list of substrates and the range of levels found for DON and DON metabolites, 
table L7 shows the synthesis of the papers where DON was studied in a multi-mycotoxin work. 
Deoxynivalenol contamination is associated to wheat and maize crop, thus the exposure is commonly linked 
to cereal based diets. In this regard, a dietary intervention study demonstrated that avoiding wheat reduced 
significantly the urinary levels of DON (Turner et al., 2008). DON, DON glucuronide and DOM1 may be present 
in urines of exposed individuals, and as shown in the table L3 a number of studies have been put in place to 
monitor the BM especially in those areas whose climatic conditions favour the proliferation of Fusarium species 
responsible of DON production.  
 
Figure 25: Number of measurements of DON and DON metabolites and substrates analysed 
3.6.3.4. Fumonisins 
FBs are present in 22 publications of which 5 are single FB1 exposure study, 3 are about FB1, FB2, FB3, Sa, 
So, while 14 are publications where FB1 is analysed in a multi-mycotoxin context study. In the dataset 
considered, FBs have been studied in urine mainly, one study detected FB1 in faeces (Phoku et al., 2012) and 
one in breast milk (Magoha et al., 2014).  
The research on fumonisins has been sought for long time in order to define putative BM. The metabolism of 
fumonisins is limited, FBs are poorly absorbed, distributed and eliminated rapidly by the organism. The oral 
bioavailability is generally below 5% for FB1, and the measurement of the free urinary fumonisins (B1 and 
B2) seems to be a choice for biomonitoring the exposure with sensitive techniques. Van der Westhuizen (van 
der Westhuizen et al., 2011) presented a study where the relationship between urinary FB1 and FB1 ingestion 
gave good results, confirming the potential use of free FB1 as a validated biomarker. 
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Sphinganine (Sa) to sphingosine (So) ratio has been alternatively proposed as putative biomarker on the basis 
that FB1 potently inhibits the enzyme ceramide synthase which catalyses the acylation of Sa and re-acylation 
of So. This inhibition accumulates intracellular Sa altering the Sa/So ratio. In a large range of animal species, 
the changed ratio occurs in a dose dependent manner, but the same ratio in humans is a debate (Shephard 
et al., 2007). Plasma has been explored for the Sa and So levels under this hypothesis (van der Westhuizen 
et al., 2010; Cano-Sancho et al., 2011). 
Excepting for one article, which used ELISA, the 99% of the studies carried out the analyses with HPLC-FLD 
(53%) and LC-MS/MS (46%). Almost all the articles (excepting 4) reported LOQ/LOD values. 
In ANNEX L, table L4 shows the list of substrates and the range of levels found for fumonisins as biomarker. 
 
Figure 26: Number of measurements of FB1, FB2, FB3, Sa and So and substrates analysed 
3.6.3.5. Zearalenone 
ZEN is present in the dataset with a high number of metabolites. Figure 27 shows the kind of substrates for 
ZEN and the list of ZEN metabolites measurements in the dataset. In total 19 studies were selected for ZEN, 
and its metabolites. The majority of the studies take into consideration ZEN and its phase I metabolites (ZAN, 
α- and β- zearalenols and zearalanols). There is only one study in the dataset who analysed ZEN together with 
its phase I and glucuronides forms (Mauro et al., 2015). In a quite high number of publications (74%), ZEN 
was included in a multi-mycotoxin study (with 2 to 6 other mycotoxins) where phase I metabolites were always 
considered, often including glucuronides. ZEN, ZAN, α- and β-ZEL, α- and β-ZAL, ZEN4G, ZEN14Oglucuronides 
have been always quantified in urine (100%), in 2 cases also in serum (Mauro et al., 2015; Fleck et al., 2016). 
The glucuronide forms ZEN14 ZEN14Oglucuronide was analysed by four authors (Abia et al., 2013; Ezekiel et 
al., 2014; Gerding et al., 2015; Cirlini et al., 2017).  
The 100% of the studies carried out the analyses by LC-MS/MS but one fourth of the articles did not report 
information about LOQ/LOD values. 
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Figure 27: Kind of substrates for ZEA and number of ZEN and ZEN metabolites measurements in the 
dataset 
Table L5 shows the list of substrates and the range of levels found for ZEN as biomarker. 
3.6.3.6. Citrinin and tenuazonic acid 
Citrinin has been only recently introduced as biomarker in exposure studies. In the available dataset, there 
are 9 works of which 3 papers investigated CIT and CIT metabolite, dihydrocitrinone (OHCIT), while 6 
publications have introduced CIT in a multi-mycotoxin study. CIT is excreted in urine as such and as OHCIT 
in above 70% of the subject studied (Blaszkewicz et al., 2013; Ali et al., 2015a; Ali et al., 2015b), either adults 
and children (Blaszkewicz et al., 2013). The studies were carried out using HPLC-FLD and LC-MS/MS, one 
study did not report LOD/LOQ values. 
Tenuazonic acid (TeA) is one of the Alternaria spp. mycotoxins that may be present in cereals as well as in 
tomatoes and respective processed products. The two publications reporting urinary TeA showed that it was 
detectable in all German subjects. Moreover, Hövelmann (Hövelmann et al., 2016) showed a trend regarding 
elevated intake of cereal products and higher excretion of tenuazonic acid. The epimerization product of TeA 
under basic or acidic conditions forms alloTeA, thus seems to be of upmost importance to measure the 
presence of both isomers in risk assessment context. 
Table L6 summarises the publication information about CIT and OHCIT and TeA. 
3.6.3.7. Multi-mycotoxins 
The multi-biomarker measurement was realized in 66 of the publications reported. The parent molecule and 
its metabolites or groups of 2 up to 7 mycotoxins have been analysed in biological fluids as shown in Figure 
28. Of the 27 studies reporting multi-mycotoxin, different combinations were registered as it is shown in Table 
17. 
The simultaneous determination of more than one mycotoxin in human biological fluids by means a multi-
biomarker method is a new challenge in mycotoxin biomonitoring. Especially urine seems to be the preferred 
specimen either for the easiness and approachability of the matrix and for its handy non-invasive collection, 
better accepted by study participants. Besides, kidneys are the primary routes for the elimination of those 
xenobiotics that for their chemical characteristics are excreted in urine as parent mycotoxins or conjugated 
forms. However, serum, plasma and breast milk are also studied substrates in multi-mycotoxin analyses. As it 
is shown in Figure 28, AFs and DON together with their metabolites are the most studied. 
Table L7, in ANNEX L, summarized the combination of the multi mycotoxins studies. 
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In the last 5 years the number of multi-mycotoxins scientific works have been increasing and improving thanks 
to the accessibility of reliable techniques and methods of analysis. Thus, if the multi-mycotoxin analyses are 
very helpful, still there is a lot of work to be done to cope with several constraints either in the analytical 
context (the lack of method standardization, the unavailability of commercial reference standards, especially 
glucuronides) or in the exploitation of the biomarker in the exposure assessment. In fact, the lack of 
information on the human bioavailability of the toxin, the excretion rate, the definition of the right biomarker 




Figure 28: Kind of substrates for ZEA and number of ZEN and ZEN metabolites measurements in the 
dataset 
 
Table 17: Summary of the combination on the multi-mycotoxin studies 
2 mycotoxins 3 mycotoxins 4 mycotoxins 5 mycotoxins 6 mycotoxins 7 mycotoxins 




AFs, DON, FBs, 
OTA, ZEN 
AFs, DON, FBs, 
NIV, OTA, ZEN 
AFs, CIT, DON, 
ENNs, FBs, OTA, 
ZEN 
AFM1, OTA DON, FBs, ZEN - CIT, DON, ENNs, 
T2, ZEN 
AFs, DON, FBs, 
OTA, T2, ZEN 
DAS, DON, FUSX, 
NEO, NIV, T2, 
ZEN 
CIT, OTA AFS, FBs, OTA - DON, FBs, NIV, 
OTA, ZEN 
- DAS, DON, FUSX, 
NEO, NIV, T2, 
ZEN 
AFs, DON ALT, DON, 
ZEN, 
- - - - 
AFs, FBs AFM1, OTA, 
DON 
- - - - 
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3.7. Modelling framework 
 
3.7.1. Model selection and its application to risk assessment of mycotoxin 
mixtures: a data mining problem 
3.7.1.1. Toxicokinetics (in vivo) database: internal dose calculation 
 
Regarding the toxicokinetic database in vitro, only 3 studies report on F (bioavailability), while within data 
extracted and available in toxicokinetic database in vivo, only the following papers report data for all the 
parameters necessary for calculating the internal dose (F-bioavailability, Ke-rate of elimination, CL-clearance, 
Vd-volume of distribution, Tmax-maximum concentration, Kabs-rate of absorption).  
 
a) Swine DON, (Saint-Cyr et al., 2015) 
b) Swine DON, (Paulick et al., 2015) 
c) Chicken DON, (Osselaere et al., 2013) 
d) Chicken ZEN, (Buranatragool et al., 2015) 
e) Chicken T2, (Sun et al., 2015) 
f) Chicken NIV, (Kongkapan et al., 2015) 
g) Chicken ENNB ENNB1 (Fraeyman et al., 2016) 
- PIGS + DON 
 
All the chemical properties of mycotoxins for internal dose modelling were recovered and are available online 
on the MYCHIF repository and EFSA knowledge junction (10.5281/zenodo.3615174). 
 
For this attempt, we implemented both Toxicokinetic model (1-cmpt approach) and Toxicodynamic model 
(multi-cmpt approach). For toxicokinetic model and DON-swine case study we have also performed a global 
sensitivity analysis (GSA, FAST99) (Saltelli et al., 1999). All the r-code and model outputs are available are 
available online on the MYCHIF repository and EFSA knowledge junction (10.5281/zenodo.3615174). 
Unfortunately data availability in the literature and the great heterogeneity of the reported case studies did 
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Figure 29: Toxicokinetic model 1-cmpt, output and comparison with data reported by (Saint-Cyr et al., 
2015) DON-swine oral administration.  
 
Data reported by (Saint-Cyr et al., 2015) are used for model initialization. 
 
 
Figure 30: Toxicokinetic (1-cmpt) and toxicodynamic (multi-cmpt) models output and comparison with data 
reported by literature. ZEN-chicken intravenous and oral administration.  
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Figure 31: Sensitivity analysis for model input (F = bioavailability, Kabs = absorption rate, Ke= elimination 
rate, Vd = volume of distribution)- case study SWINE-DON, (Saint-Cyr et al., 2015). 
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3.8. Case studies 
3.8.1. Animal case study 
3.8.1.1. Dose-response modelling for mycotoxin mixtures using a component-based 
approach in pigs and chicken 
From the in vivo toxicity database, dose response data were modelled for mycotoxin mixtures in chicken and 
pigs using component-based approaches assuming either dose addition or response addition using the drc R-
package (analysis of dose response)(EFSA, 2019). For chicken, 14 combinations of mycotoxins mixtures were 
extracted and modelled of which one with 3 components and 13 as binary mixtures (Table 18). For pigs, 9 
combinations were extracted and modelled of which one with 3 mycotoxins and 5 as binary mixtures ( 
 
Table 19).  
 
Table 18: Modelling of multiple mycotoxins in chicken using component-based approach  
ID_case MIXTURE Target 
      
1 DON,FB,AF  Body weight 
2 DON,FB Intestinal villus height 
3 DON,AF Blood heterophils to lymphocytes 
ratio 
4 AF,FB Blood alanine aminotransferase 
5 AF,FB Blood albumin 
6 AF,FB Blood aspartate 
7 AF,FB Blood calcium 
8 AF,FB Blood colesterol 
9 AF,FB Blood total protein 
10 AF,FB Blood triglycerides 
11 AF,FB Blood γ-glutamyltransferase 
12 AF,FB Feed conversion ratio 
13 AF,FB Feed intake 
14 AF,FB Liver weight 
 
 
Table 19: Modelling of multiple mycotoxins in pig using component-based approach  
ID_case Mixture Target 
1 DON,ZEN,AF  Blood aspartate aminotransferase 
2 DON,ZEN,AF Body weight gain 
3 DON,ZEN,AF  Feed intake 
4 DON,ZEN,AF  Liver weight 
5 DON,ZEN  Blood alanine aminotransferase 





www.efsa.europa.eu/publications 80 EFSA Supporting publication 2020:EN-1757 
The present document has been produced and adopted by the bodies identified above as authors. This task has been carried out exclusively by the authors in the 
context of a contract between the European Food Safety Authority and the authors, awarded following a tender procedure. The present document is published 
complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food 
Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the 
rights of the authors. 
 
7 DON,ZEN  Blood glutathione peroxidase 
8 DON,ZEN  Blood SOD 
9 DON,AF  Blood urea nitrogen  
 
 
Figure 32: Model results for pig case study1 (DON/ZEN/AF target blood aspartate aminotrasnferase) 
 
All the tables, model parameterisation, plots and R-code are available online on the MYCHIF repository and 
EFSA knowledge junction (10.5281/zenodo.3615174). 
Subsequently, the combination of 2 toxins (OTA and AF) was selected on the basis of the data availability, in 
terms of dose-response, that enabled a new modelling attempt. It was modelled both the single and the 
combined toxicity also by the use of Curve Fitting and Mixture Toxicity Assessment - MixTox R-package (Zhu 
and Chen, 2016). In this case from the toxicity in vivo database the two species with a sufficient amount of 
data were leghorn chicken and marek chicken.  
Data for the two species was not aggregated and they were modelled separately. The following endpoints 
were considered: 
- 5 endpoints per the chicken “marek breed” (bodyweight, feed conversion, feed intake, kidney relative weight, 
liver relative weight, spleen relative weight) 
- 2 endpoints per white leghorn (final bodyweight, feed intake) 
Where the standard deviation was available (in one of the two data sets DSs were missing), a data bootstrap 
(n = 100) was performed for the response data and it was analysed against the doses reported in the database. 
Due to the distribution of dose-response data for the combinations of AF & OTA, only the dose-addition 
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3.8.1.2. Dose-response modelling for mycotoxins in pigs and chicken using benchmark 
modelling approaches 
 
In the context of mixture toxicology, the combined toxicity of two or more substances may be based on the 
concept of dose-addition (EFSA, 2008, 2013b). Substances can be seen as dose-additive when they act in a 
similar manner with the same mechanism/mode of action, but may differ only in their potencies. The concept 
stipulates that the total effect after simultaneous exposure to such compounds can be estimated from the sum 
of the doses or concentrations of each component (Zeilmaker et al., 2018). For this purpose, dose-response 
data were extracted, from in vivo toxicity database, for chicken and pig only for three targets Body Weight 
Gain (BWG), liver and kidney weight and for the available mycotoxins AF, DON, FB, OTA, T2 and ZEN Table 
20. 
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Table 20: Case studies extracted from EFSA Hazards database “Openfoodtox”* for the selected target animal and mycotoxin. Number of studies, number of 
samples and range of doses were reported. 
  BWG Liver Kidney 


















Chicken DON 4 29 4 - 18 3 6 15 - 16 3 6 15 - 16 
 AF 13 87 0.05 - 3.5 12 57 0.2 - 3.5 8 51 0.5 - 3.5 
 T2 3 18 4 - 6 4 8 4 - 6 4 8 4 - 6 
 FB 3 21 50 - 300 6 22 50 - 300 4 11 100 - 300 
 OTA 4 24 1 - 4 4 10 1 - 4 4 10 1 - 4 
 ZEN n/a n/a n/a n/a n/a n/a n/a n/a n/a 
           
Pig DON 3 31 2.5 - 3.5 1 4 3 - 12 1 4 3 - 12 
 AF 5 56 0.05 - 3 3 15 0.05 - 2.5 1 9 0.25 - 0.5 
 T2 3 36 0.4 - 10 1 5 0.4 - 3.2 1 5 0.4 - 3.2 
 FB 4 9 10 - 100 3 10 10 - 100 n/a n/a n/a 
 OTA 3 9 0.35 - 2 n/a n/a n/a n/a n/a n/a 
 ZEN 3 17 0.25 - 3 2 7 0.25 - 3 1 4 1 - 3 
(a): Excluding controls. Dose unit is mg/kg feed. n/a = data not available 
For each dataset, based on different case studies, a mathematical dose-response function was fitted to the data, using fitting models in concordance with EFSA 
guidelines (EFSA, 2017d) for continuous data. Subsequently, fitted dose-responses were used to calculate the benchmark doses (BMD) for each of the three 
targets. The BMD is the dose which results in a pre-set effect size or response, the benchmark response (BMR). In this attempt, a BMR5% and BMR10% were 
applied by using DRC R-package (Ritz et al., 2015) and a BMR based on a biological relevant effect was used (PROAST v65.5) (Table 21). 
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Table 21: Benchmark dose modelling outputs  
 Target Mycotoxin BMD5 BMDL5 BMDU5 BMD10 BMDL10 BMDU10 BMDL Proast BMDU Proast Variance 
Pig            
 BWG AF 0.11  0.01  0.21  0.12  0.03  0.21  0.70  1.53  0.051  
 BWG DON 2.67  1.07  4.28  2.72  2.56  2.89  n/o n/o 0.052  
 BWG FB 19.26  8.23  30.29  22.38  9.91  34.85  3.37  9486.00  0.151  
 BWG OTA 0.00  0.00  0.00  0.01  0.00  0.01  n/o n/o 0.096  
 BWG T2 4.28  1.67  6.88  3.86  2.68  5.04  2.30  4.79  0.041  
 BWG ZEN 0.19  0.08  0.30  0.07  0.03  0.10  0.02  0.69  0.003  
 Kidney AF 0.10  0.07  0.13  0.11  0.07  0.14  n/o n/o 0.026  
 Kidney T2 3.57  1.83  5.31  2.85  1.79  3.91  n/o n/o 0.001  
 Kidney DON n/o n/o n/o n/o n/o n/o n/o n/o n/o 
 Kidney ZEN n/o n/o n/o n/o n/o n/o n/o n/o n/o 
 Liver AF 0.10  0.07  0.13  0.11  0.07  0.14  n/o n/o 0.003  
 Liver DON n/o n/o n/o n/o n/o n/o n/o n/o n/o 
 Liver FB 23.57  21.10  26.05  25.11  22.47  27.76  0.20  74.00  0.032  
 Liver T2 3.57  1.83  5.31  2.85  1.79  3.91  n/o n/o 0.003  
 Liver ZEN 1.32  0.78  1.86  0.93  0.72  1.14  0.57  1.86  0.001  
Chicken            
 BWG DON 15.06  14.58  15.55  n/o n/o n/o 0.02  359.80  0.178  
 BWG AF 0.17  0.17  0.18  n/o n/o n/o 0.01  0.98  4.190  
 BWG T2 2.11  1.85  2.37  n/o n/o n/o 2.25  4.18  0.350  
 BWG FB 30.55  21.77  39.33  569832  -117457  1257120  0.39  4485.00  0.019  
 BWG OTA 0.00  0.00  0.01  n/o n/o n/o 1.30E-05 62.30  0.173  
 Liver DON 15.94  15.27  16.61  15.93  15.27  16.60  n/o n/o 0.233  
 Liver AF 0.33  0.20  0.46  0.37  0.24  0.51  0.00013 29.33  3.404  
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 Liver T2 7.06  6.87  7.24  n/o n/o n/o n/o n/o 0.014  
 Liver FB 183.33  136.78  229.88  190.60  139.20  241.99  0.0028 8218.00  0.028  
 Liver OTA 1.51  0.82  2.19  1.47  0.86  2.09  0.01 1.73  0.098  
 Kidney DON 15.77  15.53  16.01  15.75  15.52  15.99  n/o n/o 0.187  
 Kidney AF 1.89  1.38  2.39  2.53  2.04  3.02  0.00 0.34  0.111  
 Kidney T2 4.39  4.23  4.55  4.41  4.25  4.57  n/o n/o 0.098  
 Kidney FB 270.06  261.52  278.59  287.53  279.53  295.52  n/o n/o 0.380  
 Kidney OTA 0.70  0.40  1.00  0.60  0.24  0.97  6.58E-06 59.66  2.233  
n/o = no model output 
 
 
Furthermore the same analysis was performed, but at single case study level, and only for the case studies reporting at least 4 doses (one control + 3 doses) 
(Table 22). A BMR based on a biological relevant effect was used including BMDL with and without exposure time as covariate (Table 23). 
 
Table 22: Case studies extracted from Toxicitiy database for the selected target and mycotoxins reporting at least 4 doses (one control + 3 doses). Number of 
studies, number of sample and range of doses were reported.  
  BWG Liver Kidney 


















Chicken DON 1 15 4 - 18 n/a n/a n/a n/a n/a n/a 
 AF 4 31 0.5 - 3.0 4 24 0.5 - 3.0 2 16 0.5 - 2.0 
 OTA 2 12 1 - 4 1 4 1 - 4 1 4 1 - 4 
           
  n/a n/a n/a n/a n/a n/a n/a n/a n/a 
Pig DON n/a n/a n/a 1 4 3 - 12 1 4 3 - 12 
  n/a n/a n/a n/a n/a n/a n/a n/a n/a 
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(a): Excluding controls. Dose unit is mg/kg feed. n/a = data not available 
 
Table 23: Benchmark dose model outputs. BMDL_COV and BMDU_COV refer model with exposure time as covariate. 
 Target Mycotoxin Case 
study 
BMDL BMDU Variance BMDL_COV BMDU_COV Variance Expo Time 
Pig           
 Kidney DON 1 n/o n/o n/o Single Expo  Single Expo  Single Expo  Single Expo 
 Liver DON 1 n/o n/o n/o Single Expo  Single Expo  Single Expo  Single Expo  
Chicken           
 BWG DON 1 n/o n/o n/o n/o n/o n/o 7 
 BWG DON 1 n/o n/o n/o n/o n/o n/o 14 
 BWG DON 1 n/o n/o n/o n/o n/o n/o 21 
 BWG AF 1 0.0269 0.0887 0.004743 Single Expo Single Expo Single Expo Single Expo 
 BWG AF 2 0.0063 0.421 0.2928 0.47 Inf 0.05107 7 
 BWG AF 2    0.011 0.248 0.03892 14 
 BWG AF 2    0.00112 0.0619 0.0375 21 
 BWG AF 3 0.0758 0.532 0.1064 0.0897 0.345 0.07477 28 
 BWG AF 3    0.156 0.479 0.02262 49 
 BWG AF 4 0.714 1.37 0.01967 Single Expo Single Expo Single Expo Single Expo 
 BWG OTA 1 0.227 1.17 0.08722 0.274 1.02 0.04833 28 
 BWG OTA 1    0.433 1.08 0.01893 49 
 Liver AF 1 0 0.459 0.03701 Single Expo Single Expo Single Expo Single Expo 
 Liver AF 2 0.688 1.28 0.136 Single Expo Single Expo Single Expo Single Expo 
 Liver AF 3 0.00574 0.599 0.05346 0.293 Inf 0.009215 7 
 Liver AF 3    0.138 Inf 0.01222 14 
 Liver AF 3    0.00313 0.523 0.06229 21 
 Liver AF 4 0.0441 0.351 0.03798 Single Expo Single Expo Single Expo Single Expo 
 Liver OTA 1 0.101 2.79 0.05308 Single Expo Single Expo Single Expo Single Expo 
 Kidney AF 1 0.0177 0.484 0.1244 0.00289 Inf 0.03541 7 
 Kidney AF 1    0.000186 0.152 0.03218 14 
 Kidney AF 1    0.0000454 0.0687 0.1658 21 




www.efsa.europa.eu/publications 87 EFSA Supporting publication 2020:EN-1757 
The present document has been produced and adopted by the bodies identified above as authors. This task has been carried out exclusively by the authors in the context of a contract between the European Food Safety Authority and the authors, 
awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety 
Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors. 
 
 Kidney AF 2 n/o n/o n/o Single Expo Single Expo Single Expo Single Expo 
 Kidney OTA 1 0.623 1.71 0.03022 Single Expo Single Expo Single Expo Single Expo 
n/o = no model output. Single Expo = data with a single exposure time. 
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3.8.2. Human case study: risk assessment of multiple mycotoxins using 
component-based and provisional daily intake approaches 
The present human case study (HCS) for the risk assessment of multiple mycotoxin integrates the results of 
the data collection combining the contribution of the MYCHIF consortium work (namely the occurrence and 
co-occurrence data, the toxicological data and the biomarker of exposure data). The information on 
environmental, ecological, and agronomic factors affecting the relative abundance of co-occurring mycotoxins 
in the contaminated crops, as well as (co-)occurrence data and toxicity of multiple mycotoxin investigated, 
was collected and used to develop the current case study on risk assessment for humans exposed to co-
occurring mycotoxins. 
This case study follows the harmonised framework for risk assessment of combined exposure to multiple 
chemicals that consist of well-defined steps: (i) problem formulation, (ii) exposure assessment, (iii) hazard 
assessment, and (iv) risk characterisation. In the context of this framework, two different approaches were 
investigated, namely (i) the component-based approach (CBA) and (ii) the provisional daily intake (PDI).  
The CBA is a procedure applied for the risk assessment of mixtures when the exposure levels and effect data 
of their components are known. The individual components of the mixture are organised into assessment 
groups (AG) following grouping criteria (e.g. physicochemical properties, hazard characteristics, exposure 
considerations). The dose addition is used as default model, and predictions of combined toxicity of compounds 
of the AG are measured from data of the toxicity of the individual components (EFSA, 2013a, 2019).  
The PDI approach models the internal dose information with the available human biomarker data to derive 
exposure to the mixture. Several authors have performed this exercise obtaining estimated PDI, also defined 
by other authors as estimated daily intake (EDI), for single mycotoxins and have published a number of peer-
reviewed papers (Warth et al., 2013; Ezekiel et al., 2014; Solfrizzo et al., 2014; Heyndrickx et al., 2015; Al-
Jaal et al., 2019).  
Problem formulation. The occurrence and co-occurrence evidences gathered in the literature led to the 
identification of two mycotoxin mixtures (selected among Fusarium mycotoxins), belonging to a group of 
contaminants to which humans are exposed on a chronic basis, mainly from cereal food sources (i.e. mixture-
1: DON, FBs and ZEN, and mixture-2: T2/HT2, DON and NIV). Exposure and hazard data of the individual 
components of the two identified mixtures were collected.  
Exposure assessment. The conventional dietary exposure assessment paradigm uses consumption and 
occurrence data to derive exposure scenarios of groups of populations to a single mycotoxin between two 
extreme intake values, i.e. the lower bound (LB) and upper bound (UB), for the percentile 50 (P50) and a high 
percentile (most frequently the P95). In the CBA, the (co)-occurrence and consumption data of cereal-food 
based products for each single mycotoxin were combined to obtain an individual mycotoxin exposure (Exp i) 
and then summed up to obtain the total exposure, under the dose addition assumption. In the context of the 
PDI approach, the data of BM measured in specimen for mixture-1 were used to define the exposure estimate 
for the mixture. The PDI (expressed as μg of mycotoxin per kg bw per day) was estimated by combining i) 
the mycotoxin concentration in urine, ii) the available excretion rate for each of the mycotoxin in the mixture, 
iii) the human body weight (bw) and iv) the daily urine excretion volume (μg/L mycotoxin, L urine in 24 h, % 
excretion rate, kg bw, respectively). The PDI was calculated both for single components and for the mixture. 
Hazard assessment. Hazard information were collected for the individual mycotoxins of mixture-1 and 
mixture-2 from toxicity studies, EFSA opinions and the chemical hazard database called OpenFoodTox (e.g. 
toxicity data, reference point (RP) or point of departure (POD) from chronic studies in test species (i.e. rat, 
mouse, pig), and reference values (TDI)).  
Risk Characterisation. In the context of CBA, an equivalent factor approach is proposed using simply the 
RPs as conservative estimates. The Equivalent Factor (EF) of each mycotoxin of the mixture (EFi) was 
calculated dividing the POD of the identified index compound (PODindex) (i.e. the most potent compound) by 
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the POD of each individual mycotoxin (PODi). Dose addition is applied using a margin of exposure approach 
(MOE). Being the considered mycotoxins neither genotoxic nor carcinogenic, a value of 100 has been chosen 
as a reference/cut-off value: MOE superior to a 100-fold was interpreted as a scenario of low concern for 
compounds that are not genotoxic and carcinogenic whereas a MOE inferior to 100-fold suggests the need to 
refine the risk assessment or that the compounds in the assessment group may be of concern. The budget 
uncertainty for the whole approach should consider the lack of data on potential interaction among the 
considered mycotoxins (i.e., synergistic/additive or antagonistic effect) in the hazard assessment step and the 
use of reference points derived from a diverse Mode of Action (MOA). Since all this may lead to under or over 
estimation, a thorough scrutiny of the approach with the application of an uncertainty factor would be 
appropriate. 
In PDI, the Hazard exposure index (HI) is proposed, defined as the sum of the ratio between the exposure 
values of each component and the respective reference value (i.e., TDI), and the resulting value was 
interpreted to understand the acceptability of the risk.  
 
3.8.2.1. Component based approach  
The CBA is presented as an exploratory case study of human risk assessment of combined exposure to multiple 
mycotoxins in food. In the tiered approach, the human risk assessment of combined exposure is explored 
considering exposure and effect data of the individual mycotoxin. In the present human case study, the 
following was considered: 
- Cereals and cereal-based food diet, aggregate chronic exposure assessment. 
- Occurrence, co-occurrence for cereal commodities. Occurrence and co-occurrence data were extracted 
from MYCHIF database (all cereals-based food), which include all data collected in EU countries in 
food samples and accounts only for records reporting MeanTot value or MeanPos value or 
Concentration value (available online on the MYCHIF repository and EFSA knowledge junction 
(10.5281/zenodo.3615174)). In absence of these values, when Min and Max and % of samplings 
>LOD values were reported, the median values were considered. Two datasets, one based on 
occurrence data and one on co-occurrence data, were made available and used separately as input 
for the model. 
- Consumption data for the specific cereal commodities. EFSA Comprehensive European Food 
Consumption Database was used for extracting data of FoodEx2 at level 1 associated to consumers’ 
only and mean and high consumers (95th percentile consumption). Exposure data were calculated 
following the equation (eq. 1):  
EXPi = [consumption (g/day) / 1000] * 1/kgbw * mycotoxinOcc/Co-occ (µg/kg)  (eq. 1) 
where: 
consumption (g/day), are mean and P95 consumption values. Data were extracted from EFSA 
Foodex2-level-1 (Grains and grain-based products) for adolescent, adult and elderly 
mycotoxinOcc/Co-occ (µg/kg), are data extracted from MYCHIF database for all cereals-based food, when 
mycotoxin occurred as single compound or co-occurred in a group. 
Exposure estimates were calculated for three scenarios: minimum Lower Bound (LB), medium Lower 
Bound (MB) and maximum Upper Bound (UB) in µg/kg bw per day. For each substance, the three 
scenarios were obtained by substituting LOD=0 and LOQ=LOD in the LB, LOD=0.5*LOD and 
LOQ=LOQ*0.5 in MB and LOD=LOD and LOQ=LOQ in the UB (EFSA, 2010b; Ingenbleek et al., 2019). 
- Hazard and Equivalent Factors (EFs). Toxicological end points as PODs (such as BMDL or NOAEL) have 
been extracted from the EFSA CONTAM opinions (tracing author, year, study, test type, species, 
endpoint, value, unit, effect, toxicity) for each mycotoxin. EFs were calculated taking as the identified 
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index compound (PODindex) the value of the most potent compound for which the EFindex is considered 
=1. The EFi of each mycotoxin is then calculated with the following equation (eq. 2) 
EFi = PODindex / PODi    (eq. 2) 
- Risk characterization. As far as the risk characterization, the margin of exposure (MOE) was estimated 
(eq. 3), as the ratio between the POD of the index compound (the most potent compound) and the 
sum of normalised individual exposures Sum(Expi)*(EFi).  
MOE = PODindex / Sum(Expi)*(EFi)  (eq. 3) 
Being the three considered mycotoxins neither genotoxic nor carcinogenic, a value of 100 has been 
chosen as a reference/cut-off value: MOE values above 100 do not raise human health concern, values 
below 100 suggest a scenario of concern. 
It is recognised that all values below 100 indicate a signal to proceed to a higher tier, with the possible 
need to adjust the approach with additional data such as those deriving from animal data analysis. 
The budget uncertainty for the whole approach should consider the lack of data on potential interaction 
among the considered mycotoxins (i.e., synergistic/additive or antagonistic effect) in the hazard 
assessment step and the use of reference points derived from a diverse MOA. Since all this may lead 
to under or over estimation, a thorough scrutiny of the approach with the application of an uncertainty 
factor would be appropriate. 
 
Mixture-1: DON, FBs and ZEN  
Problem formulation. The harmonised framework is applied for the human risk assessment of the mixture-1 
(consisting in DON, FBs and ZEN) from cereal-based food sources. The risk assessment is performed for 
European consumers. Each mycotoxin of the AG is well characterized for its structure, the chronic exposure 
levels in food are assessed for each single mycotoxin, the hazard properties are defined and were derived 
from assessment studies as listed in Table 24. The assessment group was set based on the (co)-exposure as 
the three compounds can reasonably occur together in food commodities. 
Hazard identification and characterization. For DON and FBs, hazard characterisation was performed using 
benchmark dose lower confidence limits for 5 and 10% of effect (BMDL5 and BMDL10) as PODs (110 and 100 
µg/kg bw/day for DON and FBs, respectively). They were based on reduced feed intake and reduced body 
weight gain for DON and on non-neoplastic hepatotoxicity in mice with a critical effect associated with an 
increased incidence of megalocytic hepatocytes in the liver (histopathology) for FBs. For ZEN, hazard 
characterisation was performed using a NOAEL of 1000 µg/kg bw per day based on an increased incidence of 
hepatocellular cytoplasmic vacuolization in male rats. PODs were extracted from EFSA assessments. Relative 
equivalent factors were calculated using the FBs as the index compound (most potent compound) Table 25. 
EFs for each substance were calculated as in equation 2. No evidence of interactions between the compounds 
was available from the literature. 
The summary of hazard data is listed in Table 24. PODs (µg/kg bw per day) and calculated EFs are shown in 
Table 25. 
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Table 25: Equivalent Factors 
Mycotoxin Point of departure (POD) 
(µg/kg bw per day) 
Equivalent 
Factor (EF) 
DON BMDL5= 110  0.91 
FB BMDL10= 100  1  
ZEN NOEL = 1000 0.10  
 
Exposure. Exposure assessment was performed as the product between occurrence data and consumption 
data. In particular, occurrence of DON, FBs, ZEN (and their modified forms) were extracted from the MYCHIF 
database (all cereals-based food category, for more details see 3.4), both as occurrence of each single 
mycotoxin as well as co-occurrence of the three mycotoxins. These data were extracted for each country and 
aggregated at EU level. Then, αZEL and βZEL concentrations were corrected on the basis of their Potency 
Factors (i.e. PF: 60 for αZEL, 0.2 for βZEL). 
Consumption data were gathered from EFSA Comprehensive European Food Consumption Database. In order 
to estimate the chronic dietary exposure to cereal products, consumption data for average and high consumers 
(P95) were extracted for cereal commodities at Foodex2-level-1 (i.e. Grains and grain-based products) and 
aggregated at EU level.  The exposures were estimated for average and high consumers at LB/UB (µg/kg bw 
per day) in three subpopulations, namely ‘Adolescents’ (≥ 10 years to < 18 years old), ‘Adults (≥ 18 years to 
< 65 years old) and ‘Elderly’ (≥ 65 years to < 75 years old). Exposure estimates were calculated using either 
occurrence data of single mycotoxins and co-occurrence data (  
Table 26). Table 27 reports the P95 at LB and UB of the normalised exposure (Expi)*(EFi) obtained for each 
of the mycotoxins considered in occurrence and co-occurrence conditions. After summing each normalised 
exposure (Expi)*(EFi), the UB and LB range of combined dose addiction was defined for the two occurrence 
conditions.  
Risk characterization. The risk characterization was carried out comparing the sum of normalised individual 
exposures (Sum(Expi)*(EFi)) with the PODindex of the index compound (i.e. FB). The MOE was calculated as 
the ratio between the PODFB and the sum of the individual exposures, as follows (eq. 7) 
MOE = PODFB / Sum(Expi)*(EFi)  (eq. 7) 
Table 27 also reports the MOE values obtained for both occurrence and co-occurrence conditions. 
MOE superior to a 100-fold was interpreted as a scenario of low concern for compounds that are not genotoxic 
and carcinogenic whereas a MOE inferior to 100-fold suggests the need to refine the risk assessment or that 
the compounds in the assessment group may be of concern. All values resulted in values below 100. To noted 
that as a critical approximation, the grouping principle is not based on the same MOA.  
Uncertainty in the hazard assessment step is dealing with the miscellaneous of endpoints derived from diverse 
modes of action, and the lack of data on potential interaction among the considered mycotoxins (i.e. 
synergistic/additive or antagonistic effect). This may lead on under- or over- estimate the risk of multiple 
mycotoxins, therefore the application of an uncertainty factor would be appropriate. 




www.efsa.europa.eu/publications 92 EFSA Supporting publication 2020:EN-1757 
The present document has been produced and adopted by the bodies identified above as authors. This task has been carried out exclusively by the authors in the 
context of a contract between the European Food Safety Authority and the authors, awarded following a tender procedure. The present document is published 
complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food 
Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the 
rights of the authors. 
 
A reporting table summarizing the human risk assessment of combined exposure to the mixtures, is shown 
in Table 36.  
Table 26: Exposure estimates for single mycotoxins and for the mixture 
 
 
Table 27: Normalised exposure (Expi)*(EFi) and MOE values 
 
Mixture-2: T2/HT2, DON and NIV 
Problem formulation. The harmonised framework is applied for the human risk assessment of the mixture-2 
(consisting in T2/HT2, DON and NIV) from cereal-based food sources. The risk assessment is performed for 
European consumers. Each mycotoxin of the group is well characterized for its structure, the chronic exposure 
levels in food are assessed for each single mycotoxin, the hazard properties are defined and were derived 
from assessment studies as listed in Table 28. The assessment group was set on the basis that the mixture-2 
can occur in food commodities. 
Hazard identification and characterization. For all the mycotoxins of mixture-2, hazard characterisation was 
performed using benchmark dose lower confidence limits for 5 and 10% of effect (BMDL5 and BMDL10), so 
as PODs were 110, 350 and 3.33 µg/kg bw/day for DON, NIV and T2/HT2, respectively. They have been based 
on reduced feed intake and reduced body weight gain in the case of DON, on a reduction of total leukocyte 
count in in-vivo subchronic toxicity study for T2/HT2 and on reduced white blood cell counts observed in a 90-
day rat study for NIV. PODs have been extracted from EFSA assessments (Table 28). Relative equivalent 
factors were calculated using the FBs as the index compound (most potent compound) Table 29. EFs for each 
substance were calculated as in equation 2. No evidence of interactions between the compounds was available 















LB LB UB  UB 
Mean P95 Mean P95 Mean P95 Mean P95 
DON 1.333 2.458 0.871 1.607 1.412 2.605 0.992 1.830 
FB 0.783 1.444 0.569 1.049 0.849 1.566 0.734 1.355 
ZEN 0.317 0.585 0.675 1.245 0.614 1.133 1.030 1.900 






























EF LB UB LB UB LB UB LB UB LB UB LB UB 
P95 P95 P95 P95 














FB 1 1.4442 1.5657 1.0492 1.3547 
ZEN 0.10  0.0585 0.1133 0.1245 0.1900 
  3.7376 4.0472 2.6341 3.2082 
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Exposure. Occurrence data and co-occurrence data used for the exposure calculations were extracted from 
the MYCHIF database (all cereals-based food). Occurrence on DON, NIV, T2/HT2 and their masked forms 
were extracted for each EU country (sampCountry), including all data collected in EU countries in food samples 
and accounting only for records reporting MeanTot value or MeanPos value or Concentration values in. In 
absence of these values, the median values were also included when Min and Max and % of samplings >LOD 
values were reported. Two datasets, one based on occurrence data and one on co-occurrence data, were then 
prepared and used separately as input for the model. Consumption data were taken from EFSA Foodex2-level-
1 (Grains and grain-based products, mean and 95th percentile consumption in total population). Countries 
were clustered in eight macro areas (Battilani et al., 2012) taking into account both climate characteristics and 
latitude as indicated in Table 30. For each considered macro area, LB, MB, and UB exposure values were 
calculated for adolescent, adult and elderly including both consumption scenarios (i.e., mean and P95).  
Figure 34, Figure 36 and Figure 38 present a visual analysis of the co-occurrence data available for each 
involved EU country. For each mycotoxin (i.e., DON, T2/HT2 and NIV) average values, number of records, 
min and max were reported. Figure 35, Figure 37 and Figure 39 present a visual analysis of the exposure 
calculated for each mycotoxin (co-occurrence dataset) at macro-area level for adults, MB scenario and mean 
consumption value. Figure 40, Figure 42 and Figure 44 present a visual analysis of the occurrence data 
available for each EU country. For each mycotoxin (DON, T2/HT2 and NIV) average values, number of records, 
min and max were reported. Figure 41, Figure 43 and Figure 45 present a visual analysis of the exposure 
calculated for each mycotoxin (occurrence dataset) at macro-area level for adults, MB scenario and mean 
consumption value. 
Table 31 (a, b, c) summarizes the LB and UB P95 exposure estimates for either occurrence or co-occurrence 
conditions for adolescent, adult and elderly. 
Table 32 (a, b, c) reports the P95 at LB and UB range of the normalised exposure (Expi)*(EFi) obtained for 
each one of the mycotoxins considered in occurrence and co-occurrence conditions.  
After summing each normalised exposure (Expi)*(EFi), the UB and LB range of combined dose addiction was 
defined for the two occurrence conditions. Table 32 reports values for adolescents, adults and elderly. 
Risk characterization. The risk characterization was carried out comparing the sum of normalised individual 
exposures (combined dose addiction, Sum(Expi)*(EFi)) with the PODindex of the index compound (i.e., T2/HT2) 
(see summary in Table 33). The MOE was calculated as the ratio between the PODindex (T2/HT2) and the sum 
of the individual exposures Sum(Expi)*(EFi), by using (eq. 3). 
Table 34 summarizes the MOE values obtained for the group of populations considered (adolescents, adults 
and elderly), for both occurrence and co-occurrence conditions. The whole picture of values shows a great 
heterogeneity. Geographical area 5 shows values >100 for adolescents and <100 for adults, while 
geographical area 6 shows the opposite scenario (<100 for adolescents and >100 for adults). All the other 
geographical areas report values <100. On the other hand, when the calculations are done for ALL, MOE 
values are far below 100. It should be noted that the most critical approximation is for the grouping principle 
that is not based on the similarity of the MOA.  
In addition, the uncertainty in the hazard assessment step deals with what derived from diverse MOA (despite 
the use of same end reference points), and with the lack of data on potential interaction among the considered 
mycotoxins (i.e. synergistic/additive or antagonistic effect) (see Table 35). It should be noted that values 
below 100 indicate a signal to proceed to a higher tier, with the possible need to adjust the approach with 
additional data. A table summarizing the risk assessment of combined exposure to multiple mycotoxins, as 
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Table 28: Hazard data. Points of departure 
Mycotoxi
n 










chronic Mouse BMDL05 110 µg/kg 
bw/da
y 





























Table 29: Equivalent Factors 
Mycotoxin Point of departure (POD) 
(µg/kg bw per day) 
Equivalent 
Factor (EF) 
DON BMDL5= 110  0.03  
NIV BMDL5= 350 0.0095  
T2+HT2 BMDL10 = 3.33 1  
 
Table 30: Macroarea clusters 
Macroarea  Countries 
1 BALKGREE Balkans countries, Bulgaria, Greece, Cyprus 
2 BALTIC Estonia, Latvia, Lithuania 
3 EEUROPA Slovakia, Hungary, Romania, Poland 
4 ENG Ireland and United Kingdom 
5 IBERIA 
 






France, Switzerland, Austria, Belgium, Netherlands, Germany, Czech Rep, Denmark 
8 SCAND 
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Table 31 a, b, c: Exposure estimates for adolescents, adults and elderly 
 
 
a) Mycotoxin Adolescents - Exposure (µg/kg bw/d) 
LB P95 
 Adolescents - Exposure (µg/kg bw/d)   
UB P95 
 
Area  Area   
1 2 3 4 5 6 7 8 ALL 1 2 3 4 5 6 7 8 ALL 
DON (Co-occ) 1.712      2.603  0.270  7.514  0.799    1.956  1.712      2.603  0.628  7.818  0.903    2.228  
DON (Occ) 0.844  1.146    0.643  2.203  0.782  4.229  5.229  2.994  1.052  1.146    0.729  2.303  1.023  4.503  5.242  3.172  
NIV (Co-occ)       0.686  0.062  0.105      0.273        0.686  0.072  0.209      0.530  
NIV (Occ)        0.313  0.000    0.447  0.425  0.354        0.318  0.441    0.500  0.442  0.436  
T2+HT2 (Co-occ)       2.567  0.018  0.027  0.094    0.433        2.567  0.029  0.039  0.143    0.514  
T2+HT2 (Occ)  0.175  0.085    0.059  0.055    0.187  0.149  0.164  0.211  0.085    0.059  0.207    0.240  0.169  0.207  
b) Mycotoxin Adults - Exposure (µg/kg bw/d) 
LB P95 
 Adults - Exposure (µg/kg bw/d)   
UB P95 
 
Area  Area   
1 2 3 4 5 6 7 8 ALL 1 2 3 4 5 6 7 8 ALL 
DON (Co-occ) 1.695    0.768  2.060  0.162  5.030  0.577    1.406  1.695    1.240  2.060  0.377  5.233  0.653    1.602  
DON (Occ) 0.836  0.712  1.132  0.509  1.320  0.523  3.058  5.117  2.152  1.041  0.712  1.164  0.577  1.380  0.685  3.256  5.129  2.281  
NIV (Co-occ)     0.152  0.543  0.037  0.070      0.196      0.545  0.543  0.043  0.140      0.381  
NIV (Occ)      0.000  0.248  0.000    0.323  0.416  0.255      0.052  0.252  0.264    0.361  0.432  0.314  
T2+HT2 (Co-occ)     0.014  2.031  0.011  0.018  0.068    0.311      0.178  2.031  0.018  0.026  0.103    0.369  
T2+HT2 (Occ)  0.173  0.053  0.054  0.046  0.033    0.135  0.145  0.118  0.209  0.053  0.069  0.046  0.124    0.173  0.165  0.149  
c) Mycotoxin Elderly - Exposure (µg/kg bw/d) 
LB P95 
 Elderly - Exposure (µg/kg bw/d)   
UB P95 
 
Area  Area   
1 2 3 4 5 6 7 8 ALL 1 2 3 4 5 6 7 8 ALL 
DON (Co-occ)     0.783  2.046  0.131  4.571  0.513    1.270      1.265  2.046  0.305  4.755  0.580    1.447  
DON (Occ)   0.576  1.155  0.506  1.068  0.476  2.718  4.880  1.944    0.576  1.187  0.573  1.117  0.623  2.894  4.892  2.060  




www.efsa.europa.eu/publications 96 EFSA Supporting publication 2020:EN-1757 
The present document has been produced and adopted by the bodies identified above as authors. This task has been carried out exclusively by the authors in the context of a contract between the European Food Safety Authority and the authors, 
awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety 





Table 32 a, b, c: Normalised exposure (Expi)*(EFi) for adolescents, adults and elderly 
 
NIV (Co-occ)     0.155  0.539  0.030  0.064      0.177      0.555  0.539  0.035  0.127      0.344  
NIV (Occ)      0.000  0.246  0.000    0.288  0.397  0.230      0.053  0.250  0.214    0.321  0.412  0.283  
T2+HT2 (Co-occ)     0.015  2.017  0.009  0.016  0.061    0.281      0.181  2.017  0.014  0.024  0.092    0.334  
T2+HT2 (Occ)    0.042  0.055  0.046  0.026    0.120  0.139  0.106    0.042  0.071  0.046  0.100    0.154  0.157  0.134  
a) Mycotoxin Adolescents - (Expi)*(EFi) 
LB P95 
 Adolescents - (Expi)*(EFi) 
UB P95 
 
Area  Area   
1 2 3 4 5 6 7 8 ALL 1 2 3 4 5 6 7 8 ALL 
DON (Cco-occ) 0.051      0.078  0.008  0.225  0.024    0.059  0.051      0.078  0.019  0.235  0.027    0.067  
DON (Occ) 0.025  0.034    0.019  0.066  0.023  0.127  0.157  0.090  0.032  0.034    0.022  0.069  0.031  0.135  0.157  0.095  
NIV (Co-occ)       0.007  0.001  0.001      0.003        0.007  0.001  0.002      0.005  
NIV (Occ)        0.003  0.000    0.004  0.004  0.003        0.003  0.004    0.005  0.004  0.004  
T2+HT2 (Co-occ)       2.567  0.018  0.027  0.094    0.433        2.567  0.029  0.039  0.143    0.514  
T2+HT2 (Occ)  0.175  0.085    0.059  0.055    0.187  0.149  0.164  0.211  0.085    0.059  0.207    0.240  0.169  0.207  
b) Mycotoxin Adults - (Expi)*(EFi) 
LB P95 
 Adults - (Expi)*(EFi) 
UB P95 
 
Area  Area   
1 2 3 4 5 6 7 8 ALL 1 2 3 4 5 6 7 8 ALL 
DON (Cco-occ) 0.051    0.023  0.062  0.005  0.151  0.017    0.042  0.051    0.037  0.062  0.011  0.157  0.020    0.048  
DON (Occ) 0.025  0.021  0.034  0.015  0.040  0.016  0.092  0.153  0.065  0.031  0.021  0.035  0.017  0.041  0.021  0.098  0.154  0.068  
NIV (Co-occ)     0.001  0.005  0.000  0.001      0.002      0.005  0.005  0.000  0.001      0.004  
NIV (Occ)      0.000  0.002  0.000    0.003  0.004  0.002      0.000  0.002  0.003    0.003  0.004  0.003  
T2+HT2 (Co-occ)     0.014  2.031  0.011  0.018  0.068    0.311      0.178  2.031  0.018  0.026  0.103    0.369  
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Table 33: LB and UB range of combined dose addiction (Expi)*(EFi) 
T2+HT2 (Occ)  0.173  0.053  0.054  0.046  0.033  0.000  0.135  0.145  0.118  0.209  0.053  0.069  0.046  0.124  0.000  0.173  0.165  0.149  
c) Mycotoxin Elderly - (Expi)*(EFi) 
LB P95 
 Elderly - (Expi)*(EFi) 
UB P95 
 
Area  Area   
1 2 3 4 5 6 7 8 ALL 1 2 3 4 5 6 7 8 ALL 
DON (Cco-occ)     0.024  0.061  0.004  0.137  0.015    0.038      0.038  0.061  0.009  0.143  0.017    0.043  
DON (Occ)   0.017  0.035  0.015  0.032  0.014  0.082  0.146  0.058    0.017  0.036  0.017  0.033  0.019  0.087  0.147  0.062  
NIV (Co-occ)     0.001  0.005  0.000  0.001      0.002      0.005  0.005  0.000  0.001      0.003  
NIV (Occ)      0.000  0.002  0.000    0.003  0.004  0.002      0.001  0.002  0.002    0.003  0.004  0.003  
T2+HT2 (Co-occ)     0.015  2.017  0.009  0.016  0.061    0.281      0.181  2.017  0.014  0.024  0.092    0.334  






Area  Area   















0.05    0.04  2.10  0.02  0.17  0.09    0.36  0.05    0.22  2.10  0.03  0.18  0.12    0.42  
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Table 34: MoE 
 
Sum(Expi)*(EFi) 
(Occurrence)   
Adults 
 
















Area  Area   





64.25    1.24  122.0
3  




16.46  27.75   40.78  27.35  140.6
8  
10.39  10.66  12.84  13.61  27.75   39.50  11.77  107.4
8  





64.90   85.21  1.57  203.6
0  
19.45  38.56   9.29  64.90   14.99  1.57  112.9
7  
17.87  26.85   7.84  
Sum(Expi)*(EFi) 
(Occurrence)   
Adults 
 
16.63  44.66  37.72  51.53  45.63  210.1
4  
14.37  10.89  17.87  13.75  44.66  31.56  49.92  19.64  160.5
5  





  83.56  1.58  251.6
8  
21.40  43.38   10.29    14.70  1.58  139.6
4  
19.67  30.20   8.68  
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 55.24  36.99  51.89  56.41  231.2
8  
16.16  11.42  19.78   55.24  30.95  50.27  24.28  176.6
9  
13.53  10.71  16.60  
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Table 35: Summary of uncertainties 
Hazard assessment Lack of data on potential interaction among the considered mycotoxins (i.e. synergism 
or antagonism). Use of reference points derived from diverse Mode of Action. 
Exposure 
assessment 
A deterministic approach was adopted even if uncertainties of the input modeling data 
(mycotoxin concentration) were not negligible. Due to the scarcity of concentration 
data for many countries, a probabilistic approach can only be applied at EU level (as 
done for the PDI).  
Data 
representativeness 
Different availability and geographic distribution of mycotoxins concentrations in both 
dataset (occurrence and co-occurrence). Some countries, for which consumption data 




Table 36: Summary of the human risk assessment of combined exposure to multiple mycotoxins 
Problem 
formulation 
Description mixture Mixture of mycotoxins, namely Fusarium toxins. 
Mixture-1 (DON, FBs and ZEA) and mixture-2 (T2/HT2, 
DON and NIV) 
Conceptual model Exposure to a group of mycotoxins through food either 
in the case when they co-occur and occur in food 
Exposure pattern: chronic  
Common source for grouping: co-exposure 
Hazard data: different reference point for each 
compound 
Methodology Assessment group: grouping on the basis of exposure 
as they can co-occur in cereal-based food commodities 
Analysis plan Risk assessment in food for European consumers’ health  
Exposure 
assessment 
CBA Component-based approach 
Summary occurrence data Occurrence, co-occurrence from MYCHIF database and 
exposure assessment for chronic exposure using EFSA 
Comprehensive European Food Consumption Database 
was used extracting data of FoodEx2 at level 1. 
Assumptions LB and UB Highest 95th centile chronic exposure 
(conservative)  





CBA Component-based approach (CBA)-assessment group 
and set using the exposure as grouping criteria  
Reference points For each component as NOAEL/ BMDL10 from chronic 
studies in test species (rats etc.) EF using indexed 
compound (FB in mixture-1 and T2/HT2 in mixture-2) 
Combined toxicity Dose addition 
Summary hazard metrics Equivalent Factor (EF) for each component  
Uncertainties Uncertainties in POD (LOEAL, NOEL, BMDL5, BMDL10 
values) for each component. Use of reference points 
derived from diverse Mode of Action 
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Decision points  Margin of exposure (MOE) 
Assumptions Dose addition 
Summary risk metrics MOE 
Uncertainties Uncertainties in exposure, hazard assessment (methods 
for exposure, human relevance of effects in rats etc.) 
Conservative approach 






Figure 34: DON extracted from Co-occurrence dataset for each EU country. Panel upper left reports 
mean value of DON, panel upper right reports number of records, panel lower left min value of DON 
and panel lower right max value of DON. 
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Figure 35: Exposure calculated for DON (co-occurrence dataset) at macro-area level for Adult, MB 
scenario and mean consumption value. 
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Figure 36: NIV extracted from Co-occurrence dataset for each EU country. Panel upper left reports 
mean value of NIV, panel upper right reports number of records of NIV, panel lower left min value of 
NIV and panel lower right max value of NIV.  
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Figure 37: Exposure calculated for NIV (co-occurrence dataset) at macro-area level for adult, MB 
scenario and mean consumption value. 
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Figure 38: T2+HT2 extracted from Co-occurrence dataset for each EU country. Panel upper left 
reports mean value of T2+HT2, panel upper right reports number of records of T2+HT2, panel lower 
left min value of T2+HT2 and panel lower right max value of T2+HT2.  
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Figure 39: Exposure calculated for T2+HT2 (co-occurrence dataset) at macro-area level for Adult, 
MB scenario and mean consumption value. 
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Figure 40: DON extracted from Occurrence dataset for each EU country. Panel upper left reports 
mean value of DON, panel upper right reports number of records, panel lower left min value of DON 
and panel lower right max value of DON.  
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Figure 41: Exposure calculated for DON (occurrence dataset) at macro-area level for Adult, MB 
scenario and mean consumption value. 
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Figure 42: NIV extracted from Occurrence dataset for each EU country. Panel upper left reports 
mean value of NIV, panel upper right reports number of records of NIV, panel lower left min value of 
NIV and panel lower right max value of NIV.  




www.efsa.europa.eu/publications 110 EFSA Supporting publication 2020:EN-1757 
The present document has been produced and adopted by the bodies identified above as author(s). In accordance with Article 36 of Regulation (EC) 
No 178/2002, this task has been carried out exclusively by the author(s) in the context of a grant agreement between the European Food Safety 
Authority and the author(s). The present document is published complying with the transparency principle to which the Authority is subject. It cannot 
be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues 




Figure 43: Exposure calculated for NIV (occurrence dataset) at macro-area level for Adult, MB 
scenario and mean consumption value. 
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Figure 44: T2+HT2 extracted from Occurrence dataset for each EU country. Panel upper left reports 
mean value of T2+HT2, panel upper right reports number of records of T2+HT2, panel lower left min 
value of T2+HT2 and panel lower right max value of T2+HT2.  
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Figure 45: Exposure calculated for T2+HT2 (occurrence dataset) at macro-area level for Adult, MB 
scenario and mean consumption value. 
 
 
3.8.2.2. PDI approach 
From the MYCHIF biomarker dataset, urine data samples for mixture-1 (DON, FBs, and ZEN) were 
judged to be quali/quantitatively consistent with the purpose for the PDI approach. A Biomarker dataset 
was prepared for each mycotoxin including only data sampled in EU countries, merging adolescent and 
adult groups and choosing healthy people excluding any kind of study where patients were enrolled. 
The number of records in the dataset (corresponding to the number of references), number of samples, 
average and range values for each biomarker of exposure (urine, μg/L) is summarized in Table 37. 
 
Table 37: Number of records, samples, average and range for each biomarker of exposure (urine, 
μg/L) 
Mycotoxin N° of 
Records 




FBs 3 559 0.028 0.004 - 0.07 
ZEN 3 352 0.0267  0.02 - 0.03 
DON 528 2090 11.90 0 - 225.2 
 
The selected urine BM value was used for the estimation of single mycotoxin exposure (PDIMYCO) and 
for the estimation of a PDI for the group of mixtures (PDIMIX).  
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The formula of reference used for the PDI calculation is derived from the general equation (eq. 4): 
PDIMYCO (μg/kgbw) = CMYCO x VURINE x 1/kgbw x 100/ER  (eq. 4) 
where: 
CMYCO = mean concentration value for mycotoxin in urine (μg/L) 
VURINE =Volume (L) of urine output in 24 h 
kgbw = kilogram (kg) of body weight 
ER = Excretion Rate (%) 
The estimation was also carried out for mycotoxin mixture, PDIMIX, combining the mean concentration 
value (Ci_myco) for each mycotoxin following the equation (eq. 5): 
PDIMIX (μg/kgbw) = VURINE x 1/kgbw x i (Ci_myco x 100/ERi) (eq. 5) 





𝑖=1    (eq. 6) 
where Expi: is the exposure of the individual substance in the mixture; RVi: is the reference value of the 
individual substance in the mixture (i.e. TDI).  
When HI is calculated, a HI ≤ 1 indicates that the combined risk is acceptable, whereas when it exceeds 
1, it is considered that a potential concern is possible. 
As any other estimation, the PDIMYCO assessment has different uncertainties due to a number of 
approximations. The approximation on metabolism and toxicokinetics assumption are taken (in fact, the 
assessment is based considering a fixed excretion % and a fixed urine volumes), while urine dilution 
issues were totally neglected.  Table 38 summarises the sources of uncertainties to be considered in 
the PDI assessment. 
Table 38: Uncertainties on PDI values 
Body weight  70 kg is the average value for adults, considering that we combined adolescents and 
adults, this takes a 13% of variability. 
Excretion rate  Values derived from single study or from correlation approximations 
Urine volumes This is an average value of 2 L of fixed urine output. Urine is not corrected for dilution 
factors.  
Data representativeness Different geographic distribution of data used for PDI model calculation 
 
Each single source of uncertainty for the single mycotoxin is integrated to a combined budget 
uncertainty to be applied to the PDI calculation of the mixture (PDIMIX). In the case of the mixture, even 
more variables should be considered for all the unknown toxicokinetics and toxicodynamics combined 
interferences and for the unknown synergistic/additive possible effects. 
The analysis of BM data provided a data-driven insight on the presence of the BM in urine of European 
population groups (De Santis et. al, in preparation). 




www.efsa.europa.eu/publications 114 EFSA Supporting publication 2020:EN-1757 
The present document has been produced and adopted by the bodies identified above as author(s). In accordance with Article 36 of Regulation (EC) 
No 178/2002, this task has been carried out exclusively by the author(s) in the context of a grant agreement between the European Food Safety 
Authority and the author(s). The present document is published complying with the transparency principle to which the Authority is subject. It cannot 
be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues 




The main objective of MYCHIF was to develop an integrated innovative method, supported by modelling, 
for the risk assessment of mycotoxin mixtures in food and feed, i.e. from fungal growth and mycotoxin 
production and occurrence to harmonised risk characterisation in humans and animals, promoting 
complex system understanding and knowledge gaps identification.  
Adequate literature was available on cropping systems and mitigation actions at pre- and post-harvest 
as well as on mycotoxin occurrence in many crops.   
In maize, most of the published work related to contamination with Aspergillus and Fusarium species 
and the resulting occurrence of AFs, DON, ZEN, FBs, NIV, T-2 and HT-2 toxin. Substantial literature 
exists on fungal growth and mycotoxin production as well as on factors impacting plant-pathogen 
interaction. In maize and small grains, including barley, oats, wheat and other grains, preventive actions 
have been considered worldwide, both at pre-harvest, as part of the cropping system and harvest 
management, and post-harvest through storage, processing and detoxification. A major role was 
confirmed in maize for the biological control of As. flavus to minimize contamination with AFs. 
In rice, a considerable amount of literature exists on Aspergillus and Fusarium contamination. Penicillium 
species are also able to grow on rice during storage, namely P. verrucosum. This fungus has the 
toxicogenic ability to concurrently produce CIT and OTA; although different studies exist, reports on the 
mycotoxin contamination of rice are limited compared to those on other cereals.  
In grapes, most of the published work relate to the occurrence and the ecology of Aspergillus species 
(predominantly black Aspergilli), to the occurrence of OTA in wines, grape juice, currant and raisin, and 
to the prevention of OTA production. 
The principal nuts of concern include peanuts and some of the most popular tree nuts consumed 
globally, such as pistachio nuts and almonds. The most frequent mycotoxins detected in nuts are AFs.  
As a general finding, a very limited amount of information has been found on mycotoxin co-occurrence 
in all crops, and it is very rare to find data on the co-occurrence at a single sample level. 
Methods of analysis ranged from cheap rapid screening tools, to be used both for lab and field, to more 
sophisticated confirmatory analytical instruments. The main need regards the availability of screening 
tools for field-based testing for the detection of more than one mycotoxin or mycotoxin families. Even 
if high or ultra-performance chromatography systems coupled to mass spectrometry have now been 
widely reported for their valuable use in the determination of the co-occurrence of multiple mycotoxins 
in different food commodities. Their remains an urgent need for lower cost, fit for purpose methods 
characterized by the ability to measure multiple mycotoxins, with lower limits of quantification for all 
the co-occurring mycotoxins, including their metabolites investigated in vivo, as well as ad hoc reference 
materials (matrix-RM and of metabolites), for providing reliable quantitative results.  This is required to 
better determine the toxin mixtures present across many feed and food types and allow the data to 
better inform stakeholders in terms of their effects on human and animal health. There is also a high 
potential for tools based on combining spectroscopy with chemometric modelling that can be used to 
screen crops for mycotoxin contamination to serve as part of decision support tools for actors across 
the feed and food supply chains.  
Regarding the toxicity of multiple mycotoxins mixtures, including toxicokinetic and toxicodynamic, the 
available literature is rather scarce in terms of number of published papers needed by stakeholders. 
What is available only covers a very limited combination of mycotoxins. Toxicokinetic data is mainly 
available for pigs and chickens (as relevant species important from an agro-economic point of view) and 
rats. Mycotoxin type, dosage, exposure pathway, inter- and intra-species differences have been 
identified among the most important parameters that may influence the toxicokinetic of mixtures. 
Concerning the toxicodynamic, the data available could be used to set structure-based models 
describing the mechanisms of action of certain mycotoxins (e.g. ZEN) in some species (i.e. humans and 
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pigs). However, they could not support the modelling of TD of mycotoxin mixtures. Concerning the 
modelling of mixtures’ toxicity, some macroscopic endpoints have been modelled on selected species 
(i.e. pigs and chickens); though, the limited availability of data resulted in a moderate coverage of all 
the possible combinations of mycotoxin mixtures.    
BM studies on mycotoxins have been increasing considerably over the last 10 years, either in 
toxicological studies and biomonitoring context, both on animal species and humans. As far as the 
amount and quality of information available, a wide spectrum of observations and indications was 
available in the published literature. However, there is still a lack of harmonization in the experimental 
settings and design of biomonitoring studies, in the data collection and in the definition of performance 
criteria of fit for purpose analytical methods (which are generally taken from the food sector). These 
issues make extremely difficult to exploit this data for exposure assessment goals. International study 
guidelines should be prepared to support the production of data, which can better contribute also to 
toxicological studies.  
Biomonitoring approaches for assessing exposure to environmental chemicals should use analytical 
methods with low limit of detection and quantification and with accurate, robust methodology (e.g. 
double isotope dilution, selective and specific clean-up steps) capable of measuring low-level 
concentrations. However, this is frequently not the case and again guidelines would help enormously. 
It is suggested EFSA convene a working group to address this identified need. Moreover, a further weak 
point for BM analytics is the lack of analytical standards for the majority of the glucuronide metabolites, 
the lack of reference material in biological matrix and the lack of inter-laboratory studies, mandatory 
tool for guaranteeing the comparability of measurements.  
The main BM of exposure for the most concerning mycotoxins has been identified, either as parent 
compounds or altered metabolic forms (e.g. glucuronide, sulphate or hydroxylated ones). It is known 
that the sampling strategy is a key step but also an important source of variability, adding extra 
uncertainty to that already related to the toxicokinetic parameters. However, it has been observed that, 
in most cases, inadequate attention was paid to the sampling strategies (e.g. knowledge on the BM 
stability, defined time of sampling, way of sample collection and storage). 
Regarding BM in animals, the majority of studies has been conducted on AFs followed by DON, OTA, 
and ZEN, while among the emerging mycotoxins, ENNs has been studied in a small number of 
publications and other emerging mycotoxins as T2, NIV, BEA and STC have been investigated in only 
one publication each. The most studied animal species are included in one of the five identified clusters: 
suidae (pigs and wild boars), bovidae (cow, cattle, buffalo, sheep and goat), poultry (chickens, hens 
and turkeys), rodents (rat and mice); and other animal species (dog and horses). From the collected 
information it was found that metabolic patterns change depending on the animal species; therefore, a 
species-specific information is now available. Urine is the most investigated matrix followed by serum, 
milk, faeces and bile. Finally, few observations on multi-mycotoxins in any of the possible combination 
animal species-mycotoxin-matrix were found to be available.  
Regarding BM in humans, AFs is the most widely studied mycotoxin followed by OTA, DON, FBs, ZEN 
and other emerging mycotoxins such as ALT, TEA, FUSX, NEO, CIT, NIV, T2, DAS, and ENNs in a very 
few studies. Any possible association of metabolic patterns in animals with the human model suffers 
from a certain degree of uncertainty, depending on the closeness of the animal model to the human. 
Also, in studies on humans, urine was found to be the most investigated matrix followed by 
serum/plasma/blood, faeces and breast milk. 
Biomarkers represent a good integration of the exposure estimates as they take into consideration the 
overall exposure to multiple chemicals while providing information on the variability and trends in 
exposure scenarios. The ability to match the results of BM, which measure the exposure via the internal 
dose, in the health risk assessment context, which in turn refers to external dietary doses, should count 
on i) suitable/validated Physiologically-Based Toxico-Kinetics (PBTK) models to properly quantify the 
biotransformation, metabolism and excretion of all the BM compounds, ii) applicable MOA or adverse 
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outcome pathway (AOP) and toxicological frameworks to describe biological key events leading to an 
effect, iii) available flexible approaches to multiple chemicals and iv) a structured schemes of biological 
fluid sampling and related analysis. Whilst for a number of environmental contaminants a well-structured 
framework can support the satisfactory interpretation of biomonitoring data in the health risk 
perspective, also in a context of combined exposure of mixtures, for the mycotoxins issue there is still 
a lack of important data either for single and combined exposures. 
The description of RA scenarios in hierarchy maps was possible for the HCS considering exposure to 
Mixture-2 (i.e., T2/HT2, DON and NIV) for adults, MB contamination and mean consumption values.  
Visual hierarchy maps have been used to emphasize risky areas with important exposure values over 
less important exposure areas in EU countries. The maps were defined for each mycotoxin of the 
mixture-2 and were possible since occurrence and consumption values were made available in the EU. 
These maps represent useful pictures where it is immediately noticed where the highest ranks in the 
visual hierarchy are placed. 
 
5. Data gaps and recommendations for future work 
 
Pre- and post-harvest management of mycotoxins. Scarce information is available for the co-
occurrence of mycotoxins, as well as for the co-occurrence of modified mycotoxins and their fate during 
processing is not clearly understood. It is therefore suggested to plan research actions to fill such data 
gaps. 
Methods of analysis. Available methods are, in general, satisfactory for the evaluation of the 
occurrence of mycotoxin mixtures, especially those based on high-resolution mass spectrometry 
(HRMS). However, the transfer of literature-based methods to the routinely monitoring plans is often 
difficult, due to the costs of the instrumentation. The development of high-throughput multi-analyte 
biosensors is promising, but still in the R&D phase. Overall, while perfectly developed for compliance 
analysis, the routinely methods are not always fit-for-purpose for risk assessment, with inadequate 
sensitivity, leading thus to an higher percentage of left-censored data in the occurrence database.  
Toxicity. Data so far available are overall scarce and the following aspects need to be considered in 
future investigations to provide a proper ground for modelling:   
 The development of prioritisation criteria of mycotoxin mixtures to be tested in vivo and in vitro 
is urgently needed since it would be unfeasible to test all possible combinations  
 Harmonisation of methodologies and consensus guidelines for generating in vitro and in vivo 
TK and TD are needed to provide consistent data for PBTK and BMD modelling of mycotoxin mixtures.  
 The texting of possible combinations of mycotoxins mixtures that can really occur in the real 
world is needed for a broader assessment of mycotoxins 
 The use of structure-based TD models (i.e. 3D in silico modelling) should be considered to 
understand the mechanisms of toxicity of mycotoxins, to provide a reasonable foothold to develop 
prioritization criteria, and to mechanistically explain inter- and intra-species variability 
 The use of predictive TK and TD modelling including uncertainty and inter- and intra-species 
variability analysis should be considered in the future to assist in reducing the overall uncertainty and 
the production of a more robust risk assessment of chemical mixtures for animals and humans. 
Biomarkers. In order to match the information from the quantitative analysis of BM and dietary intakes 
assessments, and to establish a correlation with the food intake by which animal species and human 
beings may be reached, the following gaps should be dealt with: 
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 Need to define models of derive qualitative and quantitative correlation between mycotoxin 
intake from food and from other possible routes of exposure like contact or inhalation, the latter very 
important in some working environment like cereal management and store houses;  
 Lack of quantitative determination of the metabolic pathway of the parent compounds. There 
are numerous sources of uncertainties affecting the quantitative determination of the overall metabolic 
pathway of the parent compounds that makes the PBTK modelling for human a big challenge. Among 
the uncertainties, i) the low bioavailability rates ascertained with no information on the destiny of the 
missing percentage not bioavailable in vivo, ii) the insufficient toxicological data for defining 
bioavailability rates for animal species, iii) the insufficient data for toxicokinetic pathway definitions in 
animals to be transferred in humans (also taking different doses of intake), iv) need of clarification on 
the critical effects and mode of actions, v) the lack of commercially reference standards of all the 
metabolised  forms found in vivo so far, vi) the lack of harmonization in the availability of analytical 
methods able to detect very low concentration levels of in vivo mycotoxins and to search for discovering 
new metabolic forms in their conjugated forms; 
 Complete lack of information on the possible differences in the metabolic pattern of a mycotoxin 
between its presence in vivo as single or as co-occurring with other mycotoxins and of the corresponding 
toxic effects; 
 Overall evaluation of the differences in transferring the scientific knowledge and findings from 
animal models to humans, in consideration of the high difference of the corresponding biological 
systems; 
 Scarce molecular epidemiology findings derived from the acquisition of the profile of BM; 
 The role of the dose of the single toxin on the profile of the metabolic pathways with scarce 
possibility to correlate the dose itself with food intake and toxic effect as well. 
 The use of forward/reverse approaches (i.e. use of the pharmacokinetic knowledge to derive 
biomonitoring steady state concentrations or adapt steady-state concentrations calculated from the 
pharmacokinetic model integrating the actual biomonitoring data) to be relied on comprehensive PBTK 
models. Actually, these models are are scarce and incomplete for mycotoxins. The future availability of 
PBTK model implementation in addition to dietary dose estimations is a considerable step towards 
source-to-dose-to-effect prediction of toxicity for mycotoxins.  
 Finally, the use of visual hierarchy maps to describe RA scenarios and to emphasize risk areas 
with important exposure values over less important exposure areas could be a useful tool for risk 
managers and for communication purposes. The availability of massive occurrence and consumption 
data in combination with modelling and predicting approaches may optimize the maps representing 
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AFB1alb aflatoxins B1-Alb 
AFB1lys aflatoxins B1-Lysin 
AFB1N7guanine aflatoxins B1-N7-Guanine 
alloTeA allo-Tenuazonic Acid 
AST aspartate aminotransferase 
aw water activity 
BCRP breast cancer resistance protein 
BEN balkan endemic nephropathy 
BM biomarkers 
BM biomarker 
BMD benchmark doses 
BMR benchmark response 
bw body weight 
BWG body weight gain  
CDF plot cumulative distribution function plot 
CFU colony forming unit 
CKD chronic kidney disease 
CL clearance 
DM dry matter 
DMI dry matter intake 
drc dose-response curves 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
ELS extensive literature search 
EU european union 
F bioavailability 
FFQ food frequency questionnaire 
FLD fluorescence detection 
FUMzyme carboxylesterase fumonisin D 
GAPs good agricultural practices 
GSPE grape seed proanthocyanidin extract  
HA humic acid 
HFB1 hydrolysed fumonisin B1 
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HPLC high performance liquid chromatography 
HSCAS hydrated sodium calcium alimunosilicate 
I.p. intraperitonal 
I.v. intravenous 
Kabs rate of absorption 
Ke rate of elimination 
LC liquid chromatography 
LOD  limit of detection 
LOQ limit of quantification 
MixTox   curve fitting and mixture toxicity assessment 
MS mass spectrometry 
OHCIT dihydrocitrinone 
OTP oxidised tea polyphenols 
P-gp P-Glycoprotein 
pHFB1 partially Hydrolysed Fumonsin B1 
P-P plot probability–probability plot 
Q-Q plot quantile-quantile plot 






TLC thin layer chromatography 
Tmax maximum concentration 
UV UV detector 
Vd volume of distribution 
VFM velasco fluorotoxinmeter 
y years 
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Appendix A – Formats used in WP1 
A.1 - Data model for mycotoxin occurrence in crops 
 
 





DB_origin Database origin  string Alphanumeric 
strings 
data provider 




sample country origin, 
ISO ALPHA-2 Code 




sample continent origin, 
ISO 7 continents 
sampContinent Sampling continent string Alphanumeric 
character 
sample continent trial 
site/analysis, ISO 7 
continents 
paramType Type of parameter string Alphanumeric 
character 
toxin parameter 
sampCountry Sampling country  string Alphanumeric 
character 
sample country trial 
site/analysis, ISO ALPHA-
2 Code 
sampRegion Sampling region  string Alphanumeric 
character 
sample region trial 
site/analysis 




Double sample field trial site, 
latitude decimal degree N 
sampInfo.longitude Sampling info 
longitude 
floating Double sample field trial site, 
longitude decimal degree 
N 
sampInfo.altitude Sampling info 
altitude 
floating Double sample field trial site, 
altitude above sea level 
(m)  
sampY Sampling year integer Short starting year of sampling 
sampYearIncreas Sampling year 
increase 
integer Short number of years of 
sampling  
sampSize Sample size integer Short number of samples 
sampMethod Sampling method string Alphanumeric 
character 
sampling methodology 
sampPoint Sampling point string Alphanumeric 
strings 
food chain level where the 
sample has been taken 




food chain level sampling 
point extra info 




type of sample taken, 
sub-domain of the matrix 
catalogue to be used 


















extra info for the matrix 
level coding 
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Appendix B – Formats used in WP2 
 
growingSystem Growing system string Alphanumeric 
character 
matrix production info 
anMethRefId Analytical method 
identification 




resUnit Result unit string Alphanumeric 
character 
measurement unit 
resLOD Result LOD  floating Double limit of detection (LOD)  
resLODinfo Result LOD info string Alphanumeric 
character 
info limit of detection 
(LOD) 
resLOQ Result LOQ  floating Double limit of quantification 
(LOQ) 
resLOQinfo Result LOQ info string Alphanumeric 
character 
info limit of quantification 
(LOQ) 
exprResPerc Percentage of 
moisture 
floating Double sample moisture (%) 




floating Double standard deviation for 
meanTot sample values 
meanTot Mean of total values floating Double mean of total sample 
values 




floating Double standard deviation for 
meanPos sample values 
meanPos Mean of positive 
values 
floating Double mean ot positive sample 
values 
median Median value floating Double median of sample values 
medianInfo Median value Info string Alphanumeric 
character 
info for median of sample 
values 
min Min value floating Double min of sample values 
max Max value floating Double max of sample values 
>LOD (%)  floating Double % of samples >LOD 
IQRmin Interquartile min floating Double min of interquartile 
IQRmax Interquartile max floating Double max of interquartile 
Concentration  floating Double concentration sample 
value 
DataSampLevel Data at sample 
level  
logic Boolean Data at sample level 
Co-occurrence Data on co-
occurrence 
logic Boolean Cooccurrence 
Ref Reference  string Alphanumeric 
strings 
Paper Reference 
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B.1 - Standard data model to collect key data of toxicity in vivo 
parameters. Example on data extraction of key toxicity parameters for the 
1976-2010 time frame 
 
Indicator/category Explanation Example 
Refence Reference paper with the 1st 
author name and year of 
pubblication 
Grenier et al. 
DOI The Digital Object Identifier 
(DOI) of the paper 
10.1007/BF01139334 
 
Species Animal species tested in the 
paper 
Broiler chicken 
Sex Sex of the animal  male 
Weight Body weight of the animal at 
the start of the experiment 
409 
Weight.sd Standard deviation 3 
Weight.unit The unit of measurement g 
Number_of_animals  Number of animals used in 
the experiment 
5 
Mycotoxin Mycotoxin that was 
administrated 
DON 
Production Mycotoxin source Commercial (Sigma Aldrich) 
Purity Mycotoxin purity >96 
Purity.percentage Percentage of purity % 
Origin Origin of extracted 
mycotoxins 
Aspergillus parasiticus 
Dose  The amount of mycotoxin  0.5 
Dose.sd Standar deviation 0.5 
Dose.unit The unit of measurement mg/Kg 
Other compounds Presence of additional 
chemicals 
2-acetylaminofluorene 
Other_compound_concentration Concentration of other 
compounds 
20 
Other_compound_concentration.units Units of measurement mg/Kg 
Matrix Source of mycotoxins 
exposure 
feed 
Route_of_administration Route of mycotoxin 
admistration 
Oral 
Exposure Lenght of exposure 7 
Exposure.units Units of mesurements day 
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Note: the last part of the template includes the measured endpoint with the respective standard deviation and units of 
measurement. As an exmaples, “Bodyweight_gain”, “Bodyweight_gain.sd” and “Bodyweight_gain.unit” indicate the gain 
of body weight (e.g. 140), the standard deviation (e.g. 0.94) and the unit of masurements (e.g. g), respectively.  
 
B.2 - Example on data extraction of key toxicity parameters in vivo for the 
2010-2017 time frame 
Indicator/category Explanation Example 
Author Reference paper with the 1st 
author name 
Smith 
Year Year of pubblication 2011 
Title Title of paper The Impact of the Fusarium 
Mycotoxin Deoxynivalenol 
on the Health and 
Performance of Broiler 
Chickens 
Species Animal species tested in the 
paper 
Broiler chicken 
Strains Strain of animal used Ross 308 
Sex Sex of the animal  male 
Initial age (day) Initial age of animals tested 1 
Initial body weight  (g) Initial body weight of animal 
tested 
41.9 
Sample size Number of animal per sex per 
experiments 
6 
Mycotoxin Mycotoxin that was 
administrated 
DON 
Time of exposure (days) Length of treatment 35 
Dose in the feed (mg/kg feed) The abundance of mycotoxin 
in the feed 
1 
Dose (mg/bw) The amount of mycotoxin 
used to treat animal 




B.3 - Example on data extraction of key toxicokinetic parameters in vivo 
Indicator/category Explanation Example 
reference Reference to the paper with name 
of first author and year 
Han et al 2012 
DOI The digital object identifier of the 
paper 
10.1039/c2ay25891a 
Species Animal species tested in the paper Broiler chicken 
Sex_species Sex of the animal  male 




www.efsa.europa.eu/publications 138 EFSA Supporting publication 2020:EN-1757 
The present document has been produced and adopted by the bodies identified above as author(s). In accordance with Article 36 of Regulation (EC) 
No 178/2002, this task has been carried out exclusively by the author(s) in the context of a grant agreement between the European Food Safety 
Authority and the author(s). The present document is published complying with the transparency principle to which the Authority is subject. It cannot 
be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues 
addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s). 
 
 
Region Where the study took place  UK 
s_size Number of animals 6 
Exposure days Number of days the animals were 
exposed to the toxin 
5 
Toxin.1 1st Mycotoxin that was 
administrated 
DON 
Dose.1  The amount of the chemical given 
in a solution 
0.5 
Units.1 The units of the amount of 
chemical given 
mg/kg bw 
Admin.route Route of administration oral 
Exposure.dose If the exposure to administrated 
dose of the toxin was in a single 
dose or in an amount of days  
Single dose 
Exposure.info Information on state of the animal  fastened 
Toxin.2 2nd Mycotoxin that was 
administrated 
ZEN 
Dose.2  The amount of the chemical given 
in a solution 
0.5  
Units.2 The units of the amount of 
chemical given 
mg/kg bw 
Admin.route.2 Route of administration oral 
Toxin.3 3rd Mycotoxin that was 
administrated 
OTA 
Dose.3 The amount of the chemical given 
in a solution 
0.5  
Units.3 The units of the amount of 
chemical given 
mg/kg bw 
Admin.route.3 Route of administration oral 
Toxin.4 4th Mycotoxin that was 
administrated 
AFB 
Dose.4 The amount of the chemical given 
in a solution 
0.5  
Units.4 The units of the amount of 
chemical given 
mg/kg bw 
Admin.route.4 Route of administration oral 
AUC Area under the curve 36.24 
AUC_units Units of AUC μg/l/h 
AUC.SD The standard deviation of AUC 3.8 
Absorption rate The Lowest Observed Adverse 
Effect Level value for the chemical 
56 μg/kg bw per day 
Absorption units The mean value on the adverse 
effect observed  
/h 
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Absorption.sd The units of the Mean observed 
value 
2.7 
Bioavailability% The main statistical descriptor used 
(Standard Error, Standard 
Deviation)  
92% 
Bioavail.SD The value of the statistical 
descriptor used 
5.6 
T1/2el.h Elimination half life 1.36 hours 
T1/2el.h info Description on the type of numeric 
value of the elimination half life 
(i.e. single value, range) 
Single value 
T1/2el.h sd Standard deviation of the 
elimination half life 
0.29 h  
cmx The maximum concentration of the 
toxin observed 
15.9 
cmx_units The units of the cmx ng/ml 
Cmx.sd The standard deviation of cmx 4.5 
tmax The time the maximum toxin 
concentration was observed (in 
hours) 
15 h  
Tmax.sd The standard deviation of tmax 1.44 
vmax Maximum elimination capacity 6.4 
v.sd Standard deviation of vmax 0.17 
Vmx_units The units of vmx L/kg 
Ke Constant of elimination 0.53 
Ke_units Units of the elimination constant /h 
SD-SE Standard deviation or standard 
error of elimination constant 
0.11 
Cl Clearance  0.34 
Cl_units The units of clearance  L/h/kg 
Cl.SD Standard deviation of clearance 0.03 
Ex_route Excretion route of the chemical urine 
Excretion.rate The rate of excretion of the 
chemical 
0.27% 
Ex_timeobs The time the excretion rate was 
measured 
72h 
C_over_rate The carry over rate of the chemical 15.51% 
Targ_tissue1 The 1st target tissue  Kidney  
Targ1_toxin1 The 1st toxin for the 1st target 
tissue 
AFB1 
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Targ1_toxinN The Nth toxin for the 1st target AFB2 
Targ_tissueN The Nth target tissue  muscle 
TargN_toxin1 The 1st toxin found in the Nth 
target tissue  
AFB1 
TargN_toxinN The Nth toxin found in the Nth 
target tissue  
AFB2 
 
B.4 - Example on data extraction of key toxicokinetic parameters in vitro 
Indicator/category Explanation Example 
Reference Reference to the paper 
with name of first author 
and year 
Ajandouz et al 2016 
DOI The Digital Object 
Identifier (DOI) of the 
paper 
10.3390/toxins8080232 
Species Animal species tested in 
the paper 
Broiler chicken 
Sex Sex of the animal  male 
Replicates Number of experimental 
replicates 
3 
Mycotoxin The mycotoxin used to 
treat   
DON 
Dose Dose of treatment 100 
Dose.sd Standard deviation 3 
Dose.unit Unit of measurements µM 
Cell/Tissue Cell or tissue type used Caco-2 cell 
Organelle Organelle used treat 
mycotoxins 
Microsomes 
Transport from Transport direction: 
where mycotoxins come 
from 
Apical monolayer 
Transport to Transport direction: 
where mycotoxins were 
directed 
Basolateral monolayer 
Transport from Transport direction: 
where mycotoxins come 
from 
100 
Exposure_time Time of treatment 6 
Transport_time.units Unit of measuments h 
Phase_I_metabolite Phase I metabolites 
produced 
4-OH-AOH (free) 
Phase_II_metabolite Phase II metabolites 
produced 
ZEA-glucuronide 
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Further_metabolites Additional metabolic 
transformation 
N-C18:0-FB1 
Amount_of_remaining_mycotoxins The amount of not 
transformed mycotoxins 
2.03 
Amount_of_remaining_mycotoxins.sd Standard deviation 0.23 
Amount_of_remaining_mycotoxins.unit Unit of measurment µM 
Excretion_of_mycotoxins/metabolites The amount of excreted 
mycotoxin/metabolites 
2.03 
Excretion_of_mycotoxins/metabolites.sd Standard deviation 0.23 
Excretion_of_mycotoxins/metabolites.unit Unit of measurment µM 
 
B.5 - Screening template for mycotoxin mixtures 
Mycotoxins in 
mixture 





















TK No absorption (Gambacor
ta et al., 
2016) 

















n et al., 
2015) 




AFB1+T2 Male Sprague-Dawley 
(SD) rats 
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OTA+AFB1 White Leghorn breeder 
hens, 45 weeks 








DON+FB1 Male and female Swiss 












DON+ZEN 5 week old Kunming 
mice male and female 
TK and 
TD 




(Ji et al., 
2017) 










32 first-parity Yorkshire 













Friesian female heifers, 










DON+FBs One-day old Ross 308 
broiler chickens 
TK No various TK 
parameters 
(Antonisse





Hybrid turkey poults 
















rats TK No tissue 
residues 
(Versilovsk
is et al., 
2012) 
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e dose  
Endpoints Reference 
















et al., 2014) 
T-2 









et al., 2015) 
DON 
male piglets, 21 





























































one day-old chicks 
(LohmannLSL) 






chickens male and 
female  
TD No  
nutrient 
absorption 
(Awad et al., 
2014) 










(Kong et al., 
2011) 
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(Di et al., 
2015) 
OTA 
15 week old male 






et al., 2010) 
DON 
broiler chickens 
3weeks old, male 








3weeks old, male 


























TK No TK parameters 
(Fraeyman 
et al., 2016) 









TK No TK parameters 





TK No TK parameters 
(Buranatrago





male/female,         
broiler chickens 
(Ross 308) 
male/female,                  









Male B6C3F1, 7 
weeks old 
TK No bioavailability 
(Tamura et 
al., 2013) 
ENN B1 piglets TK No bioavailability 
(Devreese et 
al., 2014b) 
DON pigs TK No TK parameters 
(Paulick et 
al., 2015) 
DON pigs TK No TK parameters 
(Saint-Cyr et 
al., 2015) 
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B.7 - Example on data extraction of key parameters on biomarkers 
Indicator/category Data Type class Explanation 
Reference  Alphanumeric strings Reference paper with the 1st author name and year 
Type of study Alphanumeric strings Biomarkers of exposure 
Biomarkers of effect 
Toxicological studies with data on biomarkers 
Toxicokinetic study with data on biomarkers 
Validation of the analytical method for biomarker 
analysis 
Specie (H/A) Double Human/Animal 
Single or Multiple 
Biomarker Study 
Double (M) for multibiomarker or (S) for single biomarker 
study 
ParamType_Mycotoxin Alphanumeric character Mycotoxin source of exposure (ex: case of AFB1 
toxin, and AFM1 biomarker)  
ParamType_Biomarker Alphanumeric character Biomarker molecule/molecules measured  
Substrate Alphanumeric character Indicate the substrate (urine, serum, human milk, 
etc.) where the biomarker is measured 
sampCountry Alphanumeric character  
SampleSize Double Size of the population involved 
SampleType Alphanumeric character Infants: up to and including 11 months  
Toddlers: from 12 up to and including 35 months of 
age  
Children: from 36 months up to and including 9 
years of age  
Adolescents: from 10 up to and including 17 years 
of age  
Adults: from 18 up to and including 64 years of age  
Elderly: from 65 up to and including 74 years of 
age  
Very elderly: from 75 years of age and older  
SampleType_INFO_de
scription 
Alphanumeric character Sex info 
SampleType_INFO Alphanumeric character Other info 
Age Double Age in years 
SampPeriodYear Alphanumeric character Period or year of sampling 
meanPos Double Value 
Median Double Value 
GeometricMean Double Value 
SD Double Value 
Percentile Double Value 
Percentile_ INFO Alphanumeric character Which percentile is available 
resUnit_Unit Double Units which the values are referred to 
Min Double when< LOD use ( -1) 
Max Double Value 
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Alphanumeric character Report the units t which the values are referred to 
Biomarker_info Alphanumeric character Additional description/information  
anMethRefId_Analytic
al method 
Alphanumeric character Type of analytical technique 
Method 
Validation_Y(1)_N(-1) 
Double 1 (=Y); 0 (=N) 
Method 
Validation_Info 
Alphanumeric character i.e. Reference for the validation used 
resLOQ_Method LOQ Double Value 
resLOD_Method LOD Double Value 
LOQunit Alphanumeric character Report the units which the values are referred to 
LODunit Alphanumeric character Report the units which the values are referred to 
Other_parameter_INF
O 
Alphanumeric character  
Sampling strategy 
used_INFO 
Alphanumeric character sampling strategies used for sample collection (i.e. 
urine 24 h) 
Correlation_food_Y(1)
_N(-1) 
Double If there is correlation with food: 
1 (=Y); 0 (=N) 
Any correlation with 
food intake_INFO 




Double If there is exposure assessment calculations: (=Y); 
0 (=N) 
Values ExpAss_Value Double  
Values expass_Unit Alphanumeric character  
Biomarker validation 
process_INFO 
Alphanumeric character  
 
B.8 - List of recurrent indicators and explanation retrieved 
Indicator  
Mycotoxin Single 71% 
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Substrate Plasma (14%) 
Urine (41%) 
Breast milk (8%) 
Blood (4%) 
Serum (19%) 
Animal milk (7%) 
Other (11%) 
























Pregnant woman_Rural and suburban 
Workers_Exposed _Non exposed to dusts in two mills 
Undernutrition and diarrheal disease  
Incidence of undernutrition and diarrheal disease  
Recurring aflatoxicosis_Group I placebo 
Recurring aflatoxicosis_Group I treatment 
Recurring aflatoxicosis_day 1 
Recurring aflatoxicosis_day 21 
Women_Mixed diet 
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Mothers with no habit of mouldy food consumption 
Healthy German  
Healthy Turkish origin 
3 villages Kigwa, Nyabula and Kikelelwa in Tabora, Iringa and 
Kilimanjaro regions Visit1 
3 villages Kigwa, Nyabula and Kikelelwa in Tabora, Iringa and 

























EH + LLE + LC–MS/MS 
UHPC-MS/MS_ESI 
UPLC-MS/MS 
Type of sampling strategy used Samples collected at 15 months 
Good health participants 
Morning urine (Monday and Friday) 
First morning void urine  
Cow’s milk and other milk for investigation of human exposure to 
AFM1  
First morning void urine  
24 h urine 
50 ml of breast milk samples 
Urine samples were collected at the first visit  
Blood samples were collected at the first visit  
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Appendix C – Formats used in WP3 
 
C.1- Encoding Keys 
Encoding Keys 
missing value = -999 
value<LOD = -1 
value<LOQ = -2 
data at sample level (yes=1; not=0) 
cooccurrence (yes=1; not=0) 
 
C.2 - Paramtype (toxins coding) 
Code Toxins 
15AcDON 15-Acetyl-deoxynivalenol 
15OHculmorin 15 OH culmorin 
2AOD3ol 2-Amino-14,16-dimethyloctadecan-3-ol 
3AcDON 3-Acetyl-deoxynivalenol 
3NP 3 nitropropionic acid 
5OHculmorin 5 OH culmorin 
AcDONs acetyldeoxynivalenols 
AFB1 Aflatoxins B1 
AFB2 Aflatoxins B2 
AFG1 Aflatoxins G1 
AFG2 Aflatoxins G2 
AFM1 Aflatoxin M1 
AFs Aflatoxin total 
AFalb Aflatoxin-albumin 
AFB1alb Aflatoxins B1-albumin 
AFB1lys Aflatoxins B1-lysin 
AFB1N7guanine Aflatoxins B1-N7-guanine 
ALT altenuene 
Alterperylenol Alterperylenol 
AME alternariol monomethyl ether  
AME3G alternariol monomethyl ether-3-glucoside 
AME3S alternariol monomethyl ether-3-sulfate 
AND A  Andrastin A 




Asterric acid Asterric acid 
ATE altenuene 
ATX1 Altertoxin I 
ATX2 Altertoxin II 
Aurofusarin Aurofusarin 
Avenacein Y Avenacein Y 
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CPA Cyclopiazonic acid  
Culmorin Culmorin 
Curvularin Curvularin 
Cytochalasin E Cytochalasin E 
DAS diacetoxyscirpenol 
DASG diacetoxyscirpenol 
Deepoxy HT2 de-epoxy-HT2 








ENA enniatin A 
ENA1 enniatin A1 
ENB enniatin B 
ENB1 enniatin B1 
ENB2 enniatin B2 
ENB3 enniatin B3 
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EtOTB OTB ethyl esters 
EAs Ergot alkaloids 
FB1 Fumonisin B1 
FB2 Fumonisin B2 
FB3 Fumonisin B3 
FB4 Fumonisin B4 
FBs Fumonisin total 
Festuclavine Festuclavine 
FUS Fusaproliferin 
FUSX Fusarenone X 
HFBs hydrolysed fumonisins B 
HFB1 hydrolysed fumonisin B1 
HT2 HT-2 
HT23G HT-2 toxin-3-diglucoside 






LSD lysergic acid diethylamide 
MacrosporinA MacrosporinA 
MalforminC MalforminC 
MARCFORTINE A MARCFORTINE A 
MAS monoacetoxyscirpenol 
MeOTA methyl Ochratoxin A 
MeOTB methyl Ochratoxin B 
MON moniliformin 





OHLSD 2-oxo-3-hydroxy lysergic acid diethylamide 
OTA Ochratoxin A 
OTB Ochratoxin B 
OTC Ochratoxin C 
OTs Ochratoxins 
PAC penicillic acid 
PAT patulin 
Penitrem A Penitrem A 
ROQC Roquefortine C 
ROQE Roquefortine E 
STC Sterigmatocystin  
STO scirpentriol 
T2 T-2 
T2 tetraol T-2 tetraol 
T2 triol T-2 triol 
T2G T-2-glucoside 
TeA tenuazonic acid 
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Appendix D – Guidelines for MYCHIF repository 
Partners can upload their data to the repository in any format (text files or images or code). IBIMET will 
manage everything related to the repository, reviewing folder chain and also, if requested, creating 
metadata.  
During repository implementation, a software platform was installed. OwnCloud                                      
(http:/owcloud.com) has been chosen because it fits well with the data management requested by the 
project. OwnCloud is a self-hosted file sync and share server that provides the creation for community 
based data-centre. With ownCloud, users have a single interface from which they can access, sync and 
share files on any device, anytime, from anywhere. Users can quickly find and share the files they need 
whether shared by others or created by themselves. With features like password protection, link 
expiration, anonymous and full access sharing, files are managed accordingly. It provides access to data 
through a web interface, sync clients or WebDAV while providing a platform to view, sync and share 
across devices easily — all under users and administrator control. ownCloud’s open architecture is 
extensible via a simple, but powerful, API for applications and plugins and it works with any kind of 
storage.  
ownCloud has been chosen also because it is open source, defined as priority in the project, and it is 
not limited by corporate requirements in terms of new features implementation still preserving the 
original high performance in terms of security and privacy. Further ownCloud has the ability to configure 
a shared link as read-write, which means users can seamlessly edit the shared files (protected with a 
password or not) or upload new files to the server without being forced to sign up to another web 
service that wants their private data. A LAMP web host, supporting and including Apache, PHP5, MySQL 
and a URL for remote access were configured and ownCloud service was installed on a virtual machine 
with the following requisites: 
- Ubuntu 16.05.2 LTS  
- CPU: 1 - 4 core 
- RAM: 2Gb 
- HDD: 512 GB 
The web access is located at the URL https://mychifrep.fi.ibimet.cnr.it/owncloud/ - A 2048 self-signed 
key assures a strong protection providing a communications protocol for secure communication on 
Internet. In the last update of MYCHIF Share repository 14 accounts (at least one user for any partner) 
are authorized to access, share and modify data. One of the CNR-IBIMET staff is instead configured as 
group administrator managing the disk space, the numbers of users and their sharing space, taking care 
of software maintenance and update, enabling applications and synchronizing accounts. 
Main screen views are shown in Fig.D.1 and Fig. D.2. 
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Figure D.1: Login page for MYCHIF repository website  
 
Figure D.2: Sharing files and folders 




www.efsa.europa.eu/publications 155 EFSA Supporting publication 2020:EN-1757 
The present document has been produced and adopted by the bodies identified above as author(s). In accordance with Article 36 of Regulation (EC) 
No 178/2002, this task has been carried out exclusively by the author(s) in the context of a grant agreement between the European Food Safety 
Authority and the author(s). The present document is published complying with the transparency principle to which the Authority is subject. It cannot 
be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues 




Repo Maintenance and backup. Once the digital repository is created it needs to be maintained. 
Administrator provided a self-restore of the whole repository and weekly a data backup of the whole 
content shared by users.   
Practical implications. Guidelines were provided to assist setting up and access to any users. Retrieval 
of information and knowledge sharing regarding the MYCHIF projects, data extraction and data mining 
are now possible with the creation of MYCHIF repository. 
Literature data mining 
The task of targeted data extraction from ELS is heavy and several specific resources for a generic data 
extraction are widely available on the web. In order to simplify this MYCHIF-workflow a set of tools have 
been evaluated by using MYCHIF repository with the main aim to extract reliable data from PDF textual 
documents. Mainly in the software evaluation the skill regarding the data table extraction from the 
digital documents was taken into account and tested in a group of articles selected by MYCHIF partners. 
The evaluation of the tools was carried out taking into account the following features: 
1. the licence openness of code 
2. the ability to extract data and save them in different format such as .txt .csv and zipped folders 
3. the richness of documentation and the availability of an online supporting service 
4. the ability to recognize special characters 
5. the ability to extract data from tables placed in articles both in vertical and horizontal position 
 
After evaluating their pros and cons we concluded that the most suitable software that could be used 
in MYCHIF project is Tabula (https://github.com/tabulapdf/tabula). Tabula is an offline software, 
available under MIT open-source license for Windows, Mac and Linux operating systems, that allows 
users upload PDF files and extract a selection of rows and columns from any table it may contain. Indeed 
for MYCHIF project’s purposes thank to Tabula it was possible not only a supervised extraction but also 
a light automation implementing the R tabula-extractor library (https://github.com/ropensci/tabulizer) 
able to: 
1. to read documents stored in MYCHIF repository 
2. to perform data extraction  
3. to store results in predefined folder in MYCHIF repository  
 
Finally, the MYCHIF workflow of document data extraction could be framed in the following roadmap, 
where the steps are: 
a) Log in to the MYCHIF repository; 
b) Upload the files from which you want to extract data in the "Data_pdf" folder (Fig. D.3); 
c) launch the R extraction code when is possible or perform a supervised extraction (currently available 
only at CNR-IBIMET); 
d) select the section of the table you want to extract, or select all if you are extracting the full table and 
text. Note: you can always adjust your selection.  
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e) immediately after making your selection, your data will be immediately stored in the "Data extraction" 
 
Figure D.3: Uploading PDF filesin the "Data_pdf" folder 
  
 
Figure D.4:"Data extraction" folder 
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The extracted data are saved in txt format (editable with any software) and can be imported into 
Excel. Each extracted file is saved with the same name as the original pdf file (Fig. D.5). 
Figure D.5: Extracted .txt files 
Furthermore, you have also the option to open the .txt file directly in MYCHIF repository as copy to 
clipboard and paste wherever you like or as well as you download your txt file which can be opened in 
any spreadsheet application (Microsoft Excel, LibreOffice Calc, Google Spreadsheet) (Fig D.6 and D.7). 
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Figure D.6: Opening .txt files in MYCHIF repository 
Figure D.7: Copying .txt files in MYCHIF repository  
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Annex A – Mycotoxin producing fungi  
Annex A can be found online in the MYCHIF platform and EFSA knowledge junction 
(10.5281/zenodo.3615174). 
Annex B – Pre- and post-harvest strategies to mitigate mycotoxin contamination in 
small grains 
Annex B can be found online in the MYCHIF platform and EFSA knowledge junction 
(10.5281/zenodo.3615174). 
Annex C – Pre- and post-harvest strategies to mitigate mycotoxin contamination in 
nuts 
Annex C can be found online in the MYCHIF platform and EFSA knowledge junction 
(10.5281/zenodo.3615174). 
Annex D – Pre- and post-harvest strategies to mitigate mycotoxin contamination in 
sorghum 
Annex D can be found online in the MYCHIF platform and EFSA knowledge junction 
(10.5281/zenodo.3615174). 
Annex E – Pre- and post-harvest strategies to mitigate mycotoxin contamination in 
spices 
Annex E can be found online in the MYCHIF platform and EFSA knowledge junction 
(10.5281/zenodo.3615174). 
Annex F – Methods of analysis for multiple mycotoxin detection, including masked 
mycotoxins 
Annex F can be found online in the MYCHIF platform and EFSA knowledge junction 
(10.5281/zenodo.3615174). 
Annex K – Biomarkers in animals 
Annex K can be found online in the MYCHIF platform and EFSA knowledge junction 
(10.5281/zenodo.3615174). 
Annex L – Biomarkers in humans 
Annex L can be found online in the MYCHIF platform and EFSA knowledge junction 
(10.5281/zenodo.3615174). 
 
 
 
